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1.1.  Hemostasis and Thrombosis 
The hemostatic process maintains the vascular integrity of our body and needs to be immediately 
activated after tissue injury to reduce the extravasation of blood from the vasculature. Hemostasis 
represents normal physiological condition. However, strict regulation in thrombus formation at site of 
injury is important to maintain the circulation. Therefore, hemostasis represents a delicate balance 
between coagulation (thrombus formation) and fibrinolysis (thrombus dissolution). Slight disturbance of 
this natural dynamic balance due to genetic (haemophilia, mutations in von Willebrand factor (vWF) 
and factor V and deficiency of prothrombin, protein C, protein S and antithrombin, etc.) or acquired 
(pregnancy, surgery, obesity, hormonal therapy, anticoagulant therapy, autoimmune disorders, and 
cancer, etc.) factors could lead to either thrombotic or hemorrhagic complications (Fig. 1.1) [1-5].  
 
Figure 1.1: Regulation of hemostatic system (adapted from Mishra et al. [6]). Exposure of tissue factor (TF) with blood 
and some pathological conditions (atherosclerosis and bacterial infection) trigger activation of the coagulation cascade 
through the activation of extrinsic pathway (factor IX and factor X) or intrinsic pathway (factor XIa and factor XIIa), 
respectively which results in formation of first hemostatic plug and ultimately thrombus. During fibrinolysis, t-PA- and/or u-PA-
mediated activation of plasminogen degrades fibrin blood clot into fibrin degradation product (FDP). Plasminogen activator 
inhibitor-1 (PAI-1), α2-antiplasmin (α2-AP) and activated thrombin-activatable fibrinolysis inhibitor (TAFIa) work as inhibitory 
molecules in fibrinolysis. Targets of anticoagulants [vitamin K antagonists (VKAs), heparins, direct thrombin inhibitors (DTIs) 
and factor Xa inhibitors (FXaIs)] and thrombolytic drugs [t-PA, PAI-1 inhibitors (PIs) and TAFI inhibitors (TIs)] are also 
indicated. RBCs; red blood cells.  
1.1.1. The coagulation system 
The coagulation system is a network of sequentially interacting coagulation factors which ultimately 
leads to the formation of a stable blood clot/thrombus. The current “cell-based three phase coagulation 
model” of the coagulation highlights (a) tissue factor (TF) as the major regulator of thrombus formation 
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(initiation phase), (b) the necessity of the rapid amplification of thrombin generation for development of 
stable clot (amplification phase) and (c) the simultaneous involvement of cellular elements (activated 
platelets) and coagulation factors in stabilization of a hemostatic plug (propagation phase) [7]. A 
hemostatic plug is formed due to the earliest response to vessel wall injury and involves vWF- and 
fibrinogen-mediated anchoring of platelets to vessel wall at site of injury. Coagulation/thrombogenesis 
is initiated by release of TF into the circulation either from the activated/damaged endothelium or from 
activated platelets followed by excitation of coagulation cascade leading to formation of a stable clot 
that contains a network of polymerized fibrin with aggregated platelets (Fig. 1.1 and Fig. 1.2)[7, 8].  
 
Figure 1.2: The cell-based three phase coagulation model (adapted from Adams and Bird [7]). Figure represents three 
phases of coagulation. (1) Initiation phase: exposure of TF to circulation leads to complexation of TF-FVIIa on plasma 
membrane of cells within vascular wall (smooth muscle cells and fibroblasts). Small amounts of FIXa, FXa and thrombin are 
formed due to antagonistic effect of tissue factor pathway inhibitor (TFPI). (2) Am plification phase: generation of FIXa:FVIIIa 
and FXa:FVa complexes on the plasma membrane surface of Plt results into a thrombin burst. (3) Propagation phase: the 
thrombin burst leads to generation and stabilization of fibrin blood clot. 
BM: basal membrane; Endo: endothelium; Plt: blood platelet; PS: phosphatidyl serine, TF: tissue factor; vWF: von Willebrand 
factor.  
During initiation phase generation of thrombin is limited by formation of inactive 
TF:FVIIa:FXa:TFPI complex resulting in very low concentration of thrombin. However, generation of 
this little amount of thrombin is sufficient enough to activate FV and FVIII to form FIXa:FVIIIa and 
FVa:FXa complex essential for thrombin burst and to push the coagulation process into amplification 
phase. Co-localized FXa:FVa and FIXa:FVIIIa complexes on plasma membrane of blood platelets in 
the presence of Ca
++
 as well as FIX-mediated positive feed-back of thrombin on self generation 
significantly amplifies the thrombin generation. Generated thrombin is now able to further activate FIX 
and to release more FVIIIa from its complex with von Willebrand factor (vWF), resulting into stable clot 
formation. vWF is also involved in platelet adhesion and FVIII stabilization. Moreover, thrombin-
mediated platelet activation also leads to sensitization of platelet receptor glycoprotein IIb/IIIa (a 
receptor for fibrinogen and vWF) and degranulation of α-granules which are responsible for enhanced 
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platelet aggregation and thus acceleration of the clot formation. Finally, during the propagation phase 
more platelets are conscripted to the site of injury to provide the proper localization of vital 
components like Ca
++
, intrinsic tenase complex, prothrombinase complex and a phospholipid surface 
for efficient thrombin generation. Thrombin converts fibrinogen into fibrin and also activates FXIII 
which can be covalently crosslinked to fibrin strands. This results into generation of stable insoluble 
fibrin blood clot. In addition, activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) also 
protects the clot from plasmin-mediated degradation [7, 9].  
1.1.2.  The fibrinolytic system 
Fibrinolysis is initiated, when plasminogen is converted into plasmin by tissue-type plasminogen 
activator (t-PA) and urokinase-type plasminogen activator (u-PA), present in the blood. In response to 
venous occlusion, endothelial cells release t-PA which is primarily involved in the dissolution of fibrin 
blood clot. u-PA is synthesized in a variety of cell-types including monocytes/macrophages, 
trophoblasts and epithelial cells and is mainly involved in pericellular proteolysis. Proteolytic cleavage 
of fibrin by plasmin generates C-terminal lysine residues which work as a cofactor for the 
plasminogen-plasminogen activator complex, thereby stimulating plasmin generation and augmenting 
fibrinolysis (Fig. 1.1). This positive feedback mechanism is regulated by activated thrombin activatable 
fibrinolysis inhibitor (TAFIa) which removes C-terminal lysine residues from the surface of partially 
degraded fibrin, thereby abolishing its cofactor function, impeding plasmin formation and attenuating 
fibrinolysis. Plasminogen activation is also regulated by Plasminogen Activator Inhibitors-1 (PAI-1) and 
α2-antiplasmin (α2-AP). PAI-1 directly inhibits t-PA and u-PA. α2-AP forms an inactive complex with 
free circulating plasmin, whereas fibrin-bound plasmin remains protected from inhibition by α2-AP [7, 
10-12]. Although human and mouse share a conserved fibrinolytic system, however, some 
interspecies differences exists. Higher resistance of mouse clots to lysis with t-PA compared to human 
clots is probably due to a shorter plasma half-life of mouse t-PA (6.5 min vs. 80 min for mouse and 
human t-PA, respectively). Resistance of mouse plasminogen to t-PA-mediated activation is also 
observed [13].  
1.1.3.  Thrombosis 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide (17.3 million deaths 
annually; 30% of total deaths worldwide) [14]. Myocardial infarction (MI), stroke and venous 
thromboembolism (VTE) are ranked among the top three leading cause of death associated with 
CVDs and are the consequences of thrombosis. Thrombosis is the formation of localized blood clot 
i.e., thrombus due to excessive coagulation/thrombogenesis in the artery (arterial thrombosis: MI and 
strokes) or in the vein (venous thrombosis: deep vein thrombosis and pulmonary embolism) [1]. The 
formation of a localized thrombus results into a blockage of artery or vein and thus prevents blood flow 
to the organ, leading into cell necrosis and loss of organ function. Therefore, thrombosis represents a 
pathological condition. Arterial thrombi/white thrombi are formed near unstable atherosclerotic plaque 
(composed of foam cells and lipids) after rupturing of endothelium and are mainly composed of 
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platelets. Venous thrombi/red thrombi are a result of alterations in blood vessel, blood flow and/or 
blood composition and mainly composed of fibrin and red blood cells [1, 3, 4, 7, 8]. 
 
 
 
Figure 1.3: Targets of antiplatelet drugs (adapted from Mishra et al. [6]). Platelet activation (panel A) and 
adhesion/aggregation (panel B) is mediated by a variety of cell-surface receptors (black rectangles on cell membrane). The 
ligands for these receptors are shown in front of them (oval or square). Targets of antiplatelet drugs include ADP receptor 
P2Y12, protease-activated receptor 1 (PAR1), thromboxane A2 (TXA2), cyclic nucleotide phosphodiesterase III (PDEIII) and 
αIIbβ3-integrin. 
The currently available antithrombotic therapy targets coagulation by inhibition of platelet 
activation/aggregation, by inhibition of coagulation factors and/or by stimulation of fibrinolysis by 
profibrinolytics. Antiplatelet drugs target platelet activation (thromboxane inhibitors; Aspirin and ADP 
receptor antagonist; Clopidogrel) and platelet aggregation (αIIbβ3-integrin inhibitors or GpIIb/IIIa 
inhibitors; abciximab) (Fig. 1.3). Anticoagulant therapy is mainly used for the management of venous 
thrombosis. Vitamin K antagonists (warfarin), heparins, direct FXa inhibitors (rivaroxaban) or direct 
thrombin inhibitors (Argatroban and Dabigatran) are the main drugs used in this class (Fig. 1.1). 
Plasminogen activators like streptokinase and genetically modified t-PA (alteplase, reteplase, 
tenecteplase) are used as thrombolytic or profibrinolytic drugs for treatment of acute thrombotic 
events. However, timing of intercession i.e. within 4.5 hours after the onset of symptoms for MI and 
stroke is a critical factor for the success of the therapy. Infusion of t-PA is often associated with 
bleeding complications. [1, 7, 8, 15, 16]. 
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1.2. Thrombin Activatable Fibrinolysis Inhibitor (TAFI) 
Thrombin activatable fibrinolysis inhibitor (TAFI) has been defined as an important regulator of 
fibrinolysis and is polyonymous in literature: plasma procarboxypeptidase B (proCPB), arginine 
procarboxypeptidase R (proCPR) and unstable procarboxypeptidase U (proCPU) as identified by 
independent research groups about 20 years ago [17-21]. 
1.2.1.  Properties of TAFI 
1.2.1.1. TAFI synthesis and distribution 
In humans, TAFI is encoded by CPB2 gene which is located on chromosome 13 (13q14.11) and 
spans 48 kb of genomic DNA. The CPB2 gene contains 11 exons which transcribes into a 1.7 kb 
long transcripts encoding 423 amino acids [22, 23]. However, alternative splicing of mRNA encoding 
TAFI can also synthesize intracellular proteins without TAFIa activity in different cell types [24]. 
Nineteen single nucleotide polymorphisms (SNPs) have been recognized in the CPB2 gene, out of 
which only six SNPs are located in the coding region of TAFI. Out of these six SNPs only two 
(+505G/A and +1040C/T) of them resulted in an amino acid substitution corresponding to a 
147AlaThr and 325ThrIIe polymorphism, respectively, resulting in four TAFI isoforms (TAFI-A
147
-
T
325
, TAFI-A
147
-I
325
, TAFI-T
147
-T
325
 and TAFI-T
147
-I
325
) [25]. 
Human TAFI is a prepropeptide of 423 amino acids, which is separately synthesized in the 
liver and megakaryocytes as indicated by the differences in their glycosylation pattern [19, 26-28]. 
After the cleavage of the 22 amino acid signal peptide (Met
1
-Ala
22
), a 401 amino acid TAFI propeptide 
(Phe
1
-Val
401
) is secreted into the circulation as the highly glycosylated 56 kDa plasma zymogen. In 
blood, two different pools of TAFI, i.e. the plasma pool (liver-derived) and the platelet pool 
(megakaryocytes-derived) are present. The platelet pool is only secreted from α-granules upon 
platelet activation and contributes only 0.1% (50ng/10
9
 platelets) of the total amount of TAFI present in 
the plasma. However, the concentration of TAFI inside the platelet is of the same order of magnitude 
as that in the plasma. Platelet-derived TAFI and liver-derived TAFI have comparable biochemical and 
enzymatic properties related to its activation, TAFIa instability and inhibition by TAFIa inhibitors except 
the glycosylation pattern which is also reflected in the difference between their molecular mass (50 
kDa vs. 56 kDa for platelet- and plasma-derived TAFI, respectively). Liver-derived TAFI contains five 
potential N-glycosylation sites (Asn
22
, Asn
51
, Asn
63
, Asn
86
 and Asn
219
) which except for Asn
219
 are 
always glycosylated [29]. In plasma, TAFI circulates at a concentration range between 73-275 nM 
which corresponds to 4-15 µg/ml [30, 31]. The large variation in plasma concentration of TAFI might 
be the result of (a) the effect of some SNPs on mRNA stability and TAFI gene expression, (b) non-
genetic factors (cytokines, hormones and diseases) involved in TAFI gene expression and (c) the 
different reactivity of the 325ThrIle polymorphism in different commercially available ELISAs [25, 32, 
33].  
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A recent study also reported the presence of CPB2 mRNA in various human non-hepatic cell 
types (macrophages, megakaryocytes, monocytes, human peripheral blood mononuclear cells and 
arterial and venous endothelial cells) along with hepatic cells. However, no TAFI expression was 
detected in these cells except for macrophages [27]. Alternative splicing of mRNA encoding TAFI may 
be an explanation for the presence of CPB2 mRNA without TAFI expression in various cell-types [24]. 
Human and mouse TAFI not only share 85% amino acid sequence identity but also show 
conservation of important residues involved in substrate binding, glycosylation and zinc binding. Both 
TAFI have similar biochemical characteristics with respect to their activatability and their antifibrinolytic 
effect. TAFI levels in mouse plasma are 2-6 µg/ml,which is comparable to those in human plasma. 
Therefore, it can be concluded that TAFI pathways are conserved in human and mouse and 
conclusions depicted from mouse models can in most cases be extrapolated to humans [34-36]. 
 
Figure 1.4: TAFI activation and inactivation (adapted from Marx et al. [37]). TAFI can be activated by thrombin, the T/TM 
complex or plasmin by proteolytic cleavage at Arg92, resulting in the release of highly glycosylated activation peptide (20kDa) 
and generation of TAFIa (36kDa). TAFIa reveals an intrinsic temperature dependent instability and converted into inactive 
TAFIai due to conformational changes. TAFIai is further proteolytically cleaved into two fragments of 25kDa and 11kDa each. 
Alternatively, plasmin can also cleave TAFI at Lys327 and Arg330, resulting in a truncated inactive form of TAFI (45 kDa) which 
can be further cleaved at Arg92 and Arg302 leading to the generation of two fragments of 25kDa and 20kDa each. 
1.2.1.2. TAFI activation and TAFIa instability 
TAFI can be proteolytically activated by trypsin-like serine proteases such as thrombin, the thrombin-
thrombomodulin (T/TM) complex and plasmin in vitro by cleavage at Arg
92
 [38, 39] (Fig. 1.4), resulting 
into the release of the activation peptide (Phe
1
-Arg
92
, 20kDa) from TAFIa (Ala
93
-Val
401
, 36 kDa) which 
allows access of large macromolecular substrate like fibrin to the active site of the enzyme [40]. While 
thrombin promptly activates TAFI, the T/TM complex activates TAFI with a 1250-fold higher catalytic 
efficiency compared to thrombin alone [38, 41] and therefore the T/TM complex is supposed to be the 
most important physiological activator of TAFI as suggested by some in vitro [42, 43] and one in vivo 
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analysis [44]. However, the T/TM complex could only activate TAFI at the endothelium as TM is only 
located on the surface of endothelial cells [45, 46]. However, often the fibrin-rich clot, where TAFIa 
regulates fibrinolysis extends away from the endothelium. Since, only very small amounts of TAFIa are 
needed to attenuate fibrinolysis [20, 47], the contribution of other TAFI activators in the regulation of 
fibrinolysis within the clot cannot be precluded. Plasmin was also shown to activate TAFI in vitro and is 
a stronger activator of TAFI than thrombin [37, 39]. In presence of glycosaminoglycan like heparin the 
catalytic efficiency of plasmin increased 16-fold which still remained 10-fold lower than the T/TM 
complex.  
TAFIa is an unstable enzyme with half life (t1/2) of 8 and 15 min at 37°C depending on the 
polymorphism at position 325 (Thr
325 
vs. Ile
325
) [48, 49]. The half-life of TAFIa also correlates with its 
anti-fibrinolytic effect [49, 50]. The antifibrinolytic effect of TAFIa is regulated by its intrinsic thermal 
instability [17, 51] which results in inactivation TAFIa into TAFIai due to conformational changes. The 
induced conformational changes also make the catalytic domain more vulnerable to proteolysis by 
thrombin, the T/TM complex and plasmin at Arg
302
 which is further cleaved into two fragments of 25 
kDa and 11 kDa (Fig. 1.4). In addition, plasmin can also cleave TAFI at Lys
327
 and Arg
330
 and therefore 
a truncated ~45 kDa inactive form of TAFI can also be generated. The activation peptide from this 
truncated form can still be cleaved by thrombin, the T/TM complex or plasmin, but this fragment will no 
longer be able to form an active fragment. Several mutations that enhance the half-life of the TAFIa 
have been identified [48, 49, 52, 53] and a TAFI-ACIIYQ variant (TAFI-A147-S305C-T325I-T329I-
H333Y-H335Q) was engineered with ~180-fold increased TAFIa half-life [53] (Fig. 1.5B). The 
enhanced thermal stability of the enzyme also reflects into the increased functionality of the enzyme.  
1.2.1.3. TAFI structure 
TAFIa belongs to the zinc metallocarboxypeptidase A family of proteins (TAFIa; EC 3.4.17.20) [19, 
54]. Using the search command thrombin activatable fibrinolysis inhibitor in the protein data bank 
(PDB) 24 structural hits were retrived. Out of which only five entries were for human TAFI/ human 
tissue procarboxypeptidase B whereas the others were related to bovine TAFI and porcine pancreatic 
carboxypeptidase B. Out of five PDB entries 1KWM was for human tissue procarboxypeptidase B 
which shares 42% sequence identity with human TAFI and TAFI structure was simulated from human 
tissue procarboxypeptidase B. Rest four entries were for human TAFI (Table 1.1). The latest structure 
(3LMS) from by Sanglas L et al. (2010) was for TAFIa and not for intact TAFI and entry 3D67 was for 
intact TAFI in complex with GEMSA. Superimposition of 3D67 and 3LMS on 3D66 (intact TAFI) do not 
reveal any deviation from the structure 3D66. Since throughout the thesis intact TAFI is refered, 
therefore, 3D66 is used as a representative structure of TAFI in the thesis.  
The intact TAFI can structurally be divided into two domains : (1) highly glycosylated N-
terminal activation peptide (Phe
1
-Arg
92
, 20kDa) composed of two α-helices and four β-strands (Phe1-
Val
76
) with a partially helical linker (Glu
77
-Arg
92
) and (2) the catalytic domain (Ala
93
-Val
401
; 36 kDa), 
composed of a central β-sheet surrounded by nine α-helices [55] (Fig. 1.5A). Glycosylation (9.4 kDa) 
contributes approximately to 50% and 17% of the molecular weight of the activation peptide and the 
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intact TAFI, respectively. Three disulphide bonds (Cys
156
-Cys
169
, Cys
228
-Cys
252
 and Cys
243
-Cys
257
) 
presented in the catalytic region are responsible for intra-chain linkage [56]. The catalytic domain also 
comprises the dynamic flap (Phe
296
-Trp
350
) which is responsible for instability of TAFI. The crystal 
structure of TAFI reveals the existence of hydrophobic interactions between the dynamic flap (Tyr
341
) 
and the activation peptide (Val
35
 and Leu
39
) which stabilize TAFI in its intact conformation (Fig. 1.5A) 
[55]. TAFI activation leads to disruption of these stabilizing interactions and hence results in the 
enhancement of the mobility of the dynamic flap region, which induces an irreversible conformational 
change in TAFIa. This not only leads to the disruption of the catalytic site (TAFIai) but also to the 
exposure of the thrombin and the plasmin cleavage site (Arg
302
) and consequently to further proteolytic 
degradation of TAFIai (Fig. 1.4). In the catalytic pocket, the catalytic Zn
++
 is coordinated by residues 
His
159
, Glu
162
 and His
288 
(Fig. 1.5B). Residues Asn
234
, Arg
235
 and Tyr
341
 are important for substrate 
binding and residues Arg
217
 and Glu
363
 are involved in hydrolysis. 
Table 1.1: Summary of all the TAFI structures reported in PDB. 
Structure Ligand PDB ID Resolution Author Year 
TAFIa TCI 3LMS 2.5 Å Sanglas et al. [203] 2010 
TAFI wt  3D66 3.1 Å Brondijk et al. [55] 2008 
TAFI  GEMSA 3D67 3.4 Å Brondijk et al. [55] 2008 
TAFI-IIYQ  3D68 2.8 Å Brondijk et al. [55] 2008 
Tick-derived funnelin inhibitor, TCI 
1.2.2. (Patho-)physiological functions of TAFI 
TAFIa has distinct biochemical characteristics and therefore is involved in a wide range of 
physiological processes. Recent studies revealed that along with fibrin, TAFIa also has a substrate 
specificity towards anaphylatoxins (C3a, C5a), annexin ll, bradykinin, and thrombin cleaved 
osteopontin and thus indicating its possible role in blood pressure, cell migration, inflammation and 
sepsis [25, 57-61]. However, the best studied physiological function of TAFI is its regulatory role in 
fibrinolysis.  
1.2.2.1. TAFI as an antifibrinolytic agent 
Fibrinolysis starts when t-PA and/or u-PA converts inactive plasminogen into active plasmin, a major 
component of fibrinolysis. Upon partial degradation of fibrin by plasmin, the C-terminal lysine residues 
of fibrin get exposed on the surface of the fibrin blood clot and stimulate further plasmin generation by: 
(a) increasing the affinity of plasminogen for partially degraded fibrin leading to enhancement of 
plasmin generation, (b) stimulating plasmin to convert Glu-plasminogen to Lys-plasminogen which is a 
superior substrate for t-PA, and (c) protecting plasmin from inactivation by α2-AP (Fig. 1.6). However, 
TAFIa removes these lysine residues from fibrin blood clot and regulates fibrinolysis through a 
negative feedback mechanism [62]. 
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Figure 1.5: Ribbon diagram of the human TAFI structure (based on the crystal structure of Marx et al. [55]). The 
activation peptide, the catalytic domain and the dynamic flap region (residues 296-350) is shown in grey, green and cyan, 
respectively. (A) The thrombin (Arg92 and Arg302) and the plasmin (Arg92, Arg302, Lys327 and Arg330) cleavage sites are shown 
as white spheres. Residues involved in the glycosylation (Asn22, Asn51, Asn63, Asn86 and Asn219), polymorphisms (Ala/Thr147 
and Thr/Ile325) and interactions between the dynamic flap (Tyr341) and the activation peptide (Val35 and Leu39) are depicted as 
red, orange and yellow spheres, respectively. (B) Residues important for (in)stability (Ser305, Thr325, Thr329, His333, His335), 
hydrolysis (Arg217 and Glu363), substrate binding (Asn234, Arg235 and Tyr341) and zinc binding (His159, Glu162 and His288) are 
shown in orange, magenta, yellow and blue spheres, respectively. 
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Figure 1.6: TAFIa in regulation of fibrinolysis (adapted from Leurs and Hendriks [63]). Binding of plasminogen (Plg) 
and t-PA to the internal lysine residues ( ) on the surface of fibrin blood clot leads to the generation of plasmin (Pln). α2-AP 
inhibits the free circulating plasmin but fail to inhibit fibrin bound plasmin. The fibrin bound plasmin starts degradation of the 
fibrin clot resulting in the exposure of more C-terminal lysine residues ( ) which act as a cofactor for plasminogen-t-PA 
complex resulting into a plasmin burst. TAFIa abolishes this cofactor function by removal of the C-terminal lysine residues 
( ) and thereby downregulates fibrinolysis. 
Regulation of fibrinolysis by TAFIa is a threshold-dependent phenomenon as fibrinolysis is 
only abrogated till the concentration of TAFIa is above a particular threshold level [64]. As soon as the 
concentration of TAFIa goes below this level, exponential increase in C-terminal lysine residues on 
fibrin takes place which boosts plasmin formation and speeds up fibrinolysis. The critical threshold 
level of TAFIa is directly proportional to the plasmin concentration which is dependent on the rate of 
plasminogen activation and therefore correlated with the concentrations of t-PA and plasmin inhibitors 
(α2-antiplasmin, α2-macroglobulin and antithrombin). The duration above the threshold concentration 
of TAFIa is also associated with the plasma TAFI concentration, the extent of its activation, and its 
stability. A very small amount of TAFIa (1-5 nM, < 2% of the total plasma concentration of TAFI) is 
enough to attenuate fibrinolysis and therefore a slow and continuous rate of TAFI activation should 
provide a better regulation of fibrinolysis than a massive but short-lived burst of TAFIa [64, 65].  
The TAFI zymogen also exhibits carboxypeptidase activity which has a 41-fold lower catalytic 
rate and a 2-fold higher substrate affinity, resulting into an 18-fold lower catalytic efficiency than TAFIa 
[66]. However, the contribution of TAFI zymogen in the down-regulation of fibrinolysis is a matter of 
debate. The prolongation of clot lysis by the TAFI zymogen in a t-PA-induced clot lysis assay in 
presence of TAFIa inhibitors (potato tuber carboxypeptidase inhibitor; PTCI or guanidinoethyl-
mercaptosuccinic acid; GEMSA) was previously demonstrated [67], suggesting that the TAFI zymogen 
can regulate fibrinolysis. However, in another study using snake venom batroxobin as an alternative 
for thrombin for clot induction, but without TAFI activation properties, no prolongation in t-PA-induced 
clot lysis was observed indicating no role of the TAFI zymogen in the regulation of fibrinolysis [68]. The 
contradicting results (PTCI or GEMSA vs. batroxobin) may be attributed to the differences in the clot 
induction in both experiments [67]. Later it was proposed that due to limited accessibility of the 
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catalytic cleft of the TAFI zymogen, TAFI can only cleave efficiently small substrates but no longer 
substrates like plasmin-modified partially degraded fibrin [40].  
1.2.2.2. Role of TAFI in thrombotic diseases  
Some epidemiological studies revealed a positive correlation between elevated plasma TAFI levels 
and increase in the risk of thrombotic tendencies [69, 70] while some contradicted these findings i.e. 
reported no or even a negative correlation [63, 71-74]. This can be explained by the fact that the 
majority of these studies used poorly characterized activity based or antigen-based (ELISAs) assays 
without including generalized standards/calibrator and reference samples in their assays. Due to 
different reactivity of the different TAFI isoforms, ELISAs used in these studies were also not able to 
measure TAFI concentrations accurately [33]. Furthermore, application of well characterized assays 
which can differentiate among the activation peptide, TAFIa and total TAFI seem to correlate TAFIa/ 
activation peptide concentrations with thrombotic events [75-77] .  
In addition to the epidemiological studies, both genetic and pharmacological inhibition 
approaches have also been used to investigate the in vivo role of TAFI in different thrombosis models. 
Studies revealed that TAFI deficient mice (TAFI KO) have a comparable phenotype as wild-type (WT) 
mice and showed only an enhanced fibrinolysis in ex vivo rotational thromboelastometry and in an in 
vivo mouse thromboembolism model [78]. Several studies using TAFI KO mice like a batroxobin-
induced pulmonary embolism model,which showed a reduced accumulation of I
125
-fibrin in the lungs of 
TAFI KO mice [79] and a FeCl3-induced thrombosis model which illustrated reduction in thrombus size 
and weight [80] correlated TAFI deficiency with fibrinolytic enhancement. Similarly, pharmacological 
inhibition of TAFI using the monoclonal antibody (MA) MA-TCK26D6 in a mouse thromboembolism 
model also revealed a decreased fibrin deposition in the lungs of mice upon administration of MA-
TCK26D6 [81]. However, in a photochemical injury model of arterial thrombosis no difference 
concerning time to thrombus formation as well as rate of spontaneous reperfusion due to a reduction 
in thrombus size was observed in TAFI KO and WT mice [82]. Moreover, in different other thrombosis 
models also intravenous injection of various thrombotic agents such as factor X, LPS and thrombin 
etc. have not resulted in significant increase in survival rate or significant reduction in fibrin deposition 
in lungs of TAFI KO mice than WT mice [82]. These contradicting results in different models may be 
ascribed to the differences in the nature of the agents used to stimulate thrombogenesis, their strength 
as well as the spatial localization of thrombus. However, despite different contradictory results in different 
thrombosis models the general conclusion inclined towards an improved fibrinolytic activity upon TAFI 
inhibition (Table 1.2) [60, 83].  
1.2.3.  TAFI inhibition 
1.2.3.1. Direct inhibition of TAFIa or prevention of TAFI activation 
TAFI/TAFIa [TAFI(a)] is a putative target to develop profibrinolytic drugs. No physiological inhibitors of 
TAFI(a) are reported till date. Immense research have been carried out to discover TAFI(a) inhibitors. 
TAFIa can be inhibited by chelating agents (o-phenantroline and EDTA), reducing agents 
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(dithiothreitol and 2-mercaptoethanol) and small synthetic substrate analogues like MERGETPA (DL-
2-mercaptomethyl-3-guanidinoethyl-thiopropanoic acid), GEMSA (guanidinoethyl-mercaptosuccinic 
acid) and ε-aminocaproic acid (ε-ACA) [63]. However, a cross-reactivity for other plasma 
carboxypeptidases like CPN and low oral bioavailability due to high polarity are the two main 
disadvantages of these small substrate inhibitors [62]. Efforts have been made to identify synthetic 
TAFIa inhibitors with higher potency, favourable pharmacokinetic properties (absorption, distribution 
and clearance) and less cross-reactivity toward CPN [62, 84]. However, interaction with pancreatic 
carboxypeptidase B remained associated with these synthetic inhibitors. Naturally occurring TAFIa 
inhibitors with high selectivity for TAFIa such as potato tuber carboxypeptidase inhibitor (PTCI), leech 
carboxypeptidase inhibitor (LCI) and tick carboxypeptidase inhibitor (TCI) have also been identified. 
However, the biphasic effect of some reversible TAFIa inhibitors (PTCI, GEMSA and a nanobody) in in 
vitro clot lysis eclipsed their benefits [85, 86]. The biphasic effect of reversible TAFIa inhibitors can be 
defined as their ability to enhance fibrinolysis at higher concentrations but to prolong clot lysis at lower 
concentrations. The antifibrinolytic effect of these inhibitors at low concentrations can be attributed to 
their capability to stabilize TAFIa [85, 87]. In the presence of low concentrations of a reversible 
inhibitor, when free TAFIa is irreversibly inactivated to TAFIai, the bound form that is protected against 
inactivation replenish the plasma pool due to shift in the equilibrium whereas at higher concentrations 
of inhibitor the equilibrium is driven toward its bound form resulting in the reduction of free TAFIa 
levels below the threshold.  
Alternatively, MA have been established as candidate drug molecules in different disorders 
with high potency, selectivity and desired pharmacokinetic properties. To prevail over the problem of 
non-selectivity of several TAFI inhibitors, various extremely selective monoclonal antibodies (MA) and 
nanobodies either inhibiting TAFI activation by different mechanisms or directly interfering with TAFIa 
activity have been produced [44, 86, 88-90]. MA-T9H11 and MA-RT30D8 directly inhibit human or rat 
TAFIa [88, 89] whereas MA-TCK26D6 inhibits plasmin-mediated activation of human, rat and mouse 
TAFI [81]. MA-T12D11 and mAbTAFI/TM#16 selectively inhibit T/TM-mediated human TAFI activation 
[44, 88]. Furthermore, to reduce immunogenicity of mouse antibodies in humans single-chain variable 
fragments (scFvs) derived from MA against TAFI were constructed, which in most cases revealed 
similar inhibitory properties as their parental MA [91].  
1.2.3.2. In vivo TAFI regulation 
Recent in vivo studies suggest that the use of TAFI(a) inhibitors as an adjuvant therapy next to the 
standard thrombolytic drugs can potentially reduce the therapeutic dose of thrombolytic drugs and 
thereby the risk of associated bleeding. Some in vivo studies reported no positive effect of genotypic 
(TAFI KO) or pharmacological (PTCI) inhibition of TAFI in various arterial and venous thrombosis 
models (Table 1.2) [78, 80, 82, 92, 93]. However, several in vivo studies reported an enhanced 
fibrinolysis in TAFI KO mice (Table 1.2). Similar results were also observed in various arterial and 
venous thrombosis models during pharmacological inhibition of TAFI in combination with low t-PA 
concentrations (exogenous fibrinolysis) [78, 81, 92, 94-97]. However, for the prevention of thrombotic 
events the application of TAFI inhibitors as single therapeutics to enhance endogenous fibrinolysis is 
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under debate. In various arterial and venous thrombosis models administration of TAFI(a) inhibitors 
reported to enhance endogenous/spontaneous fibrinolysis [44, 79, 80, 93, 94, 98-102]. MA-TCK26D6 
which inhibits plasmin-mediated activation of TAFI and mAbTAFI/TM#16 which inhibits T/TM-mediated 
activation of TAFI have been shown to accelerate fibrinolysis when administered in mouse 
thromboembolism model and E.coli-induced sepsis model in baboons, respectively [44, 81]. Moreover, 
increased plasmin-(α2-AP) levels in plasma of thromboembolism-induced mice in presence of MA-
TCK26D6 also suggest an augmented fibrinolysis [81]. Administration of PTCI even after thrombus 
formation was also able to increase fibrinolysis in a FeCl3–induced vena cava mouse thrombosis 
model but only in mild thrombogenic conditions [93]. Therefore, it can be concluded that TAFIa 
regulates fibrinolysis in in vivo arterial and venous thrombosis models and that the efficiency of TAFI 
inhibitors relies on the thrombogenic stimulus, localization of thrombogenesis and timing of 
intervention.  
Various companies have patented a variety of small molecule TAFIa inhibitors for the 
management of various pathological conditions associated to TAFI inhibition and some of them are 
already in different phases of clinical trials [103]. However, the potency, specificity, toxicity and 
bioavailability of a TAFI(a) inhibitor in clinical settings are still a concern. Based on limited information 
available related to the clinical application of TAFI(a) inhibitors, it can be said that more potential 
candidates are required to further proceed in clinical trials. 
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Table 1.2: Different thrombosis models used to evaluate the role of TAFI deficiency/inhibition in fibrinolysis. 
Animal Model Fibrinolysis Inhibitors Parameters Effect Ref 
A: No effect of TAFI deficiency or pharmacological inhibition on fibrinolysis 
TAFI KO 
vs. WT 
mouse 
3.5% FeCl3-induced 
carotid artery thrombosis 
Endogenous /PTCI Blood flow  [80, 93] 
Rose Bengal induced 
carotid artery thrombosis 
Endogenous  Occlusion time  [82] 
Rose Bengal induced 
jugular vein thrombosis 
Endogenous  Occlusion time  [82] 
Tail bleeding Endogenous  Blood loss  [82] 
Thrombin-induced 
thromboembolism 
Endogenous  Survival rate  [82] 
Factor X-induced 
thrombosis 
Endogenous  Survival rate and 
kidney fibrin 
deposition 
 [82] 
LPS-induced septic shock 
model 
Endogenous  Survival rate  [82] 
Tail bleeding Endogenous  Bleeding time  [78] 
FeCl3-induced mesenteric 
thrombosis 
Endogenous  Occlusion time  [78] 
Rat Tail bleeding time Exogenous PTCI Bleeding time  [92] 
B: Positive effect of TAFI deficiency or pharmacological inhibition on fibrinolysis 
Mouse TF-induced 
thromboembolism 
Exogenous MA-TCK26D6 Lung fibrin 
deposition 
 [81] 
TAFI KO 
vs. WT 
mouse 
Batroxobin-induced 
pulmonaryembolism 
Endogenous  I125-Fibrin 
deposition in 
lungs 
 [79] 
Tail bleeding Endogenous /PTCI Blooding time  [80, 93] 
3.5% FeCl3-induced Vena 
Cava 
Endogenous /PTCI Thrombus weight  [80, 93] 
TF-induced 
thromboembolism 
Exogenous  Lung fibrin 
deposition 
 [78] 
Rat Laser-induced femoral 
artery thrombosis 
Exogenous BX528 Reperfusion rate  [94] 
FeCl3-induced arterial 
thrombosis 
Exogenous PTCI Occlusion time  [92] 
Batroxobin/LPS-induced 
lung fibrin deposition 
Endogenous BX528 I125-fibrin 
deposition in 
lungs 
 [94] 
LPS-induced 
endotoxemia 
Endogenous EF6265 I125-Fibrin 
deposition in 
kidney and liver 
 [98] 
TF-induced 
microthrombosis 
Endogenous DD2, MERGEPTA 
and PTCI 
Glomerular fibrin 
deposition 
 [99, 100] 
Laser-induced mesenteric 
arterioles 
Endogenous PTCI Thrombus size  [101] 
Rabbit Ex vivo jugular vein model Exogenous BX528 Thormbus weight  [94] 
TF-induced Jugular vein 
thrombolysis 
Exogenous PTCI, 3-
Mercaptopropionic 
acid 
Thormbus weight  [95, 96] 
Arterial thrombolysis Exogenous PTCI Reperfusion time  [97] 
Ex vivo jugular vein 
thrombosis 
 Endogenous PTCI Fibrinolysis  [102] 
Dog FeCl2- induced femoral 
artery thrombosis 
Exogenous BX528 Reperfusion rate  [94] 
Baboon E. coli induced sepsis 
model 
Endogenous mAbTAFI/TM#16 FDP conc. and 
loss of fibrinogen 
 [44] 
LPS; lipopolysaccharide and TF; tissue factor.  
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1.3. Antibodies and Nanobodies 
Protein-based biologicals are animal- or microorganism-derived naturally occurring proteins or 
peptides such as growth hormone and insulin and are among some of the most powerful tools in 
therapy and diagnostics against infections and diseases [104, 105].  
1.3.1.  Antibodies/ Immunoglobulins 
Antibodies (Abs)/Immunoglobulins (Igs) are the largest, most versatile and fastest growing class of 
biologicals. In mammals, Abs are produced by B-cells and circulate in the human body through blood. 
Igs are an integral part of immune system which utilizes Igs to recognize, to bind, to neutralize and to 
remove foreign antigens such as bacteria, toxins or viruses form the body [106-109]. 
 
 
Figure 1.7: Structure of an antibody, and its derivatives (adapted from Holliger and Hudson [110]). (A) Heavy chains 
and light chains are represented in green and blue. Variable regions (VH and VL) are depicted in light green and light blue. 
The conserved glycosylation is indicated as CHO. Antigen binding is mediated via the Fv part of Fab. (B) A Fab fragment is 
composed of VL-CL and VH-CH1 and (C) a scFv is only one variable region of the heavy (VH) and light chains (VL) joined by 
short linker. (D) Heavy-chain antibody (HCAbs) lacks the CH1 domain as well as the light chains of antibody and (D) 
nanobody represents the variable domain of HCAbs.  
1.3.1.1. Structure and function 
Abs are Y-shape glycoproteins with a molecular weight of 150 kDa, which are composed of 4 
polypeptide chains i.e. two identical heavy chains and light chains, connected via disulfide bonds 
around a hinge region (Fig. 1.7). Both heavy and light chains contain an N-terminal variable region (VL 
or VH), which together form the fragment variable (Fv) responsible for antigen-binding and several 
constant domains (CL or CH: CH1, CH2 and CH3). CH1, CH2 and CH3 domains of the heavy chain are 
responsible for catalysis of peroxide formation; complement interaction and Fc-receptor interaction on 
phagocytes, respectively. The Fv part is composed of three hypervariable regions also known as 
complementary determining regions (CDRs), because the antigen-binding sites (paratope) are 
complementary to the epitope on the antigen (Fig. 1.8), which are altered with four framework regions 
(FR1-4). FRs act as a scaffold (comprising nine -strands organized in four- and five-stranded -
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sheets) on which CDRs are folded in canonical structures. At the C-terminal of the antibody, the 
crystallisable fragment (Fc) is located which is responsible for the maintenance of the structure as well 
as in vivo half-life of Igs. Fc also enables binding of Igs to different immunocomponents, such as 
effector cells or complement factors (C1q) via Fc receptors and mediates its effector functions such as 
antibody- and complement-dependent cell-mediated cytotoxicity (only IgG and IgM) [106, 108, 111, 
112].  
 
Figure 1.8: Comparison of VH (A) and Vhh (B) (adapted from Muyldermans [112]). VH segments of antibody and VHH 
segment of HCAbs (Vhh)/nanobody, respectively are composed of CDR1 (blue), 2 (green) and 3 (magenta) alternated with 
framework (FRs: grey). CDRs are folded on FR scaffold to form canonical structure. The hydrophilic substitutions in FR of 
Vhh are depicted in pink. A Vhh-fragment also has a longer CDR1 and 3 and an additional disulfide bridge between CDR1 
and CDR3 (light green).  
 Human Igs can be classified in five different isoforms (i.e. IgA, IgD, IgE, IgG and IgM), 
depending on the composition of their heavy chains (i.e. α, δ, ε, γ and μ, respectively) which also 
determines their size (monomeric vs. multimeric; ranging from 150-1150 kDa), antigen binding 
capability (2-12) and biological functions. Additionally, every Ab consists of either kappa (κ) or lambda 
(λ) light chains which do not have an impact on the biological function of the Igs. Widely used Abs for 
therapeutics and diagnostics belong to the most abundant class of Igs i.e. IgG [106-109]. 
1.3.1.2. Generation of antibodies 
In nature, exposure of antigen to the immune system generates two types of protective immune 
responses i.e. (a) a cell-mediated response and (b) a humoral response. In the humoral response, the 
antigen works as a stimulus for B cell activation leading to proliferation of a large number of diverse B-
cells and generation of diverse antibodies. These different antibodies differ in their affinity, selectivity, 
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binding site and functionality and in general are termed as polyclonal antibodies. Polyclonal antibodies 
are naturally produced by inoculating antigens in a suitable mammal like mouse, rabbit or goat and 
can be purified from the serum of the immunized animal using Prosep-A column. However, high 
heterogeneity, high non-relevant IgGs, limited supply and batch to batch variations limited its 
applicability as therapeutic molecule. In contrast, MA are derived from single cell line, therefore are 
monospecific in nature as it recognizes only one particular epitope and have identical affinity, 
physiochemical properties and functionality. Furthermore, it can be produced in unlimited amount with 
high reproducibility. Hybridoma technology is the first developed and most widely used technology to 
produce MA, described by Galfré and Milstein [113]. It implies the generation of mouse hybridomas by 
stable fusion of antigen producing B cells obtained after immunization of mice with the target antigen 
with immortal myeloma cells using polyethylene glycol or electrically induced fusion technique. Once 
the hybridoma cell line is formed, large amounts of MA can be produced by using celline systems. 
Hybridoma cell lines can also be cryopreserved for a very long time [108, 113, 114].  
1.3.1.3. Therapeutic antibodies 
Today MA are the most resourceful and fastest expanding class of drugs with high selectivity, stability 
and desired pharmacokinetic/phamacodynamic properties. Till date approximately 35 therapeutic MA 
are in the clinics and used for the treatment of autoimmune diseases, cancer and inflammatory 
diseases. Hundreds of more MA are in various developmental phases [115, 116]. Initially, antibody 
therapy started as serum therapy with administration of crude polyclonal in form of serum. Later, the 
advent and advancement of the hybridoma technology led to the therapeutic application of target-
specific MA. However, therapeutic application of these mouse MA was hindered due to their inability to 
trigger human effector function, short plasma half-life and a human anti-mouse antibody (HAMA) 
responses. Humanization of mouse MA (chimerization and CDR-grafting) and development of fully 
human antibodies facilitated to circumvent these problems (Fig. 1.9). In chimerization, the constant 
domain of mouse MA is exchanged with its human IgG counterparts whilst CDR-grafting involves 
grafting of the mouse CDRs onto a human Ig scaffold [115, 117, 118]. Currently fully human antibodies 
can be produced by (a) screening large recombinant antibody libraries constructed by expression of 
human antibody fragments on bacteriophages, yeasts, mRNAs or ribosomes [119], (b) fusing B cells 
acquired from transgenic mice carrying human Igs genes with mouse myeloma cells and (c) 
immortalization of human antibody-secreting cells by Epstein-Barr virus followed by fusion with a 
human myeloma celline (EBV-hybridoma technique) [120]. Another approach to prevail over the 
immunogenicity of MA is the production of smaller antibody fragments like Fab and single-chain 
variable fragments (scFvs) (Fig. 1.7). These fragments revealed in general a similar affinity like the 
parental MA but with higher tissue penetration. However, low yields and aggregation tendency are the 
major challenges involved in the production of the antibody fragments [103]. Furthermore, all above 
mentioned techniques do not result into a complete loss of the immune responses. Therefore, further 
studies are needed to develop methods to improve antibody therapy.  
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Figure 1.9: Schematic representation of strategies involved in generation of mouse, chimeric, humanized and fully 
human MA (adapted from Flego et al. [118]. Chimeric and humanized antibodies are composed of a human Ig scaffold 
with respective variable regions or CDRs from mouse origin (CDR grafting).  
EBV: Epstein Barr Virus and CpG: CG dinucleotide.  
1.3.2.  Heavy-chain antibodies and nanobody 
For a long time, Igs were supposed to be composed of four heteromeric polypeptide chains (two 
identical heavy chains and light chains each). However, in 1993 it was discovered that along with 
conventional Igs the members of the family Camelidae also express homomeric Igs consisting of only 
2 polypeptide chains known as heavy-chain antibodies (HCAbs) [121] (Fig. 1.7). Depending on the 
species, about 10-80% of their IgG repertoire consists of HCAbs [112, 122, 123]. As their name 
advocates HCAbs is composed of only two heavy chains which also lack the CH1 domain and thus 
have a lower molecular weight i.e. 90 kDa (Fig. 1.7) [99]. Due to its small size (40 Å long X 24 Å 
wide) the variable fragment of a HCAbs i.e. VHH is also referred as Vhh/nanobody (Nb). A nanobody is 
the smallest in vivo affinity-matured functional antigen-binding fragment (15 kDa) and can be 
expressed with very high yield in E. coli and yeast [110, 112].  
1.3.2.1. Structure of nanobody 
Amino acid sequence alignment analysis of VHH and VH revealed a high degree of sequence homology 
between the variable domains of a VHH and a human VH3 sub-family of Abs. Based on the DNA 
sequence homology, the VH domains of Abs can be classified in six discrete sub-families i.e. VH1- VH6 
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[124]. VH3 sub-family of Abs is the most abundant and highest thermodynamically stable human 
antibody in the natural repertoire. Only these Abs can be expressed as soluble protein with very high 
yield in bacterial systems [125]. However, there are still two noteworthy differences between Vhh and 
VH3 sub-family (Fig. 1.8). Firstly, four amino acid residues (V
42
, G
49
, L
50
 and W
52
) responsible for the 
interaction between VL and VH located in the framework region 2 (FR2) of VH3 are substituted by 
hydrophilic residues (F
42
, E
49
, R
50
 and G
52
) in VHH which results into increased solubility and stability of 
Nbs. Secondly, the CDR1 and CDR3 (13-24 amino acid in Vhh compared to 9-12 and 9-17 amino acid 
in mouse and human VH, respectively) domains of the Vhh are considerably longer than VH [126]. The 
extended CDR3 is probably an evolutionary replacement for the VL domain (antigen-binding surface). 
Furthermore, the elongated CDR3 domain is involved in the binding to the catalytic clefts and therefore 
has enzyme inhibitory properties. However, elongation of CDR3 loop also introduces high flexibility 
and thereby hampers its capability to bind to an antigen. A disulfide-bridge formed between CDR3 and 
CDR1 or FR2 stabilizes this flexibility and maintains its inhibitory function [106].  
1.3.2.2. Production of nanobody  
Like MA generation, Nb generation also requires animals (mammals) but only from the family of 
camelidae (typically alpaca or IIama). Generation of Nbs involve isolation of lymphocytes from the 
blood collected from immunized camelids, mRNA isolation from isolated lymphocytes, cDNA 
preparation and subsequent cloning of Vhh collection into a phage display vector, followed by 
selection of antigen specific Vhh by 2-4 rounds of panning [127]. Later the Vhh is cloned into 
expression vectors for production in large amounts [128-130].  
1.3.2.3. Properties of nanobody 
Usually, Nbs denature in 2.3–3.3 M guanidinium concentration at 60–80 C [131]. However, Nbs are 
robust under stringent conditions (detergents and high concentrations of urea) and resist chemical and 
thermal denaturation [132]. Even after incubation for 1 week at 37 °C, Nbs are fully active (80-100%) 
[128] and also appear to be stable up to 70°C [133]. Like MA, Nbs also get denature and lose its 
activity upon incubation at 90 °C, but unlike MA, Nbs are renaturable [134]. The stability of a Nb can 
also be increased by introducing an extra disulfide bond by inserting Cys at position 54 and 78 [135, 
136] which also resulted into generation of highly chymotrypsin- or pepsin-resistant Nbs [137]. Trypsin-
resistant Nbs have also been obtained after random mutagenesis [138]. Generation of protease 
resistant Nbs has opened the new door for oral administration of Nbs.  
The antigen-binding area of a nanobody is formed by the elongated CDR3 domain folded in a 
convex surface (Fig. 1.8) and most of the catalytic sites are harboured in a cleft. Therefore, Nbs are 
also efficient enzyme inhibitors [127, 139, 140]. Along with a direct inhibition of the enzyme, Nbs can 
inhibit an enzyme by allosteric inhibition as evident from the studies of Nbs with shorter CDR3 domain 
[141]. Where some Nbs inhibit enzyme activity, others can also activate enzymatic activity, possibly 
due to stabilization of enzyme in an open conformation [86, 90]. The small size, high stability, rapid 
clearance from blood and most important a high degree of sequence homology with human VH3
 
sequences (only 10 amino acids difference in the FR regions) reduces the risk for an immunological 
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reaction. Indeed, no immune response against the Nbs was detected in mice or humans injected with 
Nb-containing constructs [142-144]. This risk of immunogenicity can additionally be decreased by 
humanization of some residues without introducing any deleterious effect like loss of solubility, stability 
and yield etc. [145]. 
1.3.2.4. Use of nanobody  
Characteristics like a renewable/sustainable source, high affinities, specificity similar to MA, 
the unique structure, their beneficial biochemical and economic properties (size, stability, solubility, 
expression levels, reversible folding, recognition of non-conventional epitopes and production cost) 
and high sequence identity with human VH3 subfamily of antibodies encouraged researches and 
pharmaceutical and biotech companies to employ Nbs as a research tool, as diagnostics and for 
therapeutic applications. Moreover, in some cases, the large size of a conventional MA interferes with 
the access of hidden and essential epitopes on pathogenic agents, like bacteria, parasites and 
viruses. In such cases Nbs will have special advantages as therapeutics [112, 146].  
To date no Nb has been approved for therapeutic purposes. However, promising results were 
obtained for several Nbs evaluated in clinical trials (Table 1.3) [147]. In 2012, Boehringer Ingelheim 
along with Ablynx has also submitted clinical trials application for Nanobody-based Alzheimer‟s 
treatment. In addition, Nbs are also actively being investigated against scorpion toxins, antibacterial 
toxins and antisnake venom [148, 149]. However, Clinical trial phase 1 of CXCR4 inhibiting Nb ALX-
0651 as anti HIV agent for safety and effectiveness was terminated within one year [147]. So far no 
immunological response towards the nanobodies has been observed. To modify other desirable 
properties like plasma half-life and potency other nanobody engineering techniques like generation of 
bispecific or multivalent construct can be implemented. Generation of a bispecific construct towards a 
target molecule and serum albumin (ALX-0141) will extend the half-life [142] and multivalent 
constructs will increase the avidity of Nb leading to increase in its potency [149]. 
Table 1.3: Nanobodies in Clinical trial [147]. 
Nanobody Target Pathology Administration Clinical trial 
ALX-0061 IL-6R Rheumatoid arthritis  Intravenous Phase-2 
ALX-0081/ALX-0681 
(Caplacizumab) 
vWR PCI and TTP  Intravenous Phase-2 
ATN-103 ( Ozoralizumab) TNF Rheumatoid arthritis Intravenous Phase-2 
Vhh batch 203027 Rotavirus Children diarrhea Oral Phase-2 
ALX-0171 Human RSV Children RSV infection Intravenous Phase-1 
ALX-0141 RANKL 
Bone metastasis, osteoporosis and 
rheumatoid arthritis 
Intravenous Phase-1 
PCI; percutaneous coronary intervention, RSV; respiratory syncytial virus and TTP; thrombotic thrombocytopenic purpura. 
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1.4. Goal of study 
 
 The first objective was to evaluate the physiological role of the zymogen activity of TAFI in the 
regulation of fibrinolysis (Chapter 2).  
 The second objective was to identify and to characterize MA that impair the activation of TAFI 
through different working mechanisms (Chapter 3). 
 The third objective was to study the relative contribution of the different TAFI activators 
regulating fibrinolysis (Chapter 3 and Chapter 4).  
 The fourth objective was to confirm the inhibitory properties of the MA directed toward human 
TAFI in in vivo and in vitro models using hTAFI transgenic mice (Chapter 5). 
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2.1.  Abstract  
Background: Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a zymogen that can be activated by 
proteolytic cleavage into the active enzyme TAFIa. Hydrolysis of the C-terminal lysines on fibrin by 
TAFIa results in a down regulation of fibrinolysis. Recent studies demonstrated that the zymogen also 
exerts an intrinsic enzymatic activity.  
Objectives: Our objective was to identify and characterize zymogen-stimulatory nanobodies. 
Methods and results: Screening of 24 nanobodies against TAFI revealed that two nanobodies (i.e. 
Vhh-TAFI-a51 and Vhh-TAFI-i103) were able to stimulate the zymogen activity 10- to 21-fold 
compared to the baseline zymogen activity of TAFI. The increase in catalytic efficiency can be 
attributed mainly to an increased catalytic rate, since no change in KM-value was observed. The 
stability, the susceptibility towards PTCI and GEMSA and the kinetics of the stimulated zymogen 
activity differ significantly from those of TAFIa activity. Epitope mapping revealed that both Asp
75
 and 
Thr
301
 are major determinants in the binding of these nanobodies to TAFI. Localization of the epitope 
strongly suggests that this instability is due to a disruption of the stabilizing interactions between the 
activation peptide and the dynamic flap region (residues 296-350). 
In TAFI-depleted plasma reconstituted with a non-activatable variant of TAFI (TAFI-R92A), clot 
lysis could be prolonged by nanobody-induced stimulation of its zymogen activity as well as by 
increasing its concentration.  
Conclusions: Increasing the zymogen activity of TAFI results in an antifibrinolytic effect.  
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2.2.  Introduction 
Thrombin activatable fibrinolysis inhibitor (TAFI) is a 56 kDa zymogen secreted by the liver. It 
circulates in the blood at concentrations between 75 and 275 nmol/L [30, 31]. TAFI can be activated 
by thrombin, thrombin/thrombomodulin or plasmin, resulting in the activation peptide (20 kDa) and the 
TAFIa moiety (36 kDa) [20, 21, 38]. TAFIa is a carboxypeptidase and attenuates fibrinolysis by 
removing C-terminal lysines from partially degraded fibrin. This results in a down-regulation of tissue-
type plasminogen activator (t-PA) mediated plasmin generation. There are no known physiological 
inhibitors of TAFIa. Nevertheless, its activity is regulated by the thermal instability of TAFIa and 
depends on the TAFI isoform. The 147Ala/Thr polymorphism does not affect TAFIa instability, in 
contrast to the 325Thr/Ile polymorphism. The isoforms i.e. TAFIa-Ala147-Thr325 (TAFIa-AT) and 
TAFIa-Thr147-Thr325 (TAFIa-TT) have a half-life of 8 minutes whereas TAFIa-Ala147-Ile325 (TAFIa-
AI) and TAFIa-Thr147-Ile325 (TAFIa-TI) have a half-life of 15 minutes at 37°C [49]. The mechanism of 
this instability has been revealed by solving the crystal structure of TAFI [55]. An interaction between 
the activation peptide and the dynamic flap region (Phe
296
 to Trp
350
) in the TAFIa moiety stabilizes the 
conformation of TAFI. Upon activation of TAFI, the activation peptide is released, resulting in an 
increased mobility of the flap region. Consequently, TAFIa is inactivated due to conformational 
changes of the catalytic site. A few years ago, a TAFI variant TAFI-A147-C305-I325-I329-Y333-Q335 
(TAFI-ACIIYQ) was generated with a 180-fold longer half-life [53]. These mutations increase the 
interactions within the dynamic flap region and between the flap region and the stable core of the 
TAFIa moiety [151], thereby resulting in a reduced rate of conformational inactivation. The TAFIa 
stability is one of the crucial factors that influence the threshold dependent regulation of fibrinolysis. 
TAFIa inhibits fibrinolysis when its concentration is above a certain threshold which depends on the t-
PA concentration [64, 65]. 
Recently, it was reported that not only TAFIa, but also the zymogen itself exerts a 
carboxypeptidase activity [66, 152]. The TAFI zymogen has a 41-fold decreased catalytic rate in 
comparison with TAFIa. This is partially compensated by a 2-fold increased affinity for the substrate, 
resulting in an 18-fold lower catalytic efficiency [66]. There is still some controversy whether the 
zymogen activity of TAFI has a physiological role in the regulation of fibrinolysis. Valnickova et al. 
described that the down regulation of fibrinolysis by TAFI in a clot lysis assay without addition of 
exogenous thrombomodulin must be due to the zymogen activity of TAFI since nearly no TAFIa is 
generated under these conditions [66]. However, results of a study by Willemse et al. suggest that 
there was TAFIa generated under these circumstances [68]. In another study, Foley et al. suggested 
that the zymogen activity cannot attenuate fibrinolysis, since TAFI zymogen is unable to cleave fibrin 
degradation products [40]. 
Recently, we described the generation of a panel of nanobodies directed towards TAFI and 
identified nanobodies that inhibit TAFI(a) [90]. Surprisingly, among the initially generated panel, two 
nanobodies appeared to stimulate significantly the zymogen activity. In this study we report the 
characterization of these nanobodies, the properties of the stimulated zymogen activity and the effect 
of an increased zymogen activity on clot lysis. 
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2.3.  Materials and methods 
2.3.1.  Materials 
Human thrombin, human plasmin and rabbit thrombomodulin were purchased from Sigma-Aldrich, 
Enzyme Research Labs (South Bend, UK) and American Diagnostica (Greenwich, CT, USA), 
respectively. H-D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK), aprotinin, hippuryl-L-
arginine, guanidinoethyl-mercaptosuccinic acid (GEMSA) and potato tuber carboxypeptidase inhibitor 
(PTCI) were obtained from Biomol Research Labs (Plymouth Meeting, PA, USA), Fluka (Buchs, 
Switzerland), Bachem (Bubendorf, Switzerland) and Calbiochem (La Jolla, CA, USA), respectively. 
Tissue-type plasminogen activator (Actilyse®) was a kind gift from Boehringer Ingelheim (Brussels, 
Belgium). Citrated plasma of 33 healthy individuals was collected in-house with their written consent 
and was pooled for clot lysis experiments. 
2.3.2.  Methods 
2.3.2.1. Generation and purification TAFI  
Wild-type recombinant human TAFI-Thr
147
-Ile
325
 (TAFI-TI) and TAFI-ACIIYQ were produced in 
HEK293(T) cells and purified from the conditioned medium at 4 °C by affinity chromatography using 
monoclonal antibodies MA-T27G4 and MA-T4E3, respectively. All other TAFI variants were 
constructed and purified in a similar way, using MA-T27G4, as described before [88]. One mutant, 
TAFI-TI-R92A, in which Arg
92
 was replaced by Ala, was specifically designed to obtain a non-
activatable TAFI variant. 
2.3.2.2. Generation of nanobodies 
The generation of the nanobody library as well as the selection procedure through panning on TAFI-
ACIIYQ either in its intact form or in its active form, was described previously [90]. Screening of the 
anti-TAFI nanobodies (n = 24) for a stimulatory effect on TAFI zymogen activity resulted in the 
identification of the nanobodies Vhh-TAFI-a51 and Vhh-TAFI-i103.  
2.3.2.3. Evaluation of the effect of the nanobodies on the catalytic activity of the TAFI zymogen  
TAFI-TI or TAFI-TI-R92A (concentration during substrate conversion: 40 nmol/L) was incubated with 
nanobody (at a concentration ranging between 1 and 32-fold molar ratio over TAFI) for 10 min at 37 
°C, prior to incubation with Hippuryl-Arg (Hip-Arg, concentration during substrate conversion: 11.1 
mmol/L). Substrate conversion was allowed for 1 hour at 37 °C. Reactions were stopped and the 
absorbance was measured as described before [90]. To be able to express the TAFI activity in U/mg, 
a standard spanning 15.6 µmol/L to 2 mmol /L hippurate was used to quantify the amount of hippurate 
formed by TAFI [153]. One unit (U) carboxypeptidase activity is defined as the amount of enzyme 
converting 1 micromole of substrate per minute at 37 °C.  
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2.3.2.4. Stability of the stimulated zymogen activity 
TAFI-TI or TAFI-TI-R92A (concentration during substrate conversion: 40 nmol/L) was incubated in the 
absence or the presence of nanobody (16-fold molar excess over TAFI) at different time intervals 
ranging from 0 to 120 minutes at 37 °C. Substrate conversion was allowed for 1 hour at 37 °C and the 
activity was determined as described above. 
2.3.2.5. Evaluation of the effect of the nanobodies on TAFI fragmentation 
To exclude that the observed increase in activity was due to a proteolytic cleavage induced by the 
nanobodies, TAFI-TI (800 nmol/L) was incubated with nanobodies (32-fold molar excess over TAFI) at 
37 °C for 10 minutes. Sodium dodecyl sulfate (1% final concentration) was added, samples were 
heated for 30 seconds at 100 °C and subsequently analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) using PhastGel™ gradient 10-15% gels, followed by 
silver staining. 
2.3.2.6. Inhibitory effect of PTCI on the (stimulated) zymogen activity of TAFI-TI and TAFI-TI-
R92A 
TAFI-TI (concentration during substrate conversion: 40 nmol/L) or TAFI-TI-R92A (concentration during 
substrate conversion: 20 nmol/L) was incubated either with buffer or with nanobody (32-fold molar 
excess over TAFI) for 10 min at 37°C. Subsequently, either buffer or PTCI (concentration during 
substrate conversion, ranging between 0.11 and 56 μmol/L) was added and incubated for 10 min at 37 
°C. After addition of Hip-Arg (concentration during substrate conversion: 11.1 mmol/L), substrate 
conversion was allowed for 1 hour at 37 °C. From the comparison of the stimulated zymogen activity 
in the absence and presence of PTCI, the extent of inhibition of zymogen activity was calculated in 
U/mg and expressed as percentage inhibition. 
2.3.2.7. Inhibitory effect of GEMSA on the (stimulated) zymogen activity of TAFI-TI and TAFI-TI-
R92A 
TAFI-TI (concentration during substrate conversion: 40 nmol/L) or TAFI-TI-R92A (concentration during 
substrate conversion: 20 nmol/L) was incubated either with buffer or with nanobody (32-fold molar 
excess over TAFI) for 10 min at 37°C. Subsequently, either buffer or GEMSA (concentration during 
substrate conversion: ranging between 1.4 and 90 μmol/L) was added and incubated for 10 min at 37 
°C. After addition of Hip-Arg (concentration during substrate conversion: 11.1 mmol/L), substrate 
conversion was allowed for 1 hour at 37 °C. From the comparison of the stimulated zymogen activity 
in the absence and presence of GEMSA, the extent of inhibition of zymogen activity was calculated in 
U/mg and expressed as percentage inhibition. 
2.3.2.8. The effect of nanobodies on the enzymatic properties of the TAFI zymogen 
Hydrolysis of Hip-Arg by TAFI-TI was determined in the presence and absence of nanobody. TAFI 
(concentration during substrate conversion: 275 nmol/L) was incubated with nanobody (32-fold molar 
excess over TAFI) for 10 minutes at 25 °C. In the control condition, without addition of nanobody, a 
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higher concentration TAFI-TI was used (i.e. 936 nmol/L) in order to obtain measurable substrate 
conversion rates. Subsequently, Hip-Arg was added (concentrations during substrate conversion: 0.25 
– 6 mmol/L for the stimulated zymogen and 0.125 – 4 mmol/L for the control without stimulating 
nanobody) and the rate of Hip-Arg hydrolysis was monitored at 254 nm for 10 min at 25 °C. The kcat 
and KM values were determined by nonlinear regression of the data to the Michaelis-Menten equation 
[90]. 
2.3.2.9. Evaluation of the effect of zymogen activity and of nanobody-stimulated zymogen 
activity on in vitro clot lysis  
To evaluate the mere effect of the zymogen activity on clot lysis the generation of TAFIa must be ruled 
out. Therefore clot lysis experiments were designed using TAFI-depleted plasma reconstituted with the 
non-activatable variant TAFI-TI-R92A. Alternatively in control experiments TAFI-TI was added. TAFI-
depleted plasma was obtained using MA-T4E3 coupled Sepharose 4B as described earlier [154]. Clot 
lysis was performed in a 96-well microtiter plate as described previously [154] with some 
modifications. Pooled TAFI-depleted plasma (final concentration: 30%) was mixed either with dilution 
buffer (10 mM Tris, 0.01%tween 20; pH 7.5) or with TAFI variants (final concentration: 54 nM), and/or 
nanobodies (final concentration: 1728 nM, resulting in a 32-fold molar ratio over TAFI). The plate was 
incubated at 37°C for 10 min and t-PA (120 pM) was added. Then clot formation was induced by 
addition of CaCl2 (10.6 mM) and the plate was read at 2 min intervals at 405 nm at 37°C. The 50% clot 
lysis time was determined and defined as the time interval between the time point of full clot formation 
to the midpoint of the maximum turbidity to clear transition. The effect of added compounds (i.e. TAFI 
variant and/or nanobody) on clot lysis time was expressed relative to the clot lysis time of TAFI 
depleted plasma (54.5 ± 17 min). To further explore the putative effect of zymogen activity of TAFI-TI-
R92A on clot lysis, clot lysis experiments were also carried out using a five-fold higher concentration of 
this variant (final concentration: 270 nM). 
2.3.2.10. Affinity measurements 
Affinity constants for the binding between the nanobodies and TAFI-TI, either in its proenzyme form or 
in its activated form, were determined using the Biacore 3000 analytical system (Biacore AB, Uppsala, 
Sweden) equipped with a CM-5 sensor chip [90]. Nanobodies were covalently coupled to 
approximately 1200 resonance units using a concentration of 5 µg/mL nanobody in acetate buffer (10 
mmol/L; pH 4.5). TAFI-TI (either intact or activated) was diluted in HBS-EP buffer (Biacore) to 
concentrations between 5 and 200 nmol/L and injected at a flow rate of 30 µL/min. After each cycle, 
the chip was regenerated with 10 µL of 10 mmol/L glycine; pH 1.5. Analysis of the association and 
dissociation phases was performed using the Biacore 3000 software (Langmuir binding, local fit). All 
experiments were performed at least three times independently. Activated TAFI-TI was prepared as 
follows. TAFI-TI (final concentration: 804 nmol/L in Tris buffer: 20 mmol/L, 100 nmol/L NaCl; pH 7.4) 
was incubated for 10 minutes at 37 °C with CaCl2, thrombin and thrombomodulin (concentration at 
activation step: 5 mmol/L, 20 nmol/L and 5 nmol/L, respectively). The activation was stopped by 
addition of PPACK (final concentration: 30 µmol/L).  
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2.3.2.11. Statistical data analysis 
Quantitative data were summarized by mean and standard deviation obtained from at least 3 
independent experiments. Statistical significance was determined with the unpaired t-test using Graph 
Pad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA). Values were considered as 
statistically significant at two-tailed p-values smaller than 0.05. For the clot lysis experiments paired, 
two-tailed t-test was performed.  
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2.4. Results 
2.4.1. Stimulation of the zymogen activity 
The zymogen activity of TAFI-TI without incubation with nanobody was 0.12 ± 0.04 U/mg which is in 
the range of activities reported before (Table 2.1) [152, 153]. To exclude the generation of TAFIa 
activity in clot lysis experiments (see below) a non-activatable TAFI mutant (TAFI-TI-R92A) was 
generated. The activatability of this variant was 100-fold lower compared to that of TAFI-TI. The 
zymogen activity of TAFI-TI-R92A, 0.63 ± 0.11 U/mg, was 5-fold higher (p < 0.0001 versus TAFI-TI). 
Table 2.1: Effect of Nbs on zymogen activity of TAFI variants. 
 Zymogen activity of TAFI 
 No addition TAFI-Vhh-a51 TAFI-Vhh-i103 
TAFI-TI (wt) 0.12  0.04 2.07 ± 0.23 (17) 1.15 ± 0.15 (10) 
TAFI-ACIIYQ 0.17  0.14 [1.4]  3.20  0.79 (19) 2.89  1.01 (17) 
TAFI-TI-R92A 0.63 ± 0.11 [5] 13.3 ± 0.84 (21) 8.92 ± 0.28 (14) 
TAFI-ACIIYQ: stable human TAFI variant; values presented in [] represent fold change in zymogen activity of TAFI variant 
compared to TAFI-TI and values presented in () represent fold change in zymogen activity of TAFI variant in presence of Nb 
compared to no addition. 
When TAFI-TI was incubated with either Vhh-TAFI-a51 or Vhh-TAFI-i103 at a 32-fold molar 
ratio of nanobody over TAFI, the zymogen activity was stimulated significantly, resulting in an activity 
of 2.07 ± 0.23 U/mg and 1.15 ± 0.15 U/mg, respectively (Table 2.1). For TAFI-TI-R92A, a stimulation 
of zymogen activity to 13.3 ± 0.84 U/mg and 8.92 ± 0.28 U/mg, respectively, was observed. Dose-
response curves reveal that the stimulatory effect of the nanobodies is dose-dependent (Fig. 2.1). The 
zymogen activity of the stable variant TAFI-AI-CIYQ is also stimulated by these nanobodies (0.17 ± 
0.14 U/mg in the absence versus 3.20 ± 0.79 U/mg and 2.89 ± 1.01 U/mg, in the presence of a 32-fold 
molar excess of Vhh-TAFI-a51 or Vhh-TAFI-i103, respectively). 
 
Figure 2.1: Dose-dependent effect of nanobodies on zymogen activity of TAFI variants. Dose-dependent effect of Vhh-
TAFI-a51 (circles) and Vhh-TAFI-i103 (squares) on the zymogen activity of TAFI-TI (closed symbols) and TAFI-TI-R92A 
(open symbols). (Mean ± SD, n  3).  
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2.4.2. Effect of the nanobodies on TAFI fragmentation 
To exclude the generation of TAFIa activity due to activation by cleavage of TAFI-TI by the 
nanobodies, TAFI-TI was analyzed by SDS-PAGE in the absence and presence of Vhh-TAFI-a51 and 
Vhh-TAFI-i103. Only two bands were observed: one band corresponding to intact TAFI (56 kDa) and 
one band corresponding to nanobody (15 kDa). The typical 36 kDa-fragment, generated upon 
activation of TAFI, could not be observed (data not shown); indicating that incubation with the 
nanobodies does not result in an activation of TAFI to TAFIa. 
2.4.3. Stability of the (stimulated) zymogen activity 
In order to determine the stability of the zymogen activity, TAFI-TI and TAFI-TI-R92A zymogen activity 
was analyzed at different time points in the absence and in the presence of the nanobodies at 37 °C. 
Because of the low activity of unstimulated TAFI-TI zymogen it appeared impossible to evaluate the 
half-life. For zymogen activity of TAFI-TI-R92A a half-life of 19 ± 3.2 minutes was found. The 
stimulated TAFI-TI zymogen was unstable at 37 °C with half-lives of 43 ± 10 minutes and 32 ± 4.0 
minutes, for Vhh-TAFI-a51 and Vhh-TAFI-i103, respectively. Similar values were obtained for the 
stimulated zymogen activity of TAFI-TI-R92A, i.e. half-lives of 35 ± 3.1 and 36 ± 4.6 minutes, 
respectively. Evaluation of the stimulated zymogen activity of the stable TAFI variant (TAFI-ACIIYQ) in 
the presence of Vhh-TAFI-a51 and Vhh-TAFI-i103 revealed a residual activity of 85 ± 13 % and 95 ± 6 
%, respectively after 120 minutes at 37 °C, indicative for half-lives exceeding much more than 120 
minutes. 
2.4.4.  Inhibitory effect of PTCI on the (stimulated) zymogen activity 
Because of the low activity of unstimulated TAFI-TI zymogen, its inhibition by PTCI could not be 
evaluated reliably. Addition of PTCI to TAFI-TI-R92A resulted in a dose-dependent inhibition of the 
zymogen activity with an IC50-value of 3.0 ± 0.53 µmol/L. 
Addition of PTCI after stimulation of the zymogen activity of TAFI-TI by Vhh-TAFI-a51 and 
Vhh-TAFI-i103 resulted in dose-dependent inhibition of the zymogen activity with IC50 values of 15 ± 
3.9 µmol/L and 17 ± 3.5 µmol/L, respectively (Fig. 2.2A). Corresponding IC50 values for inhibition of 
stimulated zymogen activity of TAFI-TI-R92A were 0.98 ± 0.05 and 1.9 ± 0.16 µmol/L, respectively. 
IC50 values for inhibition of activated TAFI by PTCI were 0.22 ± 0.02 µmol/L, and were not affected by 
the nanobodies. 
2.4.5.  Inhibitory effect of GEMSA on the (stimulated) zymogen activity 
Because of the low activity of unstimulated TAFI-TI zymogen its inhibition by GEMSA could not be 
evaluated reliably. Addition of GEMSA to TAFI-TI-R92A resulted in a dose-dependent inhibition of the 
zymogen activity with an IC50-value of 8.1 ± 0.84 µmol/L. 
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Addition of GEMSA after stimulation of the zymogen activity of TAFI-TI by Vhh-TAFI-a51 and 
Vhh-TAFI-i103, resulted in dose-dependent inhibition of the zymogen activity with IC50 values of 5.8 ± 
0.46 µmol/L and 6.6 ± 0.67 µmol/L, respectively (Fig. 2.2B). Corresponding IC50 values for inhibition of 
stimulated zymogen activity of TAFI-TI-R92A were 15 ± 0.99 and 13 ± 1.0 µmol/L, respectively. IC50 
values for inhibition of activated TAFI by GEMSA were 283 ± 34 µmol/L and were not affected by the 
nanobodies. 
 
Figure 2.2: Effect of PTCI (A) and GEMSA (B) on stimulated zymogen activity of TAFI variants. Dose-response curve 
of inhibition by PTCI or GEMSA of the zymogen activity of TAFI-TI (closed symbols) and TAFI-TI-R92A (open symbols) 
stimulated by Vhh-TAFI-a51 (circles) and Vhh-TAFI-i103 (squares).(Mean ± SD, n ≥3). 
2.4.6.  Effect of the nanobodies on the enzymatic properties of TAFI 
Addition of Vhh-TAFI-a51 and Vhh-TAFI-i103 resulted in a significant increase of the catalytic rate 
(kcat) of Hip-Arg hydrolysis (Table 2.2). No effect was observed on KM-values. Subsequently, the 
overall catalytic efficiency (kcat/KM) of the stimulated zymogen is significantly increased. The catalytic 
rate and catalytic efficiency of the zymogen stimulated by Vhh-TAFI-a51 differ significantly from those 
observed in the presence of Vhh-TAFI-i103 (p < 0.05 and p < 0.0001, respectively). Comparison with 
the enzymatic properties of TAFIa reveals that the KM-values of the (stimulated) zymogen activity do 
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not differ significantly from the KM-values of the TAFIa activity [90] . In contrast, the catalytic rate and 
the catalytic efficiency of TAFIa are significantly (p < 0.0005) higher than those observed for the 
(stimulated) zymogen activity. 
Table 2.2: Enzyme kinetics of Hip-Arg hydrolysis by TAFI in the absence and presence of Vhh-TAFI-a51 and Vhh-
TAFI-i103  
 Km (mM) kcat (s-1) kcat /Km (mM-1 s-1) 
No addition 1.21 ± 0.69 0.175 ± 0.063 0.240 ± 0.257 
Vhh-TAFI-a51 1.19 ± 0.21 3.01 ± 0.32** 2.56 ± 0.19** 
Vhh-TAFI-i103 1.72 ± 0.60 1.93 ± 0.10** 1.13 ± 0.31* 
TAFIa† 1.21 ± 0.26 12.4 ± 2.04** 10.6 ± 1.90** 
Mean ± SD, n ≥ 3. * p < 0.001 vs. ‘no addition’, ** p < 0.0005 vs. ‘no addition’. †Data taken from [90]. 
 
Table 2.3: Effect of TAFI variants and zymogen-stimulatory nanobodies on clot lysis time in TAFI-depleted plasma 
addition Relative clot lysis time (1) p-value 
none 1   
Vhh-TAFI-a51 0,96 ± 0,08   
Vhh-TAFI-i103 0,98 ± 0,04   
TAFI-TI 5,01 ± 0,35 **  
TAFI-TI + Vhh-TAFI-a51 4,14 ± 0,51  ** † 
TAFI-TI + Vhh-TAFI-i103 4,41 ± 0,44 ** † 
TAFI-TI-R92A 1,04 ± 0,07   
TAFI-TI-R92A + Vhh-TAFI-a51 1,63 ± 0,27 *  
TAFI-TI-R92A + Vhh-TAFI-i103 1,54 ± 0,27 *  
TAFI-TI-R92A (5-fold) (2) 1,23 ± 0,06 **  
(1) Expressed as ratio of clot lysis time in the absence of any compound over clot lysis time in the presence of the indicated 
compound (see methods); Lysis time in the absence of any compound added was 55 ± 17 minutes; 
(2) Evaluated at five-fold higher concentration;  
Mean ± SD, n ≥ 3; * p < 0.05 vs. none, ** p < 0.002 vs. ‘none’, † p < 0.01 vs. TAFI-TI,  p < 0.05 vs. TAFI-TI-R92A,  p < 
0.001 vs. TAFI-TI-R92A. 
2.4.7.  Evaluation of the effect of zymogen stimulation nanobodies on in vitro clot 
lysis  
Addition of the nanobodies to TAFI depleted plasma did not affect clot lysis times (Table 2.3). As 
expected addition of TAFI-TI significantly prolonged clot lysis times. Addition of the zymogen 
stimulatory nanobodies under these conditions slightly reduced (12 to 17 %) clot lysis times. As 
expected addition of the non-activatable variant TAFI-TI-R92A did not affect clot lysis under the 
standard conditions. However the zymogen stimulatory nanobodies significantly increased (50 to 60 
%) clot lysis times in the presence of TAFI-TI-R92A. Addition of TAFI-TI-R92A at a five-fold higher 
concentration also resulted in a significant increase (20 %) of the clot lysis time (Table 2.3). It was 
verified using an ELISA specific for the released activation peptide of TAFI [155], that TAFI-TI-R92A 
was not activated under any of those conditions (data not shown). 
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2.4.8.  Epitope mapping 
Initially, all purified TAFI variants (n = 15) available in the lab were screened for their susceptibility 
towards stimulation by Vhh-TAFI-a51 or Vhh-TAFI-i103. Mutation of the following residues did not 
affect stimulation by neither of the two nanobodies: Val41, Gln45, Gly66, Ser70, Gln81, Asp87, Thr88, 
Ala95, Phe113, Arg117, His126, Glu132, Lys133, Ala148, Ile158, Tyr223, Ser305, Thr329, His333, 
His335 (data not shown). These residues are depicted in Fig. 2.3 (orange spheres). 
Strikingly, the zymogen activity of both TAFI-TI-D75N and TAFI-AI-S305C-T329I-H333Y-
H335Q-T301A (TAFI-AI-CIYQ-T301A) could not be stimulated by Vhh-TAFI-a51 and Vhh-TAFI-i103. 
Dose-response curves were performed and revealed that even at 64-fold molar excess of nanobody 
over TAFI no stimulatory effect could be observed. Both TAFI variants exerted a zymogen activity 
comparable to that of TAFI-TI and TAFI-AI-CIYQ (data not shown). 
 
Figure 2.3: Structure of TAFI and localization of screened residues. Ribbon drawing of TAFI based on the structure of 
Marx et al. with the activation peptide shown in grey, the catalytic domain in green and the dynamic flap region (residues 
296-350) in cyan [55]. Residues involved in hydrolysis, substrate binding and zinc binding are shown in magenta, yellow and 
blue spheres, respectively. The two thrombin cleavage sites are shown as white spheres. The residues for which a mutation 
did not affect the stimulatory effect of the nanobodies are depicted as orange spheres. The residues Asp75 and Thr301 for 
which mutation resulted in a loss of stimulatory effect are depicted as red spheres. 
The binding of Vhh-TAFI-a51 and Vhh-TAFI-i103 to TAFI variants was analyzed by surface 
plasmon resonance (Table 2.4). A weak binding was observed for intact TAFI-TI as well as for intact 
TAFI-AI-CIYQ with KA-values of 4.5 and 3.8 x 10
6
 M
-1
, respectively. Upon activation of TAFI, a 10-fold 
higher affinity was observed, mainly due to a 10-fold higher association rate (ka). In line with the 
Stimulation of the zymogen activity of TAFI 
 
Page | 35  
 
absence of any functional effect, no binding could be detected between the nanobodies and TAFI-TI-
D75N or TAFI-AI-CIYQ-T301A, neither before nor after activation.  
Taken together, these data suggest that both Asp
75
 and Thr
301
 (Fig. 2.3, red spheres) play a 
role in the binding of the zymogen stimulatory nanobodies to TAFI 
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2.5.  Discussion 
Until recently it was believed that TAFI needs to be activated in order to exert a carboxypeptidase 
activity. The TAFIa moiety is thermally unstable with a half-life between 8 and 15 minutes at 37°C [49]. 
It is generally accepted that this instability contributes to the regulation of the antifibrinolytic potential of 
TAFI. A few years ago, it was reported that also the TAFI zymogen exerts some carboxypeptidase 
activity. However, the physiological relevance of this activity remained a matter of debate [40, 66-68]. 
The present study demonstrates that the zymogen activity can be modulated to accept larger 
substrates, including C-terminal lysines on partially degraded fibrin and eventually resulting in an effect 
on clot lysis. 
During our efforts to look for agents that may affect TAFI or TAFIa properties, we identified two 
nanobodies that were able to stimulate the zymogen activity. To the best of our knowledge stimulation 
of the zymogen activity of TAFI by any agent has not been described yet. The identified nanobodies 
increase the zymogen activity of TAFI-TI as well as that of the non-activatable TAFI-TI-R92A variant 
10- to 21-fold compared to their respective baseline zymogen activity. However, for TAFI-TI the 
stimulated zymogen activity is still about 10 to 30-fold lower than the TAFIa activity, generated upon 
proteolytic activation of TAFI, which is about 18 to 31 U/mg [53, 153]. In contrast, for TAFI-TI-R92A, 
exhibiting a higher zymogen activity, the stimulated zymogen activity reaches values up to 13 U/mg, 
only 1.4 to 2.4-fold lower than the typical activity of activated TAFI. 
Absence of any fragmentation product upon incubation of TAFI with these nanobodies and a 
stimulatory effect on the non-activatable variant TAFI-TI-R92A demonstrates that the observed 
increase in activity can be solely attributed to an increased zymogen activity and not to the formation 
of TAFIa. Moreover, the properties of the stimulated zymogen activity (i.e. stability, susceptibility 
towards PTCI and GEMSA and kinetics) differ significantly from the properties of TAFIa activity. 
Indeed, the half-life of the stimulated zymogen activity is about 2-fold longer than the half-life of 
TAFIa at 37°C (30-40 minutes vs. 15 min) [49]. However, since the instability of the stimulated 
zymogen is also temperature dependent (i.e. the instability was much less pronounced at 25 °C, data 
not shown) and the stimulated zymogen activity of the stable variant TAFI-ACIIYQ also shows a 
significantly prolonged half-life compared to that of the stimulated zymogen activity of TAFI, there are 
some similarities between the stability of the stimulated zymogen and the stability of TAFIa. 
Another difference between the stimulated zymogen activity and the TAFIa activity is the 
susceptibility towards the inhibitors PTCI and GEMSA. PTCI inhibits the stimulated zymogen activity 
with an IC50 in the micromolar range, in contrast to the IC50 for TAFIa which is in the nanomolar range 
[99]. Even though Valnickova et al. reported an inhibitory effect of PTCI on the zymogen activity [66, 
156], a study by Foley et al. demonstrated that the zymogen activity of TAFI is not inhibited by PTCI 
[40]. The inhibition of the stimulated zymogen activity by PTCI further indicates that the active-site 
pocket in the nanobody-stimulated TAFI is more readily accessible than the active-site pocket in the 
non-stimulated zymogen. On the other hand the data obtained with GEMSA confirms the accessibility 
of the active-site pocket, but surprisingly, the IC50-values for inhibition of the (stimulated) zymogen 
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activity are even 20- to 50-fold lower compared to the IC50-values for inhibition of TAFIa. This confirms 
that the characteristics of the stimulated zymogen activity are clearly distinct from those of the TAFIa 
activity and indicates that the affinity of GEMSA for binding into the active-site pocket is higher in the 
zymogen forms (either non-stimulated, e.g. TAFI-TI-R92A, or stimulated) than in the activated form. 
Also the results on the kinetics indicate that the characteristics of the stimulated zymogen 
activity differ from those of the TAFIa activity. The catalytic rate and the catalytic efficiency of the 
stimulated zymogen activity are about 10-fold increased compared to the zymogen activity, however, 
the catalytic rate and catalytic efficiency are still 5- to 10-fold lower compared to those of the TAFIa 
activity. It is important to note that the KM-values of the substrate Hip-Arg as determined towards the 
stimulated zymogen, the zymogen and the activated TAFI are not significantly different. This indicates 
that the binding of the substrate Hip-Arg to the stimulated zymogen is not improved compared to its 
binding to the zymogen. In contrast, the observed increase in catalytic efficiency reflects an 
accelerated hydrolysis of Hip-Arg, which is suggestive for an induced conformational change of the 
catalytic site, consequent to the binding of the nanobodies. 
Addition of Vhh-TAFI-a51 or Vhh-TAFI-i103 to plasma in the presence of TAFI-TI did not 
prolong lysis times in an in vitro clot lysis assay. The absence of prolongation under those conditions 
is somehow to be expected as the massive amounts of active TAFIa generated during clot lysis will 
obscure any possible effect of an increased zymogen activity. Importantly, stimulation of the zymogen 
activity of the non-activatable TAFI-TI-R92A variant in TAFI depleted plasma resulted in a significant 
antifibrinolytic effect. This strongly suggests that the zymogen activity, identified as the capability to 
cleave the small substrate hippuryl-arginine, also represents the ability to remove C-terminal lysines 
from the fibrin surface. This is further substantiated by the observation that a high level of zymogen 
activity, obtained by addition of higher concentrations of the non-activatable TAFI-TI-R92A variant also 
leads to a prolongation of clot lysis. It is of interest to note that it has been suggested that the flexibility 
of the activation peptide contributes significantly to the zymogen activity [156]. It is therefore tempting 
to speculate that the increased zymogen activity observed in the TAFI-TI-R92A variant is due to an 
increased flexibility of the activation peptide consequent to the replacement of an arginine to an 
alanine at the hinge between the activation peptide and the catalytic moiety. This increased flexibility 
on its turn also explains the instability of the zymogen activity of this variant. 
Screening of diverse panel of TAFI mutants (with mutations present throughout different regions 
of TAFI) revealed that both Asp
75
 and Thr
301
 are involved in the stimulation of the zymogen activity by 
the nanobodies. Taking the three-dimensional structure (Fig. 2.3) into consideration, it is very unlikely 
that the Nbs (with 24 Å × 40 Å dimensions) would bind simultaneously to Asp
75
 and Thr
301
 which are 
39 Å apart from each other. Probably Vhh-TAFI-a51 and Vhh-TAFI-i103 bind to either Asp
75
 or Thr
301
. 
Since the nanobodies are not able to stimulate the zymogen activity of mouse or rat TAFI, it was 
possible to deduce the binding region using chimeras. Preliminary experiments (data not shown) 
evaluating functional effects of the nanobodies on various chimeras (mouse/human and rat/human) 
indicated that the binding region of the nanobodies is situated between Ile
67
 and Ala
160
. This suggests 
that the primary binding site would comprise Asp
75
. If the actual binding site of the nanobodies is 
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located in the activation peptide at Asp
75
, we speculate that binding of the nanobody might result in a 
translocation of the activation peptide, leading to an increased accessibility of the catalytic site. The 
concomitant disruption of the stabilizing interactions between residues Val
35
 and Leu
39
, in the 
activation peptide, and Tyr
341
 in the dynamic flap region (residues 296-350) [55] might explain the 
rather short half-life of the stimulated zymogen. Since part of the dynamic flap is involved in the 
catalytic cleft wall, changes in the dynamic flap could explain the different enzymatic properties of the 
stimulated zymogen. Impairment of nanobody binding consequent to a mutation at position 301 could 
possibly be explained by allosteric conformational changes transferred to the activation peptide. 
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3.1.  Abstract 
Background: Thrombin activatable fibrinolysis inhibitor (TAFI) forms a molecular link between 
coagulation and fibrinolysis and is a putative target to develop profibrinolytic drugs. 
Objectives: To evaluate the inhibitory effect of anti-human TAFI monoclonal antibodies (MA) which 
inhibit the activation of human TAFI through different mechanisms. 
Methods and results: Out of a panel of MA raised against TAFI-ACIIYQ, we selected MA-TCK11A9, 
MA-TCK22G2 and MA-TCK27A4 which revealed high affinity towards human TAFI-TI-wt. MA-
TCK11A9 was able to inhibit mainly plasmin-mediated TAFI activation, MA-TCK22G2 inhibited 
plasmin- and thrombin-mediated TAFI activation and MA-TCK27A4 inhibited TAFI activation by 
plasmin, thrombin and thrombin/thrombomodulin (T/TM) in a dose-dependent manner. These MA did 
not interfere with TAFIa activity. Using an 8-fold molar excess of MA over TAFI, all three MA were able 
to reduce clot lysis time significantly i.e. in the presence of exogenous thrombomodulin, MA-TCK11A9, 
MA-TCK22G2 and MA-TCK27A4 reduced clot lysis time by 47  9.1%, 80  8.6% and 92  14%, 
respectively, compared to PTCI. This effect was even more pronounced in the absence of TM i.e. MA-
TCK11A9, MA-TCK22G2 and MA-TCK27A4 reduced clot lysis time by 90  14%, 140  12% and 147 
 29%, respectively, compared to PTCI. Mutagenesis analysis revealed that residues at position 268, 
272 and 276 are involved in the binding of MA-TCK11A9, residues 147 and 148 in the binding of MA-
TCK22G2 and residue 113 in the binding of MA-TCK27A4. 
Conclusions: The present study identified three MA, with distinct epitopes, that impair the activation 
of human TAFI and demonstrated that MA-TCK11A9 which mainly impairs plasmin-mediated TAFI 
activation can also reduce significantly clot lysis time in vitro. 
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3.2.  Introduction 
Coagulation and fibrinolytic cascades preserve the integrity of the vascular system and its surrounding 
tissues. Thrombin activatable fibrinolysis inhibitor (TAFI; EC 3.4.17.20), also known as plasma 
procarboxypeptidase B (proCPB), procarboxypeptidase R (proCPR) and procarboxypeptidase U 
(proCPU), provides a very delicate balance between coagulation and fibrinolysis and acts as a 
molecular link between them [38, 157, 158]. TAFI is a zinc-dependent metallocarboxypeptidase of 401 
amino acids. It is produced in the liver as a pre-proenzyme and secreted into circulation as a highly 
glycosylated zymogen of 56 kDa. Activation of TAFI by enzymes, such as trypsin, plasmin, thrombin or 
the thrombin–thrombomodulin (T/TM) complex generates a 20 kDa activation peptide (Phe1-Arg92) 
and a 36 kDa catalytic fragment (TAFIa, Ala93-Val401) [19, 20, 159, 160]. TAFIa is unstable and its 
activity is downregulated by a temperature-dependent conformational change [37, 51, 161]. This 
instability differs between human isoforms as well as among species [35, 49].  
TAFIa removes carboxy-terminal lysine and arginine-residues from partially degraded fibrin. 
Consequently, it impedes the fibrin-plasminogen-tissue-type plasminogen activator (t-PA) interaction, 
resulting in a decreased formation of plasmin and subsequent attenuation of fibrinolysis [38, 63, 162]. 
Additionally, TAFIa also has substrate specificity towards anaphylatoxins (C3a, C5a), bradykinin, 
annexin ll and osteopontin, suggesting its probable role in blood pressure, cell migration, inflammation 
and sepsis [25, 57, 58, 60, 61]. 
Arterial and venous thromboembolism are one of the major causes of illness and death in the 
western world. Today, the available therapy is associated with a risk of severe bleeding and needs 
close lab-monitoring [62]. Therefore, there is a need for the development of clinically safe and easy to 
use drugs. Considering the fact that TAFI plays a pivotal role in fibrinolysis, while the coagulation 
cascade remains unaffected [62], TAFI based therapies may result in less bleeding complications. 
Therefore, development of TAFI inhibitors as profibrinolytic agents seems to be a good strategy to 
prevent/treat thromboembolism.  
Up till now no endogenous TAFIa inhibitor has been reported in plasma [28]. Various 
unspecific inhibitors [chelating agents such as o-phenantroline and EDTA; reducing agents like 
dithiothreitol (DTT) and 2-mercaptoethanol] and specific inhibitors [small synthetic substrate analogues 
such as 2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (MERGETPA) and 2-
guanidinoethylmercaptosuccinic acid (GEMSA) as well as natural inhibitors like potato tuber 
carboxypeptidase inhibitor (PTCI), leech carboxypeptidase inhibitor (LCI) and tick carboxypeptidase 
inhibitor (TCI)] of TAFIa have been reported [28, 54, 62, 63, 85, 87, 159, 163]. Despite of an 
increasing list of TAFI inhibitors, specificity, poor bioavailability and the biphasic effect observed for 
some TAFI inhibitors remain a problem [62, 85, 87].  
Monoclonal antibodies (MA) are established as candidate drug molecules with high specificity 
and stability. MA that hamper the activation of TAFI to TAFIa as well as MA that directly inhibit TAFIa 
activity have been described [30, 88, 89, 164]. 
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This study describes the characterization of three MA that were raised against a stable human 
TAFI variant (TAFI-ACIIYQ) [53] and that impair the activation of human TAFI through different 
mechanisms. 
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3.3.  Materials and methods 
3.3.1.  Materials 
All experiments done in this study were performed with the wild-type (wt-) form of human TAFI (TAFI-
T
147
-Ile
325
, TAFI-TI, without additional tags) unless indicated otherwise. Mouse and rat TAFI wt without 
additional tags were used throughout the study. Primers for site-directed mutagenesis and sequencing 
were purchased from Sigma-Aldrich (St Louis, MO, USA). Pfx50 DNA polymerase was obtained from 
Invitrogen (Merelbeke, Belgium). Polymerase chain reactions were carried out with the Mastercycler-
Gradient from Eppendorf (Hamburg, Germany). Restriction enzyme DpnI was provided by New 
England Biolabs (Hertfordshire, UK). Plasmid DNA purification was performed with the Plasmid mini kit 
I (Omega Bio-Tek, Doraville, GA, USA) and the Nucleobond
TM
 AX500 kit (Machery-Nagel, Düren, 
Germany). DNA was sequenced by LGC Genomics (Berlin, Germany). Human thrombin, human 
plasmin, rabbit thrombomodulin and H-D-phenylalanyl-D-prolyl-L-arginine chloromethyl ketone 
(PPACK) were obtained from Sigma-Aldrich, Enzyme Research Labs (South Bent, UK), American 
Diagnostica (Greenwich, CT, USA) and Biomol Research Labs (Plymouth Meeting, PA, USA), 
respectively. Aprotinin, hippuryl-L-arginine and PTCI were obtained from Fluka (Buchs, Switzerland), 
Bachem (Bubendorf, Switzerland) and Sigma-Aldrich (St Louis, MO, USA), respectively. Tissue-type 
plasminogen activator (t-PA, Actilyse®) was obtained from Boehringer Ingelheim. Dulbeccos modified 
Eagles medium, OptiMEM-1 medium containing glutamax and Lipofectamine
TM
 2000 were purchased 
from Invitrogen (Merelbeke, Belgium). Horseradish peroxidase (HRP) type VI was purchased from 
Sigma- Aldrich. Human plasma was collected in-house from 27 healthy volunteers with written consent 
and pooled for clot lysis. TAFI-depleted plasma was obtained using MA-T4E3 coupled Sepharose 4B 
as described earlier [155]. 
3.3.2.  Methods 
3.3.2.1. Generation of TAFI variants 
In the present study, the pcDNA3.1(+) vector (Invitrogen) with the cDNA encoding for TAFI-T
147
-Ile
325
 
(pcDNA-TAFI-TI) was used as the template for mutagenesis [33]. Mouse TAFI and rat TAFI were 
produced as described before [35, 88] and purified using MA-RT36A3F5-sepharose [89, 165]. The 
TAFI chimeras hum67mu, hum160rat, hum215rat, and hum350rat were generated, produced and 
purified as described previously [88, 89]. 
 The binding region of MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 on TAFI was 
determined using TAFI chimeras. Amino acid sequences of human, mouse and rat TAFI 
(NM_001872.3, NM_019775 and NM_053617.2, respectively) were aligned in defined regions (Fig. 
3.1) and residues specific to human TAFI were identified and visualized in PyMol (PDB ID; 3D66). All 
the surface exposed human TAFI specific residues were then mutated by site-directed mutagenesis in 
pcDNA3.1-TAFI-TI into the corresponding mouse residues or alanine. Residues within a 5Å radius of 
human TAFI specific residues were also selected and mutated into alanine.  
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Figure 3.1: Alignment of amino acid residues between human, mouse and rat TAFI for 67-160 and 215-350 residues. 
Human, mouse and rat TAFI sequences were retrieved from GenBank (accession no NM_001872.3, NM_019775 and 
NM_053617.2, respectively) and aligned with ClustalW for amino acid residues. Residues highlighted with () and indicated in 
yellow represent human specific residues and residues highlighted as grey illustrate those human residues which are either 
similar to mouse or rat but not to both. Numbers represent the first and last amino acid residues of TAFI. The region between 
these residues were used in the alignment.  
3.3.2.2. Production and purification of TAFI 
TAFI variants were transfected in HEK293T cells using Lipofectamine 2000 as per manufacturer‟s 
instruction. Culture supernatant was harvested after 96 hours of transfection and stored at -80°C till 
purification. Human TAFI variants were purified by immunoaffinity chromatography using MA-T27G4 
[33] coupled Sepharose beads. Just before use, beads were washed with PBS, mixed with culture 
supernatant and incubated overnight at 4°C. The packed column was equilibrated and washed with 
PBS. Then, bound TAFI was eluted with 0.1M glycine (pH 2.7) and fractions were collected on 100µl 
1M Tris (pH 9.0). The fractions containing TAFI were pooled and dialyzed against dialysis buffer 
(20mM Tris, pH 7.4, 100mM NaCl and 10% glycerol). The purity of preparations was determined by 
10-15% SDS-PAGE and protein concentration of the purified TAFI was determined 
spectrophotometrically at 280 nm ( = 1.28 X10
5
 M
-1
 cm
-1
) [20]. 
3.3.2.3. Monoclonal antibodies 
A panel of 54 MA was raised towards recombinant TAFI- A
147
-C
305
-I
325
-I
329
-Y
333
-Q
335
 (TAFI-ACIIYQ) 
[53] in TAFI deficient mice [60] as described previously [33]. MA were purified from hybridoma 
supernatants using protein A chromatography [33, 166] and corresponding HRP-conjugated MA were 
produced as described by Nakane and Kawaoi [167]. Based on preliminary results on their mode of 
TAFI inhibition and potency, three antibodies MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4, were 
selected for further characterization.  
 Cross-reactivity of MA with recombinant TAFI-TI, TAFI-TI variants, rat, mouse and chimeric 
TAFI was determined with a one-side ELISA using the respective TAFI antigen for capture and rabbit 
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anti-mouse-HRP for detection as described previously [88]. Data are presented as mean values of 
percentage reactivity of the MA towards the TAFI variants compared to their reactivity towards TAFI-TI 
(set at 100%). Values 5% are considered as non-reactive. MA-T12D11 was used as a control 
antibody [88]. 
3.3.2.4. Affinity Measurements by SPR 
Affinity constants (KA) for the binding of TAFI variants to MA were determined by surface plasmon 
resonance (SPR) analysis using the Biacore 3000 analytical system (Biacore AB, Uppsala, Sweden) 
equipped with a CM-5 sensor chip as described [88]. In brief, MA were covalently coupled to 
approximately 1200 resonance units using a concentration of 5 μg/mL in acetate buffer (10 mM pH 
4.5). TAFI was diluted in HBS-EP buffer (Biacore) to concentrations between 5 and 200 nM and 
injected at a flow rate of 30 μL/min. After each cycle, the chip was regenerated with 10 μL of 10 mM 
glycine solution (pH 1.5). Analysis of the association and dissociation phases was performed using the 
Biacore 3000 software (Langmuir binding, local fit). All experiments were performed at least three 
times independently. 
3.3.2.5. Evaluation of the overall inhibitory effect of MA on TAFI activation and TAFIa activity 
The overall inhibitory effect of MA on TAFI activation and TAFIa activity was measured as described 
earlier [90]. Purified TAFI [45 nM (final concentration) in HEPES buffer (25 mM HEPES, 137 mM NaCl, 
3.5 mM KCl, + 0.1% BSA pH 7.4)] was incubated (10 min at 37°C) with either buffer or MA (0- to 32-
fold molar ratio over TAFI) prior to activation by plasmin (final concentration: 500 nM), in the presence 
of CaCl2 (final concentration: 5 mM). After 10 min at 22 °C, aprotinin (1.25 µM) and the substrate 
hippuryl-L-arginine (final concentration: 4 mM) was added to the activation mixture and substrate 
conversion was allowed to proceed for 30 min at 22 °C. Reactions (100 µL) were stopped by addition 
of 20 µL of 1N HCl followed by 20 µL of 1N NaOH. Then, 25 µL of 1M Na2HPO4 (pH 7.4) and 30 µL of 
6% cyanuric chloride (dissolved in 1,4-dioxane) were added and the mixture was vortexed and 
centrifuged. 100 µL of the supernatant was transferred into a 96-well microtiter plate and the 
absorbance at 405 nm was measured. Within the concentration range used, a linear correlation 
between the generated TAFIa activity and colour development was observed. From the comparison of 
the enzymatic activity of TAFIa generated in the absence and in the presence of MA, the inhibiting 
capacity of the MA was calculated and expressed as percentage inhibition. Reduced TAFIa activity as 
detected in this experimental setup can be caused either by interference with the activation mechanism 
or by direct interference with the TAFIa enzymatic activity. 
Evaluation of the effect of the MA on T/TM-mediated TAFI activation was performed as 
described above, with some modifications. Thrombin (final concentration: 20 nM), and thrombomodulin 
(final concentration: 5 nM) was used instead of plasmin and aprotinin was replaced by PPACK (final 
concentration: 37.5 µM) to stop T/TM-mediated activation. Substrate conversion was allowed to 
proceed for 10 min at 22°C instead of 30 min. 
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Thrombin is a very weak activator of TAFI and a too prolonged activation time is counteracted by the 
instability of TAFIa. To counter this problem for evaluation of thrombin-mediated TAFI activation, the 
stable TAFI variant TAFI-ACIIYQ was used instead of TAFI-TI. A higher amount of thrombin (final 
concentration: 100 nM) was used in the absence of thrombomodulin and correspondingly a high 
concentration of PPACK (final concentration: 187.5 mM) was used to stop the reaction. The activation 
reaction and substrate conversion were allowed to proceed for 120 min at 22°C and 10 min at 22°C, 
respectively. 
3.3.2.6. Evaluation of the direct inhibitory effect of MA on TAFIa activity  
The direct inhibitory effect of MA on the TAFIa activity was measured as described previously [90]. 
Purified TAFI (45 nM in HEPES buffer) was activated by thrombin (final concentration: 20 nM) and 
thrombomodulin (final concentration: 5 nM) with CaCl2 (final concentration: 5 mM) for 10 min at 22 °C. 
The activation was stopped by adding PPACK (final concentration: 37.5 µM). Subsequently, either 
buffer or MA (16-fold molar ratio over TAFI) was added and incubated for 10 min at 37 °C followed by 
addition of the substrate hippuryl-L-arginine (final concentration: 4 mM). Substrate conversion was 
allowed to proceed for 10 min 22°C. Stopping the reaction, colour development and calculation of 
percentage inhibition was carried out as described above. Reduced TAFIa activity as detected in this 
experimental setup is the consequence of a direct interference of the MA with the enzymatic activity of 
TAFIa. 
3.3.2.7. Evaluation of the effect of the MA on the activation of TAFI  
The effect of the MA on the activation of TAFI to TAFIa was evaluated as described earlier [90]. 
Briefly, TAFI (concentration at activation step: 0.41 µM in Tris buffer; 20 mM Tris, 100 nM NaCl, pH 
7.4) was incubated with either buffer or MA (3-fold molar ratio over TAFI) for 10 min at 37°C prior to 
activation with either thrombin (23 nM)/thrombomodulin (5.8 nM) or plasmin (417 nM) in the presence 
of CaCl2 (5.8 mM). The reactions were stopped by adding PPACK (34.5 µM) or aprotinin (1.2 µM), 
respectively, and SDS (1% final concentration) to the reaction mixtures followed by heating for 30 sec 
at 100°C. The generated fragments were analyzed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), using PhastGelTM gradient 10-15% gels, followed by silver staining. 
3.3.2.8. Evaluation of the effect of MA during in vitro clot lysis 
The clot lysis assay was performed in a 96-well microtiter plate as described previously [90]. Pooled 
plasma (final concentration: 30%) was mixed either with dilution buffer (10 mM Tris, 0.01% tween 20, 
pH 7.5) or with MA (final concentration: 432 nM, resulting in an 8-fold molar ratio over TAFI assuming 
a concentration of 180 nM TAFI in plasma), or PTCI (20 µg/ml, final concentration). The plate was 
incubated at 37°C for 10 min and exogenous thrombomodulin (1 nM) and t-PA (120 pM) were added. 
Then clot formation was induced by addition of CaCl2 (10.6 mM) and the plate was read at 2 min 
intervals at 405 nm at 37°C. The 50% clot lysis time was determined, defined as the time interval 
between the time point of full clot formation to the midpoint of the maximum turbidity to clear transition. 
Reduction of the clot lysis time was calculated relative to the reduction of clot lysis time in the absence 
(0% reduction) and presence of PTCI (100% reduction). Alternatively, this assay was carried out 
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without the addition of exogenous thrombomodulin. Clot-lysis assays were also performed in TAFI 
depleted plasma in presence and absence of TM. 
3.3.2.9. Measurement of TAFIa activity during clot formation and lysis 
The clot lysis assay was performed in a 96-well microtiter plate as described above with some 
modifications [90, 155]. Pooled plasma (final concentration: 30%) was mixed either with buffer (20mM 
HEPES, 0.01% tween 20; pH; 7.4) or with MA (final concentration: 432 nM). t-PA (final concentration: 
353 pM) was added and clot formation was induced by addition of CaCl2 (10.6 mM). 100µl of this mix 
was placed in the microtiter plate and the plate was read at 2 min intervals at 405 nm at 37°C. In 
parallel/Simultaneously for analysis of TAFIa activity at different timepoints 200µl of this mix for every 
timepoint was incubated in separate tubes at 37°C and after every 10 min, one tube was taken out and 
PPACK (final concentration: 41 µM) and aprotinin (final concentration: 1.4 µM) was added to inhibit all 
thrombin and plasmin activity, respectively. Samples were stored further on ice until the 
carboxypeptidase activity was assayed. 
 TAFIa activity was measured using the chromogenic assay as described above with some 
modifications. In order to distinguish between TAFIa and CPN activity, the samples were analyzed in 
the presence and absence of PTCI (final concentration: 28 µg/ml). 80µl of each sample was mixed 
either with HEPES buffer [25 mM HEPES, 137 mM NaCl, 3.5 mM KCl, + 0.1% BSA pH; 7.4] or PTCI 
and incubated for 10 min at 22°C. Then the substrate hippuryl-L-arginine (final concentration: 5 mM) 
was added to the mix and substrate conversion was allowed to proceed for 10 min at 22°C. Stopping 
the reaction, colour development and measurement of optical density was carried out as described 
above. Values obtained in the presence of PTCI were subtracted from total values (without PTCI) to 
calculate the specific TAFIa activity in plasma and TAFIa activity was calculated in U/L [OD (TAFIa)/ m 
(slope) X 10 (time-min) = U/L]. Hippuric acid was used as standard to calculate TAFIa activity. To 
evaluate the effect of MA-TCK11A9 in the presence of plasmin inhibitor; aprotinin (final concentration: 
1µM) was added at the start of the experiment. 
3.3.2.10. Statistical analysis 
Quantitative data were represented as mean and standard deviation (SD). The data were analyzed 
using paired two-tailed t-test with Graph-Pad Prism (GraphPad, Inc. San Diego, CA, USA). The two-
tailed p-value was calculated and p < 0.05 was considered statistically significant. Dose–response 
curves were fitted to one-side binding hyperbolas. 
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3.4. Results 
3.4.1.  Reactivity of MA towards human, mouse and rat TAFI 
MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 were generated towards the stable human TAFI 
variant TAFI-ACIIYQ. One-side ELISA results revealed that these three antibodies cross-react with 
human wild-type TAFI but not with mouse or rat TAFI (Table 3.1A). The reactivity of MA-TCK22G2 and 
MA-TCK27A4 towards TAFI-TI and TAFI-ACIIYQ was confirmed by surface plasmon resonance (SPR) 
analysis, in which MA-TCK22G2 revealed a high affinity towards TAFI-ACIIYQ (KA = 22 ± 5.5  10
8
 M-1) 
and TAFI-TI (KA = 1.5 ± 0.5  10
8 M-1). MA-TCK27A4 showed high affinity towards TAFI-ACIIYQ (KA = 
16 ± 4.7  10
8
 M-1) and TAFI-TI (KA = 12  4.7 X 10
8
 M-1). MA-TCK22G2 and MA-TCK27A4 revealed no 
affinity (KA < 10
6
 M
-1
) towards mouse and rat TAFI (Table 3.2A). The affinity of TAFI variants towards 
MA-TCK11A9 could not be determined via SPR analysis due to unknown reasons. 
Table 3.1: Percentage reactivity of MA towards human, mouse and rat TAFI variants compared to the reactivity of MA 
towards TAFI-TI. 
TAFI-variants  MA-T12D11 MA-TCK11A9 MA-TCK22G2 MA-TCK27A4 
TAFI-ACIIYQ 71 180  153 140 
TAFI-TI 100 100 100 100 
 Mouse TAFI <5 <5 <5 <5 
Rat TAFI  <5 <5 <5  <5 
TAFI-TI-F113A 86 45 56  <5 
TAFI-T147R-I 97 51 <5 52 
TAFI-TI-A148I 86 91 <5 75 
TAFI-TI-K268A 97 13 81 72 
TAFI-TI-S272D 91 <5 86  80 
TAFI-TI-R276A 81 <5 53 53 
TAFI-TI-K268A-S272D 97 <5 74 65 
TAFI-TI-S272D-R276A 87 <5 104 86 
TAFI-TI-K268A-S272D-R276A 98  <5 84 67 
MA-T12D11; control antibody.  
 
Table 3.2: Affinity constants (KA; 108 M-1) of human, mouse and rat TAFI and human TAFI variants towards MA-
TCK22G2 and MA-TCK27A4. 
 
TAFI-variant 
MA-TCK22G2 MA-TCK27A4 
KA (M-1) KA (M-1) 
TAFI-ACIIYQ 22±5.5  16±4.7 
TAFI-TI 1.5±0.5 124.7 
Mouse NB NB 
Rat NB NB 
TI-F113A 1.2±0.5 NB 
T147R-I NB 8.6±2.3 
TI-A148I NB 10±3.4 
TI-K268A 1.6±0.4 11±3.0 
TI-S272D 1.5±0.4 9.9±2.9 
TI-R276A 0.9±0.3 5.8±1.3 
TI-K268A-S272D 1.3±0.5 7.9±3.1 
TI-K268A-R276A 1.3±0.5 8.5±2.1 
TI-K268A-S272D-R276A 1.4±0.7 9.0±3.1 
Mean  SD, n3. NB (no binding), KA106.  
 
A 
B 
A 
B 
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3.4.2.  Direct inhibition of TAFIa activity 
Evaluation of the effect of MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 on the activity of TAFIa 
revealed that neither of the MA affected TAFIa activity (Table 3.3). 
Table 3.3: Effect of MA on TAFIa activity, TAFI activation and on 50% clot lysis time  
 
% reduction of TAFI activation
††
 
% reduction of  
TAFIa activity
†
 
% reduction of clot-lysis time
††
 
MA T/TM Plasmin T  
Expressed relative 
to % reduction  
by PTCI (+TM) 
Expressed relative  
to % reduction  
by PTCI (-TM) 
TCK11A9 2 64 ± 4.3 2 2 47  9.1* 90  14* 
TCK22G2 2 58 ± 4.0 51 ± 1.5 2 80  8.6* 140  12* 
TCK27A4 98 ± 2.0 100 ± 0.4 96 ± 2.1 2 92  14* 147  29* 
Mean  SD, n  3;  p < 0.05 vs. no TAFI inhibitor. † evaluated at 16-fold molar ratio of MA over TAFI. †† evaluated at 8-fold molar ratio of MA over TAFI 
3.4.3.  Impairment of the activation of TAFI to TAFIa 
To determine a possible effect of the MA on the activation of TAFI, MA were added prior to the 
activation of TAFI by plasmin, thrombin or the T/TM complex. MA-TCK11A9 inhibits plasmin-mediated 
TAFI activation in a dose dependent manner i.e. 64 ± 4.3% at an 8-fold molar ratio of MA over TAFI, 
with a maximum inhibition of 84  2.5% and a corresponding IC50 value of 118 nM but does not affect 
the thrombin or T/TM-mediated activation of TAFI (Table 3.3, Fig. 3.2A).  
Using an 8-fold molar ratio of MA over TAFI, MA-TCK22G2 inhibits both the plasmin- and 
thrombin-mediated TAFI activation by 58 ± 4.0% and 51 ± 1.5%, respectively, but does not inhibit the 
T/TM activation of TAFI (Table 3.3, Fig. 3.2B). MA-TCK22G2 revealed a maximum inhibition of 
plasmin- mediated TAFI activation of 78  2.1% with a corresponding IC50 value of 141 nM and a 
maximum inhibition of thrombin-mediated TAFI activation of 51  3.3% with a corresponding IC50 value 
of 44 nM.  
MA-TCK27A4 inhibits plasmin-, thrombin- and T/TM-mediated TAFI activation by 100 ± 0.4%, 
96 ± 2.1% and 98 ± 2.0%, respectively, at an 8-fold molar ratio of MA over TAFI. The maximum 
inhibition by MA-TCK27A4 was 100  2.6%, 100  3.4% and 100  2.9%, respectively, and the 
corresponding IC50 values were 7 nM, 23 nM and 11 nM, respectively (Table 3.3, Fig. 3.2C).  
To confirm the effect of the MA on TAFI activation, fragmentation products of TAFI upon 
activation of TAFI by plasmin or the T/TM complex in the absence and presence of MA were analyzed 
using SDS-PAGE. These data confirm that MA-TCK11A9 and MA-TCK22G2 are able to inhibit 
plasmin-mediated TAFI activation and MA-TCK27A4 inhibits plasmin-, and T/TM-mediated TAFI 
activation (data not shown). 
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Figure 3.2: Dose-dependent inhibition by MA-TCK11A9 (A), MA-TCK22G2 (B) and MA-TCK27A4 (C) on plasmin- (), 
thrombin- (……) and T/TM- (----)-mediated TAFI activation. Percentage inhibition of TAFI activation was calculated 
relative to activated TAFI in the absence of MA. The results represent mean ± SD (n ≥ 3). 
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3.4.4.  Effect of MA on clot lysis 
To investigate the functional effect of the MA on clot lysis, plasma was preincubated either with buffer 
(negative control), PTCI (positive control) or MA. In the absence of both MA and PTCI, the clot lysis 
time was 133 ± 11 min in the presence of 1 nM exogenous thrombomodulin. In the presence of PTCI 
clot lysis time was shortened to 76 ± 4 min. At an 8-fold molar ratio of MA (i.e. 432 nM) over TAFI, MA-
TCK11A9, MA-TCK22G2 and MA-TCK27A4 significantly accelerated clot lysis to 106 ± 12 min, 88 ± 9 
min and 81 ± 5 min, respectively. Compared to PTCI, MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 
reduced clot lysis times by 47  9.1%, 80  8.6 % and 92  14%, respectively (Table 3.3). The effect in 
clot lysis was more pronounced in the absence of exogenous thrombomodulin. Under these 
conditions, in the absence of both MA and PTCI, the clot lysis time was 104 ± 15 min. In the presence 
of PTCI the clot lysis time was shortened to 68 ± 15 min. At an 8-fold molar ratio of MA (i.e. 432 nM) 
over TAFI, MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 significantly accelerated clot lysis to 71 ± 
20 min, 54 ± 13 min and 51 ± 7 min, respectively. Compared to PTCI, MA-TCK11A9, MA-TCK22G2 
and MA-TCK27A4 reduced clot lysis times by 90  14%, 140  12 % and 147  29%, respectively 
(Table 3.3). None of the antibodies was able to reduce 50% clot lysis time in TAFI depleted plasma 
(data not shown). 
 
Figure 3.3: TAFIa activity during clot formation and lysis. (A) Clot lysis profile and (B) TAFIa activity (expressed in U/L) 
during clot lysis in the absence (black curve;) and in the presence (grey curve;) of MA-TCK11A9 and (C) Clot lysis 
profile and (D) TAFIa activity (expressed in U/L) during clot lysis after addition of 1 µM aprotinin in the absence (black 
curve;) and the presence (grey curve;) of MA-TCK11A9. The results represent mean ± SD (n = 3). 
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3.4.5.  Effect of MA-TCK11A9 on TAFIa generation during clot formation and lysis  
To examine the effect of MA-TCK11A9 on TAFIa activity during clot lysis experiments, we measured 
TAFIa activity at various timepoints during clot lysis in the presence and absence of MA-TCK11A9. 
Under these experimental conditions, only a small second TAFIa activity peak could be observed in 
the absence of MA-TCK11A9 (Fig. 3.3B). Upon addition of MA-TCK11A9, we observed a significant 
reduction in clot lysis time (Fig. 3.3A) as well as a reduction in both TAFIa activity peaks (Fig. 3.3B). 
To further investigate the effect of MA-TCK11A9 on TAFIa generation in the absence of plasmin, we 
added 1 µM aprotinin (final concentration) in the beginning of the clot lysis experiments. Consequently, 
no clot lysis occurred (Fig. 3.3C) and a strongly decreased amount of both TAFIa activity peaks was 
observed (Fig. 3.3D). Addition of MA-TCK11A9 did not affect the clot lysis time nor the amount of 
generated TAFIa activity (Fig. 3.3C and 3.3D). 
3.4.6.  Inhibitory effect of MA towards human/mouse and human/rat TAFI chimeras 
The inhibitory effect of the MA on the plasmin-mediated activation of human, mouse, rat, 
human/mouse and human/rat TAFI chimeras was investigated using a 16-fold molar ratio of MA over 
TAFI (Table 3.4). MA-TCK11A9 was able to inhibit plasmin-mediated activation of the hum350rat TAFI 
chimera but not of other chimeras whereas both MA-TCK22G2 and MA-TCK27A4 were able to inhibit 
plasmin-mediated activation of hum160rat, hum215rat and hum350rat TAFI chimeras but not the 
hum67mu chimera. These results were confirmed by one-side ELISA (data not shown).  
 From these data, it can be concluded that the epitope of MA-TCK11A9 resides within the 215-
350 amino acid region whereas the epitope of MA-TCK22G2 and MA-TCK27A4 resides within the 67-
160 amino acid region. 
Table 3.4: Percentage inhibition of the MA on the plasmin-mediated activation of human, mouse and rat TAFI 
variants and TAFI chimeras  
TAFI variants MA-TCK11A9† MA-TCK22G2† MA-TCK27A4† 
TAFI-TI 72 ± 4 64 ± 1 100 ± 0 
TAFI-ACIIYQ 91 ± 2 81 ± 1 100 ± 0 
Mouse TAFI 15 ± 1 17 ± 6 12 ± 7 
Rat TAFI <5 9 ± 5 17 ± 10 
hum67mu 16 ± 9 9 ± 8 12 ± 7 
hum160rat <5 64 ± 4 99 ± 1 
hum215rat 6 ± 2 71 ± 3 100 ± 1 
hum350rat 72 ± 2 70 ± 6 99 ± 1 
Mean  SD, n  3. † Molar ratio, MA:TAFI = 16 
3.4.7.  Affinity and inhibitory effect of MA towards human TAFI variants 
The 67-160 amino acid and the 215-350 amino acid regions of mouse, rat and human TAFI were 
aligned (Fig. 3.1). TAFI was visualized in PyMol (PDB ID; 3D66) and surface exposed human TAFI 
specific residues were replaced either by the corresponding mouse residue or by alanine. To elucidate 
the epitope of MA-TCK11A9, the following mutations were introduced i.e. F222A, Y223H, A224K, 
H227R-I229V, E245K, S272D, Q280H, H293Q-V295L, T301N, K324S-S326N and H335S-T339S in 
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TAFI-TI. To elucidate the epitope of MA-TCK22G2 and MA-TCK27A4, the following mutations were 
introduced i.e. C69F-S70N, L73M, A74N, D75N, I84T, F113V, R117Q, T123Q, H126Y, T147R and 
A148I in TAFI-TI. All mutants were generated, expressed and conditioned medium was tested for 
TAFIa activity upon activation by plasmin (data not shown). All mutants were fully activatable by 
plasmin, except TAFI-TI-H126Y.  
 The effect of MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 on the plasmin-mediated 
activation of the generated mutants was assayed on conditioned medium. Based on the reduction in 
percentage inhibition of the MA on the plasmin-mediated activation, the following TAFI variants were 
selected for purification and characterization i.e. TAFI-TI-S272D for MA-TCK11A9, TAFI-T147R-I and 
TAFI-TI-A148I for MA-TCK22G2, TAFI-TI-F113A for MA-TCK27A4.  
 MA-TCK11A9 inhibited plasmin-mediated activation of TAFI-TI by 64 ± 4.3% (at 360 nM) and 
of TAFI-TI-S272D by 22 ± 3.3% (at 360 nM). These results revealed that the plasmin-mediated 
activation of TAFI-TI-S272D is significantly less inhibited by MA-TCK11A9. To identify other residues 
involved in the epitope of MA-TCK11A9, five surface exposed residues within the radius of 5Å of S
272
 
were selected and replaced by alanine (except for Ala
269
) generating the following TAFI variants i.e. 
TAFI-TI-K268A, TAFI-TI-A269S, TAFI-TI-F273A, TAFI-TI-R275A and TAFI-TI-R276A. Conditioned 
medium was tested for TAFIa activity. All mutants except TAFI-TI-F273A were fully activatable by 
plasmin (data not shown). Based on the reduction in percentage inhibition of the MA on the plasmin-
mediated activation, TAFI-TI-K268A and TAFI-TI-R276A were selected for purification and 
characterization. A dose-dependent effect of MA-TCK11A9 on plasmin-mediated activation of TAFI-TI-
K268A and TAFI-TI-R276A was evaluated (Fig. 3.4A). MA-TCK11A9 inhibited plasmin-mediated 
activation of TAFI-TI-K268A by 12 ± 6.9% (360 nM) and TAFI-TI-R276A by <2% (360 nM) (Fig. 3.4A). 
Subsequently, two double mutants i.e. TAFI-TI-K268A-S272D and TAFI-TI-S272D-R276A and one 
triple mutant i.e. TAFI-TI-K268A-S272D-R276A, were generated, purified and subjected to the 
inhibitory assay revealing 9 ± 4.9%, 18 ± 7% and 18 ± 11% inhibition of plasmin-mediated TAFI 
activation by MA-TCK11A9 (360nM) (Fig. 3.4A). Binding of TAFI or TAFI mutants to MA-TCK11A9 
could not be determined by SPR due to unknown reasons. One-side ELISA analysis (Table 3.1B) 
revealed a 87% lower reactivity of TAFI-TI-K268A and a 100% lower reactivity of TAFI-TI-R276A, 
TAFI-TI-S272D, TAFI-TI-K268A-S272D, TAFI-TI-S272D-R276A and TAFI-TI-K268A-S272D-R276A 
towards MA-TCK11A9. These results identified Lys
268
, Ser
272
, and Arg
276 
as major residues interacting 
with MA-TCK11A9. 
The dose-dependent effect of MA-TCK22G2 on the plasmin-mediated activation of TAFI-TI, 
TAFI-T147R-I and TAFI-TI-A148I was evaluated (Fig. 3.4B). At 360 nM, MA-TCK22G2 inhibited 
plasmin-mediated activation of TAFI-TI by 58 ± 4.0%, TAFI-T147R-I by 7 ± 7.3% and TAFI-TI-A148I 
by 4 ± 13% (Fig. 3.4B). In SPR analysis, TAFI-TI revealed a high affinity towards MA-TCK22G2 (KA = 
1.5 ± 0.5  10
8
), but TAFI-T147R-I and TAFI-TI-A148I failed to show any binding towards this MA 
(Table 3.2B). Lack of binding of the TAFI-T147R-I and TAFI-TI-A148I to MA-TCK22G2 was confirmed 
by one-side ELISA experiments (Table 3.1B). These results revealed that MA-TCK22G2 binds to 
Thr
147
 and Ala
148
.  
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Figure 3.4: Dose-dependent inhibition of activation of human TAFI and its variants by MA. (A) Effect of MA-TCK11A9 
on plasmin-mediated activation of TAFI-TI (),TAFI-TI-K268A (∙∙∙∙∙∙),TAFI-TI-S272D (- -- -), TAFI-TI-R276A (---
-), TAFI-TI-K268A-S272D (----),TAFI-TI-S272D-R276A () and TAFI-TI-K268A-S272D-R276A (----), (B) Effect of 
MA-TCK22G2 on plasmin-mediated activation of TAFI-TI (),TAFI-T147R-I (……) and TAFI-TI-A148I (----) and (C) 
Effect of MA-TCK27A4 on plasmin-mediated TAFI-TI () and TAFI-TI-F113A () as well as T/TM-mediated 
activation of TAFI-TI (----) and TAFI-TI-F113A (). Percentage activation of inhibition of TAFI activation was calculated 
relative to activated TAFI in the absence of MA. The results represent mean ± SD (n ≥ 3). 
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The dose-dependent effect of MA-TCK27A4 on plasmin-mediated and T/TM-mediated 
activation of TAFI-TI and TAFI-TI-F113A was evaluated (Fig. 3.4C). At 360 nM, MA-TCK27A4 
inhibited plasmin-mediated activation of TAFI-TI by 100 ± 0.4% and of TAFI-TI-F113A by 38 ± 5.0% 
and T/TM-mediated activation of TAFI-TI by 98 ± 2.0% and of TAFI-TI-F113A by 16 ± 4.6% (Fig. 
3.4C). SPR analysis revealed no binding of TAFI-TI-F113A to MA-TCK27A4 (Table 3.2B) and these 
results were confirmed by one-side ELISA (Table 3.1B). This revealed Phe
113
 as the major residue in 
the epitope of MA-TCK27A4.  
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3.5.  Discussion 
TAFIa exerts an antifibrinolytic effect by removing C-terminal lysines from partially degraded fibrin 
degradation products, thereby abolishing their cofactor function in the activation of plasminogen by t-
PA [38, 63, 162]. Many clinical studies have correlated TAFI antigen levels with cardiovascular events 
such as angina pectoris [168], coronary artery disease [169], ischemic stroke [170], myocardial 
infarction [73] and venous thrombosis [69]. Considering TAFI as a molecular link between thrombosis 
and coagulation, the drawbacks of presently available antithrombotic agents/therapy and the large 
population suffering from thrombosis disorders, the development of highly specific TAFI inhibitors is a 
hot topic [62, 171, 172]. The use of TAFI inhibitors as an adjuvant in thrombolytic therapy would allow 
lower amounts of infused plasminogen activators and consequently enhance thrombolytic efficiency 
and reduce side effects. Alternatively, TAFI inhibitors could also be used in the prevention of 
thrombotic events. Although a lot of basic research on TAFI has been performed, the complete in vivo 
mechanism of TAFI activation by various activators and their relative contributions in various pathways 
is lacking. MA that inhibit TAFI activation by various mechanisms (thrombin, the T/TM complex and/or 
plasmin) are excellent tools to study the mechanism of TAFI activation, regulation and its role in 
physiological conditions.  
In the present study, we characterized three MA that inhibit the activation of TAFI. MA-
TCK11A9, MA-TCK22G2 and MA-TCK27A4 were raised towards a stable variant of human TAFI. 
Although raised towards the stable TAFI variant (TAFI-ACIIYQ) containing five mutations, all three MA 
revealed a high affinity towards human TAFI-TI-wt. These three MA revealed no affinity towards rat or 
mouse TAFI (Table 3.1A and Table 3.2). None of these MA interfered with TAFIa activity (Table 3.3). 
MA-TCK11A9 is able to inhibit plasmin-mediated activation, MA-TCK22G2 inhibits plasmin- and 
thrombin-mediated TAFI activation and MA-TCK27A4 inhibits TAFI activation by plasmin, thrombin 
and T/TM (Table 3.3 and Fig. 3.2). MA that inhibit TAFI through the impairment of TAFI activation were 
previously reported by Gils et. al., Bajzar et. al. and Bouma et. al [30, 88, 164]. However, these 
previously reported MA impair mainly T/TM- as well as plasmin-mediated TAFI activation. MA that 
impairs mainly the plasmin-mediated TAFI activation have not been reported yet. However, 
nanobodies with a comparable mechanism of action were reported recently [90]. 
An association between TAFI antigen levels and in vitro clot lysis time among healthy 
individuals has been reported [31]. Previous studies also revealed a TAFI-related retardation of t-PA 
and u-PA mediated clot lysis and reported that this delay is dependent on the type and concentration 
of the plasminogen activator used [173, 174]. The in vitro clot lysis assays performed in this study 
revealed that all three MA have strong profibrinolytic properties in human plasma. Compared to PTCI, 
MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 reduced clot lysis times by 47  9.1%, 80  8.6% and 
92  14% (Table 3.3), when clot lysis experiments were performed upon addition of 1 nM exogenous 
TM. In the absence of exogenous TM reduction in clot lysis was more pronounced. Compared to 
PTCI, MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 reduced clot lysis times by 90  14%, 140  
12% and 147  29%. Thus all three MA are able to accelerate clot lysis significantly in the presence as 
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well as in the absence of exogenous thrombomodulin. Surprisingly, MA-TCK11A9 which mainly 
inhibits plasmin-mediated TAFI activation, is capable of reducing clot lysis time. 
A biphasic pattern of TAFI activation during in vitro clot lysis was previously shown 
demonstrating that a first peak of TAFIa activity is generated via T/TM activation whereas a second 
peak of TAFIa activity is generated via plasmin-mediated TAFI activation [42, 155]. A recent report 
suggested that even in the absence of thrombomodulin, thrombin but not plasmin, mediates TAFI 
activation in in vitro clot lysis assays [43]. However in these experiments 50% plasma and 40 ng/ml of 
t-PA was used and aprotinin, a selective plasmin inhibitor, was added after the formation of the first 
TAFIa activity peak. This resulted in a complete reduction of the second TAFIa activity peak indicating 
indeed that this second TAFIa activity burst is due to TAFI activation by plasmin. However, we would 
like to stress that in our clot lysis experiments 30% plasma and 8 ng/ml of t-PA was used. To be able 
to measure TAFIa activity during clot dissolution we repeated some experiments using 30% plasma 
with 24 ng/ml t-PA. Under these conditions, only a small second TAFIa activity peak was observed 
and addition of MA-TCK11A9 resulted into reduction of both TAFIa activity peaks (Fig. 3.3B). This 
indicates that in these conditions, plasmin activation of TAFI occurs during both clot formation and clot 
dissolution. This also clarifies our observation i.e. strong reduction of clot lysis time when an inhibitor 
of plasmin-mediated TAFI activation i.e. MA-TCK11A9 is added (Fig. 3.3A). Under similar conditions in 
the presence of aprotinin, no clot lysis occurred (Fig. 3.3C), a strong reduction in both TAFIa activity 
peaks was observed (Fig. 3.3D) and addition of MA-TCK11A9 had no effect on clot lysis (Fig. 3C) nor 
on the amount of generated TAFIa activity (Fig. 3.3D), confirming that the profibrinolytic effect of MA-
TCK11A9 is due to its ability to inhibit plasmin-mediated TAFI activation. All these results strongly 
demonstrate that T/TM as well as plasmin-mediated TAFI activation contributes to the TAFI activation 
during clot formation and lysis. This was also recently shown in vivo using a mice thromboembolism 
model in which a monoclonal antibody that mainly inhibiting plasmin-mediated TAFI activation was 
able to significantly reduce fibrin deposition in lungs upon injection of thromboplastin [81]. 
Epitope mapping revealed that Lys
268
, Ser
272
 and Arg
276
 are the major residues responsible for 
the binding of human TAFI to MA-TCK11A9, Thr
147
 and Ala
148
 are the major residues for the binding of 
human TAFI to MA-TCK22G2 and Phe
113
 was identified as the major residue responsible for the 
binding of human TAFI to MA-TCK27A4.  
 In a previous study, it was shown that MA-T1C10 and MA-T94H3 attenuate the T/TM as well 
as the plasmin-mediated TAFI activation whereas MA-T12D11 inhibits exclusively T/TM-mediated 
TAFI activation. The major residues for the binding of MA-T94H3, MA-T12D11 and MA-T1C10 to TAFI 
were Val
41
,
 
Gly
66 
and Gln
45
, respectively [88]. These three residues are located in the activation 
peptide region (indicated in orange, brown and yellow, respectively in Fig. 3.5). It was recently shown 
that positively charged amino acid residues (i.e. Lys
42
, Lys
43
, Lys
44
) located in the activation peptide 
are responsible for binding with TM [175]. The residues identified as major residues in the epitopes of 
the MA described in the current study are located outside the activation peptide region. Thr
147
 and 
Ala
148
 (epitope of MA-TCK22G2) are located in the loop that connects the 2
 
with the
 3 –strand 
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whereas Lys
268
,
 
Ser
272
 and Arg
276 
(epitope of MA-TCK11A9) are located in α4-helix. Binding to either 
Thr
147 
and Ala
148
 or Lys
268
, Ser
272
 and Arg
276
 might induce a conformational change or allosteric 
modulation in the TAFI molecule in such a way that plasmin and/or thrombin will no longer be able to 
activate TAFI. Phe
113
 (epitope of MA-TCK27A4) is located in 1-helix near (8Å) the Arg
92
 cleavage 
site. Through binding of MA-TCK27A4 to Phe
113
, Arg
92
 will no longer be accessible to plasmin, 
thrombin and T/TM. 
 
Figure 3.5: Illustration of epitope residues of MA-TCK11A9, MA-TCK22G2 and MA-TCK27A4 on TAFI. TAFI structure 
was visualized in Pymol using PDB ID: 3D66 [55]. Grey, green and cyan represents the activation peptide, the catalytic 
domain and the dynamic flap of TAFI, respectively. R92 is the cleavage site for plasmin, thrombin and T/TM. The epitope of 
MA-TCK11A9 (K268, S272 and R276), MA-TCK22G2 (T147 and A148) and MA-TCK27A4 (F113) are represented in blue, magenta 
and red colors respectively.  
 In conclusion, this study identified three MA that impair the activation of TAFI through different 
mechanisms involving different epitopes. Data obtained with MA-TCK11A9 which mainly impairs 
plasmin-mediated TAFI activation, reveal that plasmin-mediated activation of TAFI also plays an 
important role in clot lysis and consequently in fibrinolysis. In addition, the availability of a selective 
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inhibitor of plasmin-mediated activation of TAFI might have opportunities to be used in other 
processes like blood pressure (bradykinin), cell migration (annexin ll), infection and inflammation (C3a, 
C5a and osteopontin) [25, 57, 58, 60, 61] in which activation of TAFI by plasmin might play a role. 
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4.1.  Abstract  
Background: Activated thrombin activatable fibrinolysis inhibitor is an important regulator of t-PA-
mediated fibrinolysis. Until now the thrombin/thrombomodulin (T/TM) complex was believed to be the 
physiological activator of thrombin activatable fibrinolysis inhibitor (TAFI), but recent in vitro and in vivo 
studies revealed that plasmin could also contribute to TAFI activation during fibrinolysis.  
Objectives: To characterize TAFI variants selectively activatable by various activators to study the 
mechanism of TAFI activation during fibrinolysis. 
Methods and results: In the current study, two TAFI variants previously reported to be selectively 
activatable by the T/TM complex (TAFI-K133A) or plasmin (TAFI-P91S) were evaluated in an in vitro 
clot lysis assay for their antifibrinolytic effects in TAFI-depleted plasma. The profibrinolytic effects of 
MA-T12D11 and MA-TCK26D6 which inhibit T/TM- and plasmin-mediated TAFI activation, 
respectively, were also evaluated in the presence of these variants. Both the mutants (TAFI-P91S and 
TAFI-K133A) revealed a 1.8- to 2-fold lower antifibrinolytic effect compared to TAFI wt. The 
profibrinolytic effect of MA-T12D11 in presence of TAFI wt was similar to the reduced antifibrinolytic 
activity observed for TAFI-K133A and TAFI-P91S. MA-T12D11 was able to completely abolish the 
effect of TAFI-K133A whereas MA-TCK26D6 was able to completely abolish antifibrinolytic effect of 
TAFI-P91S.  
Conclusion: To the best of our knowledge this is the first detailed report revealing the relative 
contribution of the T/TM complex and plasmin in the regulation of fibrinolysis during in vitro clot lysis 
using selectively activatable TAFI variants and a combination of these variants with MA.  
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4.2.  Introduction 
Thrombin activatable fibrinolysis inhibitor (TAFI) is a zinc-dependent metallocarboxypeptidase, which 
is synthesized in the liver as a pre-proenzyme and secreted into the circulation as a highly 
glycosylated zymogen. Trypsin-like enzymes such as plasmin, thrombin or the thrombin–
thrombomodulin (T/TM) complex proteolytically cleave TAFI at Arg
92 
resulting into the release of the 
glycosylated activation peptide and the generation of activated TAFI (TAFIa) [19, 25, 38]. The best 
studied function of TAFIa is its role in the regulation of fibrinolysis. During fibrinolysis, the C-terminal 
lysine residues on partially degraded fibrin act as a cofactor for the t-PA-plasminogen complex and 
consequently increase the catalytic efficiency of plasmin formation. TAFIa removes these newly 
exposed C-terminal lysines from partially degraded fibrin, impedes plasmin formation and attenuates 
fibrinolysis [176, 39]. Reports suggest that only a small amount of TAFI activation (TAFIa 
concentration; 1 nM, < 2% of the total plasma concentration of TAFI) is needed to downregulate the t-
PA-mediated fibrinolysis [25, 38]. 
Thrombin is a weak activator of TAFI, but both the cellular and soluble forms of the endothelial 
cell receptor thrombomodulin enhance the activation of thrombin-mediated TAFI activation by 1250-
fold [38, 41]. Plasmin is a stronger activator of TAFI than thrombin and the efficiency of plasmin-
mediated activation is enhanced by glycosaminoglycans such as heparin [178]. However, the catalytic 
efficiency of the plasmin-heparin complex is still 10-fold lower compared to the T/TM complex [38, 
178]. In literature, in vitro analyses describe the T/TM complex as the main physiological activator of 
TAFI [42, 43]. One in vivo study also demonstrated that TAFIa generated during E.coli-induced sepsis 
in baboons is inhibited by a monoclonal antibody (MA) specifically inhibiting T/TM-mediated activation 
of human TAFI [44]. However, recent in vitro characterization of MA/Nbs which inhibit TAFI activation 
by different mechanisms, suggests that next to T/TM-mediated TAFI activation, plasmin-mediated 
TAFI activation might also play an important role in the regulation of fibrinolysis [90, 154]. The 
contribution of the plasmin-mediated TAFI activation was further demonstrated using an ex vivo whole 
blood thrombi model and an in vivo mouse thromboembolism model [81, 179]. 
Recently, Miah et al. [43] and Vercauteren et al. [81] reported TAFI variants which are resistant 
to activation by either the T/TM complex or plasmin. Previously, monoclonal antibodies (MA) which 
inhibit TAFI activation through different mechanisms have been generated and characterized [81, 88, 
154]. The present study was planned to evaluate the relative contribution of plasmin- and T/TM-
mediated TAFI activation in the regulating of fibrinolysis using different TAFI variants selectively 
activatable by different TAFI activators.  
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4.3.  Experimental procedures 
4.3.1.  Materials 
All the experiments done in this study were performed with the wild-type form of human TAFI (TAFI-
T
147
-Ile
325
, TAFI wt, without additional tags). Primers for site-directed mutagenesis and sequencing 
were purchased from Sigma-Aldrich (St Louis, MO, USA). Pfx50 DNA polymerase was obtained from 
Life Technologies (Gent, Belgium). Polymerase chain reactions were carried out with the 
Mastercycler-Gradient from Eppendorf (Hamburg, Germany). Restriction enzyme DpnI was purchased 
from New England Biolabs (Hertfordshire, UK). Plasmid DNA purification was performed with the 
Plasmid mini kit I (Omega Bio-Tek, Doraville, GA, USA) and the Nucleobond
TM
 AX500 kit (Machery-
Nagel, Düren, Germany). DNA was sequenced by LGC Genomics (Berlin, Germany). Human 
thrombin, human plasmin, rabbit thrombomodulin and H-D-phenylalanyl-D-prolyl-L-arginine 
chloromethyl ketone (PPACK) were obtained from Sigma-Aldrich (St Louis, MO, USA), Enzyme 
Research Labs (South Bent, UK), American Diagnostica (Greenwich, CT, USA) and Biomol Research 
Labs (Plymouth Meeting, PA, USA), respectively. Hippuryl-L-arginine and aprotinin were bought from 
Bachem (Bubendorf, Switzerland) and Sigma-Aldrich (St Louis, MO, USA), respectively. Tissue-type 
plasminogen activator (t-PA, Actilyse®) was obtained from Boehringer Ingelheim. Dulbeccos modified 
Eagles medium, OptiMEM-1 medium containing glutamax and, Lipofectamine
TM
 2000® were 
purchased from Invitrogen (Merelbeke, Belgium). X-tremeGene 9 was bought from Roche Diagnostics 
GmbH, Roche Applied Science (Mannheim, Germany). Horseradish peroxidase (HRP) type VI was 
purchased from Sigma- Aldrich. 
4.3.2.  Methods 
4.3.2.1. Monoclonal antibodies 
The monoclonal antibodies MA-T12D11, raised toward TAFI purified from plasma and mainly inhibiting 
T/TM-mediated TAFI activation [88] and MA-TCK26D6, raised toward the stable human TAFI variant 
TAFI-A147-C305-I325-I329-Y333-Q335 (TAFI-ACIIYQ) in TAFI-deficient mice, mainly inhibiting 
plasmin-mediated TAFI activation [81] were used throughout this study.  
4.3.2.2. Preparation of TAFI depleted plasma 
Citrated plasma of 33 healthy human individuals was collected in-house with their written consent and 
was pooled for preparation of TAFI-depleted plasma (TDP). TDP was obtained using MA-T4E3 
coupled Sepharose 4B beads as described earlier [155]. 
4.3.2.3. Generation and production of TAFI variants 
The cDNA of TAFI-TI was previously cloned into the pcDNA3.1(+) vector [33]. Site-directed 
mutagenesis (QuikChange, Stratagene) was performed to introduce the P91S mutation. The K133A 
TAFI variant was previously generated [81]. We expressed and purified TAFI wt, TAFI-P91S and 
TAFI-K133A as described previousely [33]. 
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4.3.2.4. Evaluation of activatability of TAFI variants  
The activatability of TAFI variants was measured as described earlier [90]. Purified TAFI [90 nM (final 
concentration) in HEPES buffer (25 mM HEPES, 137 mM NaCl, 3.5 mM KCl, + 0.1% BSA pH 7.4)] 
was incubated with plasmin (final concentration: 500 nM) in the presence of CaCl2 (final concentration: 
5 mM) for 10 min at 22 °C for TAFI activation. After activation, aprotinin (1.25 µM) and the substrate 
hippuryl-L-arginine (final concentration: 4 mM) was added to the activation mixture and substrate 
conversion was allowed to proceed for 30 min at 22 °C. Reactions (100 µL) were stopped by addition 
of 20 µL of 1N HCl followed by 20 µL of 1N NaOH. Then, 25 µL of 1M Na2HPO4 (pH 7.4) and 30 µL of 
6% cyanuric chloride (dissolved in 1,4-dioxane) were added and the mixture was vortexed and 
centrifuged. 100 µL of the supernatant was transferred into a 96-well microtiter plate and the 
absorbance at 405 nm was measured. To be able to express the TAFIa activity in U mg
-1
, a standard 
spanning 15.6 µM to 2 mM hippurate was used to quantify the amount of hippurate formed by TAFI 
[90, 154]. Within the concentration range used, a linear correlation between the generated TAFIa 
activity and colour development was observed. One unit (U) carboxypeptidase activity is defined as 
the amount of enzyme converting 1 micromole of substrate into product per minute at 37 °C. 
Evaluation of the effect of the T/TM complex on TAFI activation was performed as described 
above, with some modifications. Thrombin (final concentration: 20 nM), and thrombomodulin (final 
concentration: 5 nM) was used instead of plasmin and aprotinin was replaced by PPACK (final 
concentration: 37.5 µM) to stop T/TM-mediated activation. Substrate conversion was allowed to proceed 
for 10 min at 22 °C instead of 30 min. The effect of the T/TM complex and plasmin on the activation of 
TAFI-variants to TAFIa was also evaluated on SDS-PAGE as described earlier [154]. 
4.3.2.5. Evaluation of the effect of various TAFI variants in clot lysis assay 
To evaluate the effect of the various TAFI activators in vitro clot lysis experiments were designed using 
TDP reconstituted with either TAFI wt or one of the generated TAFI mutants TAFI-P91S and TAFI-
K133A in the presence and absence of antibodies MA-T12D11 and MA-TCK26D6. Clot lysis was 
performed in a 96-well microtiter plate as described previously [154] with some modifications. Pooled 
TDP (final concentration: 30%) was incubated with either dilution buffer (10 mM Tris, 0.01%tween 20; 
pH 7.5) or with TAFI variants (final concentration: 54 nM), and/or antibodies (final concentration: 432 
nM, resulting in an 8-fold molar excess over TAFI). The plate was incubated at 37 °C for 10 min and t-
PA (final concentration: 120pM) was added. Then clot formation was induced by the addition of CaCl2 
(final concentration: 10.6 mM) and the plate was read at 2-min intervals at 405 nm at 37 °C. The 50% 
clot lysis time was determined and defined as the time interval between the time point of full clot 
formation to the midpoint of the maximum turbidity to clear transition. 
4.3.2.6. Crystallographic structural representation 
The structure of TAFI was taken from the protein databank (PDB ID: 3D66) [55] and represented using 
Pymol (DeLano Scientific LLC, Palo Alto, USA) (Fig. 4.1).  
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Figure 4.1. Ribbon diagram representing the 3D structure of TAFI. Grey, green and cyan colors represent the 
activation peptide, the catalytic domain and the dynamic flap of TAFI, respectively. R92 (white residue) is the cleavage site 
for plasmin, thrombin and the T/TM complex. Residues responsible for selective activation of TAFI by plasmin (P91) and the 
T/TM complex (K133) are represented in blue and yellow colored spheres, respectively. The epitope of MA-T12D11 (G66) 
and MA-TCK26D6 (D87 and T88) are depicted in brown and pink colored spheres, respectively. 
4.3.2.7. Statistical analysis 
Quantitative data were summarized by mean and standard deviation obtained from at least three 
independent experiments. Statistical significance was determined with the unpaired t-test using Graph 
Pad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA). Values were considered as 
statistically significant at two-tailed p-values < 0.05. For the clot lysis experiments a paired two-tailed t-
test was performed. 
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4.4.  Results  
4.4.1.  Characterization of TAFI variants 
To generate a mutant which is selectively activatable by plasmin the P91S mutation was introduced 
[43]. TAFI-K133A, selectively activatable by the T/TM complex has previously been generated in our 
laboratory [81]. Residue 91 is located near the cleavage bond whereas residue 133 is located in the 
catalytic site. Purified recombinant TAFI variants were tested for TAFIa activity upon activation by 
either plasmin or the T/TM complex. TAFIa activity generated through activation of TAFI wt with either 
plasmin or the T/TM complex was 9.40 ± 1.13 U mg
-1
 and 17.8 ± 2.07 U mg
-1
, respectively (Table 4.1). 
Compared to TAFI wt, TAFI-K133A is 20-fold less activatable by plasmin and 1.4-fold more activatable 
by the T/TM complex whereas TAFI-P91S is 1.2-fold more activatable by plasmin and 9-fold less 
activatable by the T/TM complex. 
Table 4.1: Activatability of TAFI variants by plasmin and the T/TM complex 
TAFI-variant 
TAFI-TI variants activation (U/mg) 
By plasmin By T/TM 
TAFI-TI (wt) 9.40 ± 1.13 17.8 ± 2.07 
TAFI-TI-P91S 10.9 ± 1.58 2.09 ± 1.10* 
TAFI-TI-K133A 0.47 ± 0.23* 24.7 ± 4.65* 
Mean  SD, n  3;  p < 0.01 vs. TAFI. 
To confirm the effect of TAFI activators on different TAFI variants, fragmentation products of 
TAFI upon activation of TAFI variants by plasmin or the T/TM complex were analyzed using SDS-
PAGE. These data confirmed that TAFI-K133A is selectively activatable by the T/TM complex and 
TAFI-P91S is selectively activatable by plasmin (data not shown).  
4.4.2.  Effect of TAFI variants during in vitro clot lysis assay 
In order to investigate the functional effect of the different TAFI variants on clot lysis assay, TDP was 
preincubated either with buffer (negative control) or TAFI variants. Calcium was used to initiate 
coagulation and 120pM t-PA (final concentration) was used to initiate fibrinolysis. The 50% clot lysis 
time in TDP was 44 ± 12 min (Table 4.2 and Fig. 4.2). Addition of TAFI wt in TDP prolonged clot lysis 
time 4.3-fold (184 ± 34 min) whereas TAFI-P91S and TAFI-K133A were only able to prolong clot lysis 
time 2.4-fold and 2.1-fold (103 ± 24 min and 93 ± 23 min vs. 44 ± 12 min for no addition), respectively 
in TDP.  
Chapter 4 
 
Page | 70 
 
 
Figure 4.2. Clot lysis profile of TAFI variants. Clot lysis profile in TDP supplemented with TAFI wt (), TAFI-P91S (), 
TAFI-K133A (▲) and TDP alone () with 120pM t-PA and TDP alone without 120pM t-PA (). The representative curves 
are shown.  
4.4.3.  Effect of TAFI variants in presence of MA-T12D11 and MA-TCK26D6 during in 
vitro clot lysis 
MA-T12D11 mainly inhibits T/TM-mediated TAFI activation [88]. Addition of MA-T12D11 to TDP 
supplemented with either TAFI wt, TAFI-P91S, or TAFI-K133A reduced clot lysis time 2.2-, 2.3- and 
3.7-fold, respectively (Table 4.2). MA-TCK26D6 mainly inhibits plasmin-mediated TAFI activation [81]
.
 
Addition of MA-TCK26D6 to TDP supplemented with either TAFI wt, TAFI-P91S or TAFI-K133A 
reduced clot lysis time 4.1-, 4.3- and 2.3-fold, respectively (Table 4.2). 
Table 4.2: Effect of MA on 50% clot lysis time in presence of TAFI variants in TDP  
Addition 
t-PA (120pM) 
CLT (min) Relative reduction in clot lysis time 
TAFI-TI (wt) 184 ± 34 1.00 
TAFI-TI + T12D11 84 ± 17 2.20 ± 0.13 
TAFI-TI + TCK26D6 45 ± 9 4.09 ± 0.44 
TAFI-TI-P91S 103 ± 24 1.79 ± 0.08  
TAFI-TI-P91S + T12D11 79 ± 17 2.33 ± 0.05 
TAFI-TI-P91S + TCK26D6 43 ± 8 4.32 ± 0.24 
TAFI-TI-K133A 93 ± 23 1.99 ± 0.14 
TAFI-TI-K133A + T12D11 51 ± 15 3.67 ± 0.59† 
TAFI-TI-K133A + TCK26D6 83 ± 25 2.28 ± 0.33 
Mean  SD, n  3;  p < 0.02 vs. TAFI-TI;  p < 0.01 vs. TAFI-TI-P91S and †p < 0.005 vs. TAFI-TI-K133A. CLT, clot lysis time, Relative reduction in clot 
lysis time vs. TAFI-TI 
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4.5.  Discussion 
TAFIa exerts an antifibrinolytic effect by removing C-terminal lysines from partially degraded FDPs and 
thereby abolishes their cofactor function in the activation of plasminogen by t-PA [19, 25, 38]. Until 
recently it was believed that the T/TM complex is the only activator of TAFI during fibrinolysis [42, 43], 
but recent in vitro and in vivo studies suggest that the plasmin and the T/TM complex both contribute 
to the TAFI activation in the regulation of fibrinolysis [81, 90, 154, 179]. TAFI variants selectively 
activatable by various activators (thrombin, the T/TM complex and/or plasmin) might be excellent tools 
to study the mechanism of TAFI activation, regulation and its role in physiological conditions. 
Therefore, TAFI mutants selectively activatable by either plasmin (TAFI-TI-P91S) [43] or the T/TM 
complex (TAFI-TI-K133A) [81] were included in the study. 
  Compared to TAFI wt, TAFI-K133A is 20-fold less activatable by plasmin and 1.4 fold more 
activatable by the T/TM complex whereas TAFI-P91S is 9-fold less activatable by the T/TM complex 
and 1.2-fold more activatable by plasmin.  
The in vitro clot lysis assays performed in TDP supplemented with TAFI variants in this study 
revealed that TAFI-P91S and TAFI-K133A were only able to exert approximately half of the 
antifibrinolytic effect compared to TAFI wt (Table 4.2 and Fig. 4.2). A similar type of study was 
performed by Miah et al. [43] using TAFI wt and TAFI-P91S variant supplemented to TDP. Miah et al. 
concluded that plasmin-mediated TAFI activation is not important in the regulation of fibrinolysis. 
However, in their clot lysis assays they not only substituted 30% TDP with different concentrations of 
TAFI variants and CaCl2 (10 mM, final concentration), but also supplemented with exogenous 
thrombin (6 nM vs. none, final concentration), t-PA (200 pm vs. 120pM, final concentration) and 75% 
phosphatidylserine/25% phosphatidylcholine vesicles (20 µM vs. none, final concentration). Therefore, 
the contradiction in the results might be attributed to the different experimental conditions used in both 
the assays. Substition of activated TAFI wt, TAFI-P91S and TAFI-K133A in TDP revealed that both the 
mutants have similar antifibrinolytic activity compared to TAFI wt (data not shown). This indicates that 
plasmin and the T/TM complex both are involved in TAFI activation during fibrinolysis.  
To further confirm our results we also evaluated the effect of TAFI variants in presence of MA-
T12D11 and MA-TCK26D6 which mainly inhibits T/TM- and plasmin-mediated TAFI activation, 
respectively, during in vitro clot lysis. Addition of MA-T12D11 and MA-TCK26D6 to TDP supplemented 
with TAFI-K133A and TAFI-P91S, respectively showed a synergistic effect on the reduction of clot 
lysis time (Table 4.2). Moreover, the reduced clot lysis time was found to be equivalent to the clot lysis 
time of TDP. MA-T12D11 also revealed a similar clot lysis profile in TDP supplemented with TAFI wt 
and TAFI-P91S. To our surprise, addition of MA-TCK26D6 completely abolished the TAFIa effect. A 
similar profibrinolytic effect of MA-TCK26D6 was previously demonstrated by Vercauteren et al. [81] 
using TAFI wt and TAFI-K133A.  
To conclude, this is the first detailed report revealing the relative contribution of the T/TM 
complex and plasmin in the regulation of fibrinolysis using TAFI variants and a combination of TAFI 
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variants and MA reconfirming that plasmin-mediated TAFI activation also plays an important role in 
clot lysis and consequently in the regulation of fibrinolysis 
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5.1.  Abstract 
Background: Activated thrombin-activatable fibrinolysis inhibitor is an important regulator of t-PA-
mediated fibrinolysis in humans as well as mice. Recently, TAFI single-gene-deficient mice expressing 
human TAFI (hTAFI) have been generated. These transgenic hTAFI mice constitute an interesting tool 
to study the effect of TAFI inhibitors which selectively inhibit human TAFI.  
Objectives: To establish a model to evaluate the inhibitory effect of anti-human TAFI monoclonal 
antibodies (MA) which inhibit the activation of human TAFI through different mechanisms. 
Methods and results: Using an in vivo thromboembolism model in which we quantified fibrin 
deposition before and after injection of tissue factor (TF), we concluded that TF-induced fibrin 
deposition in hTAFI mice was much lower compared to WT mice (fibrin deposition in lungs after TF 
injection was 4.7, 28.1 and 84.7 µg/ml in TAFI KO, hTAFI and WT mice, respectively). Using in vitro 
thromboelastometry we were able to define conditions in whole blood i.e. 8 nM t-PA to induce clot lysis 
and evaluation of lysis 60 min after clot formation (L60) that allowed quantitative evaluation of the effect 
of human TAFI inhibitors. Under these conditions, all inhibitory anti-human TAFI MA significantly 
enhanced fibrinolysis in blood from hTAFI mice (L60; 50 ± 9%, 53 ± 9% and 78 ± 4% for MA-T12D11, 
MA-TCK11A9, MA-TCK27A4, respectively, vs. 8 ± 2% in the presence of a control MA; p  0.0001). 
Conclusion: We established an in vitro model which can be used to evaluate human TAFI inhibitors. 
Using this model we determined the profibrinolytic properties of a panel of MA that inhibit human TAFI 
activation through different mode of actions. 
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5.2.  Introduction 
The fibrinolytic system plays an important role in blood clot dissolution to preserve the blood fluidity within 
the vascular system. During fibrinolysis, inactive plasminogen is converted into active plasmin by 
tissue-type plasminogen activator (t-PA). Active plasmin then degrades fibrin into fibrin degradation 
products (FDPs) resulting in blood clot dissolution. Activated thrombin-activatable fibrinolysis inhibitor 
(TAFIa) retards fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin and 
thereby attenuates its cofactor function in the t-PA mediated plasmin generation [38, 164]. In vivo 
evidence for a role of TAFI in fibrinolysis have been obtained in several animal models through 
pharmacological inhibition [44, 78, 81, 95, 97, 102] as well as using TAFI single-gene-deficient mice 
(TAFI KO) [60, 83]. 
TAFIa is a metallocarboxypeptidase, which is synthesized in the liver and secreted into the 
circulation as a 56 kDa glycosylated zymogen. The proenzyme TAFI is cleaved at Arg
92 
by trypsin-like 
enzymes such as plasmin, thrombin or the thrombin/thrombomodulin (T/TM) complex, generating 
TAFIa [20].
 
Even though the T/TM complex is accepted to be the physiological activator of TAFI in the 
regulation of fibrinolysis [42, 43], recent in vitro and ex vivo studies suggest that plasmin also plays an 
important role in TAFI activation and consequently in the regulation of fibrinolysis [81, 154, 179]. 
However, in vivo studies are necessary to unravel the relative contribution of the different TAFI 
activators. To the best of our knowledge, only two studies reported inhibition of TAFIa generation in 
vivo. One in vivo study demonstrated that TAFIa generated during E.coli-induced sepsis in baboons is 
inhibited by a monoclonal antibody (MA) specifically inhibiting T/TM-mediated activation of human 
TAFI [44]. A second study using a specific MA that mainly inhibits plasmin-mediated TAFI activation 
demonstrated a strong profibrinolytic effect in a mouse thromboembolism model [81].  
To date, no physiological inhibitor of TAFIa is known [28]. However, TAFIa is sensitive to 
inhibition by chelating agents, by compounds disrupting disulfide bridges, by small synthetic substrate 
analog inhibitors and by naturally occurring metallocarboxypeptidase inhibitors [54, 62, 85, 87, 163]. 
Despite of an increasing list of TAFI inhibitors, the applicability of most of these inhibitors is restricted 
given their lack in selectivity, safety and the occurrence of a biphasic effect. On the other hand 
monoclonal antibodies (MA) have been established as candidate drug molecules with a high 
specificity and stability. MA that hamper plasmin-, thrombin- and T/TM-mediated activation of TAFI to 
TAFIa as well as MA that inhibit TAFIa activity directly have been described [30, 44, 81, 88, 89, 154, 
164]. Unfortunately, most of these MA reveal no cross-reactivity with mouse or with rat TAFI, thereby 
excluding their in vivo evaluation in small animals [88, 154]. 
The amino acid sequence of mouse and rat TAFI share approximately 85% identity with 
human TAFI including conservation of important residues involved in substrate binding and specificity, 
glycosylation and zinc binding. TAFI from all three species have similar biochemical characteristics 
with respect to their activatability by the T/TM complex and their antifibrinolytic effect during in vitro 
clot lysis [34-36]. Addition of human TAFI was reported to be more efficient in retarding clot lysis in 
mouse and rat TAFI-depleted plasma compared to mice and rat TAFI [35]. Recently, mice expressing 
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human TAFI (hTAFI) were generated from TAFI KO mice [181]. These mice might be an excellent tool 
to evaluate the effect of TAFI inhibitors exclusively inhibiting human TAFI.  
In the present study, we aimed to evaluate the use of human TAFI transgenic mice to confirm 
the profibrinolytic properties of anti-human TAFI MA.  
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5.3.  Experimental procedures 
5.3.1.  Animals 
C57BL/6J mice (WT) were purchased from Charles River Laboratories (Wilmington, MA, USA). TAFI 
KO mice (in a 100% C57BL/6J background) and TAFI KO mice in which the cDNA encoding human 
TAFI was transferred (transgenic hTAFI-mice in a 100% C57BL/6J background) were generated as 
previously described [60, 181]. Mice were kept in microisolation cages on a 12-h day–night cycle with 
water and food ad libitum. Housing and procedures involving experimental animals were conducted in 
accordance with institutional guidelines and on a license (P087/2011) approved by the Ethical 
Committee of the KU Leuven, Belgium. All thromboembolism experiments were carried out with 6-8 
weeks old male mice (weighing 20 to 25 g; 8 TAFI KO, 43 hTAFI and 33 WT mice in total) and all 
rotational thromboelastometry (ROTEM) analyses were carried out with 12-16 weeks old male mice (9 
TAFI KO, 17 hTAFI and 9 WT mice in total)  
5.3.2.  Methods 
5.3.2.1. Genotypic analyses 
Genomic DNA was isolated from mouse tail biopsies as previously described [78] and used as a 
template in PCR to verify the genotypes. Each sample from hTAFI mice and TAFI KO mice were 
subjected to two separate PCR reactions with the following primer sets to detect (i) the human TAFI 
gene, i.e. forward primer 5'- CTGTGAGCAGCATGTCTTCG-3' and reverse primer 5'-
CACAAGCCTCAGGAGATTGG-3', respectively), detecting a 601-bp amplification product in hTAFI+/+ 
and hTAFI+/-) samples and (ii) the mouse TAFI gene, i.e. forward primer 5'-
GCTCTGGTTCTCTGGTTGG-3' and reverse primer 5'-CAGTCTTCTATGGTAACAGC-3' (annealing in 
introns 1 and 2 [ENSMUSG00000021999]) detecting a 446-bp amplification product in TAFI
+/+
 and 
TAFI
+/-
 samples or reverse primer 5'-TATTGCTGAAGAGCTTGGCGGCG-3' (derived from the 
phosphoglycerine thymidine kinase–neomycin expression cassette, pKONEO) detecting a 574-bp 
amplification product in TAFI
+/-
 and TAFI
-/-
 sample. PCR products were electrophoresed on a 1.5% 
agarose gel, post-stained with 2 X GelRed (Biotium, Hayward, CA, USA) in 1 M NaCl, and visualized 
with a UV transilluminator and the UVP Biodoc-It Imaging System (UVP, Upland, CA, USA). 
5.3.2.2. Determination of human TAFI and mouse TAFI antigen levels in hTAFI mouse 
Following anesthesia (isoflurane; 2.5%), blood was collected via the retro-orbital vein on sodium citrate 
3.8% (1:10 v/v). Plasma was prepared by centrifugation of blood at 2000  g for 20 min. TAFI antigen 
levels in mouse plasma were determined using in-house developed ELISAs, MA-RT36A3F5/MA-
RT82F12-HRP [182] and MA-T12D11/pAb-anti-TAFI-HRP, for mouse and human TAFI, respectively. 
5.3.2.3. Monoclonal antibodies 
Monoclonal antibody MA-T12D11, mainly inhibiting T/TM-mediated TAFI activation was raised toward 
the plasma-derived human TAFI [88]. MA-TCK11A9, mainly inhibiting plasmin-mediated TAFI 
activation [81, 154] and MA-TCK27A4, inhibiting plasmin-, thrombin- and T/TM-mediated TAFI 
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activation [154] were raised toward the stable human variant TAFI-A
147
-C
305
-I
325
-I
329
-Y
333
-Q
335
 (TAFI-
ACIIYQ) [52]. All these MA only react with human TAFI. MA-Tom1-41B2 directed toward tomato pectin 
methylesterase [183] reveals no cross-reactivity with human nor with mouse TAFI and was used as 
negative control MA throughout this study. 
5.3.2.4.  In vitro rotational thromboelastometry (ROTEM) analysis  
Blood samples of the three genotypes (TAFI KO, hTAFI and WT) were collected by retro-orbital vein 
puncture into sodium citrate (3.8%, 1:10 v/v), and analyzed on a ROTEM delta instrument (Tem 
International, Munich, Germany) as described previously, with some modifications [78]. The blood 
samples (300 µL) were incubated with CaCl2 (final concentration: 20 mM) and increasing doses of 
recombinant human t-PA (final concentration: 4–20 nM; Actilyse; Boehringer Ingelheim, Brussels, 
Belgium). The clot formation and lysis reaction was monitored for 2 h. The degree of lysis (L,%) defined 
as the decrease in amplitude (mm) relative to the maximal amplitude ([(Amax-At)/Amax]*100) was 
determined at 30 min, 45 min (L45), 60 min (L60) and 120 min after start of clot formation. The effect of the 
MA (328 nM; corresponding to 8-fold molar excess over TAFI compared to the concentration of human 
TAFI in male hTAFI mice) was evaluated in TAFI KO, hTAFI and WT mice in the presence of 8 nM t-PA. 
When no MA was added, PBS was added to the reaction mixture. 
5.3.2.5. In vivo mouse thromboembolism model 
The mouse thromboembolism model and fibrin extraction was performed as described previously [81]. 
Briefly, saline was injected intravenously in the tail vein of non-anesthetized TAFI KO, hTAFI and WT 
mice. After 5 minutes, thromboplastin (2.5 µg/kg, intravenously) was administered to induce 
thromboembolism in the lungs. Control mice only received saline injections. Mice were anesthetized 
with pentobarbital (Nembutal; 60 mg/kg intraperitoneally) 10 minutes after saline/thromboplastin 
injections. To prevent postmortem coagulation, heparin (heparin LEO; 500 IU) was injected in the vena 
cava 20 minutes after thromboembolism induction. Three minutes later, lungs were perfused with 
saline containing heparin (10 IU/mL). Isolated left and right lungs were snap-frozen in liquid nitrogen 
and stored at (-80°C) until homogenization. For homogenization, 4 mL of PBS per gram of tissue was 
added to the frozen lungs. Subsequently, the lung tissues were homogenized with a tissue 
homogenizer (Ribolyzer Fast Prep 24 System, MP Biomedicals) and centrifuged. After resuspension 
of the pellet containing insoluble fibrin, ocriplasmin (final concentration: 2µM) (a kind gift from 
Thrombogenics, Leuven, Belgium) was added to convert insoluble fibrin into soluble FDPs. 
Subsequent to incubation of the samples for 4 hours at 37°C, the samples were centrifuged. The 
supernatants were collected and fibrinolysis was stopped by adding aprotinin (final concentration: 
4µM). FDPs and thereby the corresponding fibrin deposition was determined using a commercial 
„„Mouse Fibrinogen ELISA” with reactivity for FDPs (Immunology Consultants Laboratory, Portland, 
USA) as per manufacturer‟s instruction. Data represent the average of the fibrin deposition in left and 
right lungs. 
Human TAFI transgenic mice 
Page | 79  
 
5.3.2.6. Statistical analysis 
Quantitative data were summarized by mean and standard error of mean (SEM) obtained from at least 
three independent experiments except for human TAFI levels and EC50 of t-PA which were 
summarized as mean and standard deviation (SD). Statistical significance was determined with the 
unpaired t-test using Graph Pad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA). 
Differences were considered as statistically significant at two-tailed p-values < 0.05. A nonlineair 
regression (log agonist vs. normalized response-variable slope) was used to calculate the EC50 of t-
PA. D'Agostino & Pearson omnibus normality test was performed to analyze distribution of human 
TAFI antigen in the plasma of male and female hTAFI mice. 
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5.4.  Results  
5.4.1.  Genotypic analysis and TAFI plasma levels in hTAFI mouse 
Genotypic analyses confirmed that hTAFI mice only carry the human TAFI gene and lack the mouse 
TAFI gene [181]. Mouse and human TAFI protein levels were determined in plasma of hTAFI mice. No 
mouse TAFI was detected in plasma of hTAFI mice (i.e. < 0.2 µg/ml) whereas human TAFI was 
expressed at 1.8  1.2 µg/ml (average of male and female mice); range: 0.2-4.9 µg/ml; n = 237. A 3.5-
fold higher level was observed in male vs. female hTAFI mice (2.6  0.9 µg/ml; range: 0.9-4.9 µg/ml; n 
= 133 vs. 0.72  0.36 µg/ml; range: 0.2-1.9 µg/ml n = 104, respectively; p < 0.0001). Our distribution 
analyses for the plasma TAFI concentration revealed that data were not normally distributed in both 
female (p = 0.002) as well as in male (p = 0.043) hTAFI mice.  
 
 
Figure 5.1: Fibrin deposition in lungs before (grey bars) and after (black bars) induction of thromboembolism. FDPs 
are expressed as µg/ml fibrinogen equivalents and are represented as mean ± SEM. Significant differences (after vs. before 
thromboembolism) are indicated (* p < 0.05 and ** p < 0.002). 
5.4.2.  Thromboembolism model 
To quantify the fibrinolytic capacity of hTAFI mice, fibrin deposition was quantified in the lungs of male 
TAFI KO, hTAFI and WT mice before and after induction of thromboembolism (Fig. 5.1). Before 
injection of thromboplastin, TAFI KO, hTAFI and WT TAFI mice revealed very low fibrin deposition in 
lungs (2.3 ± 0.9 µg/ml, 4.4 ± 0.8 µg/ml, 8.3 ± 2.6 µg/ml, respectively). No significant difference was 
Human TAFI transgenic mice 
Page | 81  
 
observed among the three genotypes before injection of thromboplastin. Upon injection of 
thromboplastin, deposition of fibrin did not significantly increase in TAFI KO mice (4.7 ± 1.8 µg/ml n = 
5 vs. 2.3 ± 0.9 µg/ml n = 3, p > 0.05) but significantly increased in WT mice (84.7 ± 15.1 µg/ml n = 22 
vs. 8.3 ± 2.6 µg/ml n = 11, p < 0.002) as previously described by Vercauteren et al. [81]. Even though 
in hTAFI mice a significant increase in fibrin deposition was observed in the lungs upon tissue factor 
injection (28.1 ± 9.2 µg/ml n = 26 vs. 4.4 ± 0.8 µg/ml n = 17, p < 0.05), the intrinsic high variability 
precluded the use of this thromboembolism model in hTAFI mice for reliable evaluation of TAFI 
inhibitors that react with human TAFI.  
 
 
Figure 5.2. Lysis in rotational thromboelastometry with increasing tissue-type plasminogen activator (t-PA) 
concentration. Lysis (%) is expressed as the decrease in amplitude (mm) relative to the maximal amplitude ([(Amax-
At)/Amax]*100) at 30 min (A), 45 min (B), 60 min (C) and 120 min (D). Blood from TAFI KO mice (grey curve; ----) human 
TAFI-transgenic mice (black curve; ) and WT mice (solid grey curve; ). Data represent mean ± SEM, n = 5 for each 
set of experiments. 
5.4.3.  In vitro rotational thromboelastometry analysis 
To explore the effect of human TAFI on fibrinolysis in mice, whole blood samples (n = 5) from TAFI 
KO, hTAFI and WT mice were analyzed by thromboelastometry using different t-PA concentrations 
(Fig. 5.2). Compared to lysis in blood from WT mice, lysis in hTAFI mice was accelerated at all the t-
PA concentrations above 6 nM at any time point (30 min, 45 min, 60 min and 120 min, Fig. 5.2A, B, C 
and D, respectively). Compared to lysis in blood from TAFI KO mice, lysis was delayed in blood from 
hTAFI mice at 30 min, 45 min and 60 min, but this effect disappeared at 120 min (EC50 values for t-PA 
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at t=120 min: 6.8 ± 0.1 nM, 7.3 ± 0.2 nM and 14.2 ± 0.7 nM for TAFI KO, hTAFI and WT mice, 
respectively; p < 0.0001 TAFI KO and hTAFI vs. WT; Fig. 5.2D). 
Using 8 nM t-PA, L45 was 50 ± 9% 13 ± 3% and 3 ± 1% for TAFI KO, hTAFI and WT mice, 
respectively (p < 0.005, p < 0.001 and p < 0.01 for TAFI KO vs. hTAFI, TAFI KO vs. WT and hTAFI vs. 
WT, respectively) and L60 was 82 ± 5% 26 ± 5% and 7 ± 1% for TAFI KO, hTAFI and WT mice, 
respectively (p < 0.0001, p < 0.0001 and p < 0.01 for TAFI KO vs. hTAFI, TAFI KO vs. WT and hTAFI 
vs. WT, respectively). Based upon these data it was concluded that the use of 8 nM t-PA 
concentration and evaluation of the lysis at 60 min provided the most sensitive conditions for 
evaluation of the profibrinolytic effect of TAFI inhibitors. 
 
 
Figure 5.3: Effect of anti-human TAFI MA on t-PA-mediated fibrinolysis in rotational thromboelastometry. Lysis (%) is 
expressed as the decrease in amplitude (mm) relative to the maximal amplitude ([(Amax-At)/Amax]*100) at 60 min. Lysis in 
blood from TAFI KO mice (empty bars, n = 4), human TAFI mice (black bars, n = 12) and WT mice (grey bars, n = 4). 
5.4.4.  Effect of anti-human TAFI monoclonal antibodies on in vitro fibrinolysis  
The effect of anti-human TAFI MA on in vitro fibrinolysis was evaluated by thromboelastometry in 
whole blood from TAFI KO (n = 4), hTAFI (n = 12) and WT mice (n = 4) using 8 nM t-PA concentration 
and evaluation of L60 (Fig. 5.3). The human-specific anti-TAFI MA and the control antibody MA-Tom1-
41B2 did not affect fibrinolysis in WT mice (L60; 2 ± 1%, 5 ± 2%, 7 ± 4% and 6 ± 2% for MA-Tom1-
41B2, MA-T12D11, MA-TCK11A9 and MA-TCK27A4, respectively, vs. 2 ± 1% for PBS; p > 0.05 all vs. 
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PBS) and TAFI KO mice (L60; 56 ± 18%, 58 ± 21%, 63 ± 18% and 83 ± 7% for MA-Tom1-41B2, MA-
T12D11, MA-TCK11A9 and MA-TCK27A4, respectively, vs. 42 ± 21% for PBS; p > 0.05 all vs. PBS). 
However, in hTAFI mice all MA, except MA-Tom1-41B2 (L60 8 ± 2%; p > 0.05 vs. PBS) significantly 
enhanced fibrinolysis (L60, 50 ± 9%, 53 ± 9% and 78 ± 4% for MA-T12D11, MA-TCK11A9, MA-
TCK27A4, respectively, vs. 8 ± 2% for MA-Tom1-41B2; p < 0.0001 all vs. MA-Tom1-41B2). 
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5.5.  Discussion 
Thromboembolism is one of the major causes of morbidity and mortality in the western world. 
Currently available therapy is associated with bleeding complications and requires close lab-
monitoring [62]. Therefore, development of clinically safe and easy to use drugs is essential. Several 
in vitro, ex vivo and in vivo studies in various animal models, including the use of WT and TAFI KO 
mice, have indicated the important role of TAFI in the regulation of fibrinolysis [44, 60, 78, 81, 83, 95, 
97, 102, 154, 179, 184]. Numerous clinical studies have also correlated TAFI antigen levels with 
cardiovascular events such as angina pectoris [168], coronary artery disease [169], ischaemic stroke 
[170], myocardial infarction [73] and venous thrombosis [69]. Considering the fact that TAFI plays a 
pivotal role in fibrinolysis while the coagulation cascade remains unaffected, TAFI targeting based 
therapies may result in fewer bleeding complications [62] and might also be useful in lowering the 
required dose of infused plasminogen activators during thrombolytic therapy. Alternatively, TAFI 
inhibitors could also be used in the prevention of thrombotic events. Since small molecule inhibitors of 
TAFIa revealed several drawbacks such as lack of selectivity and safety as well as a biphasic effect 
[85, 87], anti-human TAFI MA might be interesting lead molecules in the development of 
biotherapeutics to prevent and/or to treat thrombotic disorders. Recently MA have been generated 
against human TAFI that impair human TAFI activation in a highly selective manner through different 
mechanisms. Due to the fact that these MA do not cross react with mouse or rat TAFI, these MA 
cannot be evaluated in vivo in mice or rat models [88, 154]. 
 In the present study we have characterized and evaluated hTAFI transgenic mice in models to 
determine the profibrinolytic properties of anti-human TAFI MA. First, we have determined the human 
TAFI antigen levels in hTAFI mice and observed that, for yet unknown reasons, male hTAFI mice 
express approximately 3.5-fold higher TAFI levels than female hTAFI mice (2.6 µg/ml vs.0.72 µg/ml, 
respectively). Therefore, we selected only male mice for further in vitro and in vivo experiments. The 
different genotypes (TAFI KO, hTAFI and WT mice) were subjected to a thromboembolism model by 
injection of tissue factor [81]. No significant differences were observed in fibrin deposition in lungs of 
TAFI KO mice before and after thromboplastin injection, whereas fibrin deposition in lungs of WT mice 
increased 10-fold after injection of thromboplastin. This is in accordance with previous studies [78, 81, 
95, 97, 102] confirming the antifibrinolytic role of TAFI in the regulation of fibrinolysis. Even though 
fibrin deposition was also increased upon injection of thromboplastin in hTAFI mice, the 6-fold 
increase was less than that observed in WT mice. These data indicate that the hTAFI mice are less 
susceptible to fibrin deposition (or have a higher fibrinolytic capacity) than WT mice. Previous in vitro 
clot lysis studies in healthy individuals suggested that plasma TAFI levels influence the clot lysis time 
in a TAFIa dependent manner [31]. However, another study revealed that only a small amount of TAFI 
activation (TAFIa concentration; 1 nM, < 2% of the total plasma concentration of TAFI) is needed to 
downregulate the t-PA-mediated fibrinolysis and that rather than the concentration, the rate of TAFI 
activation and stability of TAFIa affects fibrinolysis [38]. In this study we did not found any correlation 
between human TAFI antigen levels (2.1  0.7 µg/ml, range: 0.9-3.7 µg/ml; n = 22 in 
thromnoembolism-induced mice) and fibrin deposition in lungs of hTAFI mice (r; 0.1673 and P, 0.41). 
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The differences in fibrin deposition between hTAFI and WT mice could be result of a less efficient 
activation of human TAFI through the mouse thrombin-thrombomodulin complex or mouse plasmin. 
However, it is interesting to note however that once activated human TAFIa is 4-fold more stable than 
mouse TAFIa [35], thereby expecting rather a more pronounced antifibrinolytic effect of human TAFIa. 
Alternatively, the lower antifibrinolytic status observed in hTAFI mice could also result from a less 
efficient catalytic activity of human TAFIa on mouse fibrin. Indeed, TAFI activity in hTAFI mice was 
approx. 60% of TAFI activity in WT mice (data not shown). Inspite using twenty-six animals, we were 
only able to see a small significant TF-induced fibrin deposition in lungs of hTAFI mice (p = 0.045). 
The evaluation of TAFI inhibitors in vivo in hTAFI mice may provide some trend, but needs a large 
number of animals to evaluate multiple TAFI inhibitors which will be non-ethical and will be against the 
Russell and Burch 3R principle [185]. The lower susceptibility to fibrin deposition, the large intrinsic 
variability of the thromboembolism model and the non-ethical requirement of a large number of 
animals led us to conclude that the use of this model in hTAFI mice is not sensitive and suitable 
enough to study the effect of the TAFI inhibitors.  
Previous studies revealed a TAFI-related retardation of t-PA-mediated fibrinolysis in rotational 
thromboelastometry [78, 186]. In the current study we performed comparative in vitro rotational 
thromboelastometry using whole blood from TAFI KO, hTAFI and WT mice. Evaluation of lysis at 
different time points using varying concentrations of t-PA revealed that, in line with the in vivo 
thromboembolism data, the fibrinolytic capacity of hTAFI mice (at L30, L45 and L60) is intermediate 
between that of TAFI KO and WT mice, but similar to TAFI KO mice 120 min after start of lysis (L120). 
This might again be attributed to either less efficient TAFI activation or less efficient catalytic activity of 
human TAFIa on mouse fibrin. Since thromboelastometry appeared to be more sensitive and more 
flexible with respect to different conditions and parameters this model was further optimized for 
evaluation of the effect of human TAFI inhibitors in whole blood from hTAFI mice. All the three anti-
human TAFI MA were found to exhibit strong profibrinolytic properties when tested on whole blood 
from hTAFI expressing mice. Compared to no addition and a negative control antibody MA-Tom1-
41B2 (L60 = 7 to 8 %), MA-T12D11, MA-TCK11A9, and MA-TCK27A4 enhanced fibrinolysis up to ten-
fold (L60 = 50 to 78 %). Under these conditions (L60 at 8 nM t-PA) none of the MA demonstrated any 
effect in TAFI KO mice or WT mice. These findings confirm the strong profibrinolytic effect of MA-
T12D11, MA-TCK11A9, and MA-TCK27A4 towards human TAFI as previously demonstrated in vitro 
and also elucidated that whole blood from hTAFI mice constitute an excellent tool to evaluate TAFI 
inhibitors towards human TAFI (Fig. 5.3). 
It is of interest to note that both MA-TCK11A9 which mainly prevents activation of human TAFI 
by plasmin and MA-T12D11, that inhibits the activation of human TAFI mainly by the T/TM complex, 
exert similar profibrinolytic properties in thromboelastometry (L60 = 50 to 53 %) indicating that both 
activators contribute to the activation of TAFI in the regulation of fibrinolysis in this whole blood 
thrombus model confirming previous reports [81, 154, 179]. MA-TCK27A4, inhibiting the activation of 
TAFI by plasmin, thrombin as well as the T/TM complex [154] showed a significantly higher lysis (L60 = 
78 %; p < 0.01 vs. MA-T12D11) suggesting that the contribution of all TAFI activators is essential for 
the strongest antifibrinolytic effect. It should be taken into account however that in a recent study 
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(Semeraro et al. unpublished results) it was found that MA-TCK11A9 not only interferes with plasmin-
mediated TAFI activation but might also reduce TAFIa activity in a functional assay using fibrin as a 
substrate. Therefore, further investigations are essential to explore the role of plasmin in the activation 
of TAFI.  
This study demonstrates that hTAFI mice exhibit an intermediate fibrinolytic phenotype 
between TAFI KO and WT mice which corresponds with TAFI activity in blood.  
The current study also demonstrates that the combination of rotational thromboelastometry and 
whole blood from hTAFI mice can be used as an alternative model to evaluate the in vitro effect of 
profibrinolytic compounds exclusively reacting with human TAFI. Moreover, the results confirm the 
strong in vitro profibrinolytic effect of inhibitory anti-human TAFI MA irrespective of their mechanism of 
inhibition of TAFI activation. Accordingly, it is also clear that enhancement of the t-PA-mediated 
fibrinolytic activity by impairing TAFI activation constitutes a promising pharmacologic approach to 
improve thrombolytic therapy. 
Contributions of authors: 
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analysis and drafted the manuscript. JCMM provided hTAFI and TAFI KO mice and reviewed the 
manuscript. PJD and AG designed research, interpreted the data and reviewed the manuscript. 
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TAFI is the only metallocarboxypeptidase belonging to subfamily A (proenzymes) that demonstrates a 
zymogen activity towards small substrates. However, TAFI has an 18-fold lower catalytic efficiency 
compared to TAFIa [19, 54, 66].  
Characterization of zymogen stimulating nanobodies towards TAFI 
The crystal structure of human TAFI was found to be similar to that of pancreatic CPB which does not 
exhibit any zymogen activity. The structure also suggested that the catalytic site residues of TAFI 
readily remain in the active conformation and that activation is required only to expose the catalytic 
pocket and not to induce conformational changes at the active site [55, 187]. The absence of a salt 
bridge between the activation peptide and the catalytic domain in TAFI compared to pancreatic CPB 
provides a logical explanation for zymogen activity of TAFI. However, Foley et al. suggested that due 
to non-covalent interactions between the activation peptide (Val
35
 and Leu
39
) and the catalytic domain 
(Tyr
341
) only small substrates can reach the active site of TAFI. Therefore, TAFI zymogen can only 
cleave lysine and arginine residues from small substrates like hippuryl-arginine, but not from bigger 
substrates like partially degraded fibrin [40].  
In our laboratory, we identified Nbs (Vhh-TAFI-a51 and Vhh-TAFI-i103) which can stimulate 
the zymogen activity of TAFI. Therefore, the first part of this thesis focuses on the in vitro 
characterization of zymogen stimulating Nbs (Chapter 2) to determine the role of stimulated 
zymogen activity of TAFI in the regulation of fibrinolysis. From our results we can deduce that binding 
of Nbs to TAFI might result in a translocation of the activation peptide, leading to an increased 
accessibility of the catalytic site. That is why the stimulated zymogen activity of TAFI was able to 
exert an antifibrinolytic effect. A previous study has demonstrated that an increased TAFIa activity 
restores the impaired antifibrinolytic potential in plasma of the patients with haemophilia A [188]. 
Therefore, these zymogen stimulating Nbs might be a potential therapeutic agent for the treatment of 
haemophilia A [189]. Nbs used in current study can overcome a reduced TAFI activation problem by 
stimulating the zymogen activity of TAFI and therefore, can be used as adjuvant therapy next to the 
factor (VIII and IX) replacement therapy. Moreover, the stimulated zymogen activity might also have a 
positive effect in other (patho-)physiological processes which requires cleavage of small substrates 
like blood pressure, rheumatoid arthritis, inflammation and sepsis. In these (patho-)physiological 
processes TAFIa has a protective effect due to its ability to cleave small molecules like anaphylatoxins 
(C3a and C5a), bradykinin and thrombin-cleaved-osteopontin [25, 57-61]. Therefore, the importance of 
the TAFI zymogen stimulation can be evaluated using in vitro assays in which a non-activatable TAFI 
variant is combined with the zymogen stimulatory Nbs or in vivo using a mouse arthritis model [190]. 
However, Nbs used in the current study do not cross-react with mouse and thus cannot be tested in 
mouse model. Therefore, the generation of zymogen stimulating Nbs which cross-react with mouse 
TAFI is required. Furthermore, for therapeutic purposes Nbs should have sufficiently high affinities 
(nanomolar range) towards the target. However, the Nbs described in the study have lower affinities 
towards TAFI (micromolar range). A random mutagenesis approach could be used to increase the 
affinity of the Nbs. Another approach could be mapping of the paratopes on Nbs,which will enable us 
to mount residues involved in binding to TAFI on a high affinity Nb framework.  
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Cardiovascular diseases (CVDs) 
The world health organization (WHO) defines, CVDs as group of disorders of the blood vessels and 
the heart including cardiomyopathies, cerebrovascular disease (stroke), congenital heart disease, 
coronary heart disease (heart attack), deep vein thrombosis and pulmonary embolism, heart failure, 
hypertension, peripheral arterial disease and rheumatic heart disease. Ischemic stroke and myocardial 
infarction/heart attack are mainly acute events caused by blockage of artery or vein by a thrombus that 
prevents blood flow to the brain or heart, respectively, resulting into cell necrosis and loss of organ 
function. According to the WHO (2008), CVDs are the largest cause of sickness and morbidity 
worldwide (17.3 million deaths annually, 30% of all the global deaths) with a very high socioeconomic 
burden. It is estimated that by 2030, 23.6 million people will die annually due to CVDs, mainly by heart 
disease and stroke [14]. Every year CVDs cause approximately 1.9 million deaths (40% of the total 
deaths) in the European Union alone and are estimated to cost approximately €196 billion in 2012 
(European Cardiovascular Disease Statistics) [191].  
Thrombolytic therapy 
Currently the available thrombolytic therapy involves the administration of streptokinase (Streptase®) 
and tissue-type plasminogen activators (t-PA) like variants such as reteplase (Rapilysin®) and 
tenecteplase (Metalyse®). Streptokinase, a first generation thrombolytic, is of bacterial 
(Streptococcus) origin and therefore is the cheapest fibrinolytic agent available at the moment. 
Streptokinase exhibits a low fibrin specificity, has a high immunogenicity and is often associated with 
bleeding complications. Recombinant t-PA (alteplase: Activase® and Actilyse®) is a second 
generation thrombolytic, which has a high fibrin selectivity but is also associated with a higher risk of 
bleeding. Tenecteplase and Reteplase are genetically engineered t-PA molecules with an increased 
fibrin selectivity and increased plasma half-life and belong to third generation thrombolytics. Due to a 
similar efficacy compared to t-PA and an easy administration, the third generation thrombolytics are 
preferred over t-PA. However, these third generation t-PA derivatives are still associated with bleeding 
complications and neurotoxicity. Another limiting factor hampering the success of thrombolytic therapy 
is the timing of intervention as it is only beneficial when administered within 4.5 hours of onset of 
symptoms [1, 15, 16, 192, 193]. Therefore the development of more effective and safer thrombolytic 
therapy is still relevant and researchers are looking for alternative options.  
Plasmin is the central enzyme of the fibrinolytic system. Fibrinolysis is initiated when the 
zymogen plasminogen is converted into active plasmin via the action of plasminogen activators (t-PA 
and u-PA). Proteolytic cleavage of fibrin by plasmin generates C-terminal lysine residues that bind to 
plasminogen and t-PA both, thereby stimulating plasminogen activator-mediated plasminogen 
activation and propagating fibrinolysis. The control of the regulation of fibrinolysis is important since 
the impairment of fibrinolysis is associated with thrombosis, whereas excessive fibrinolysis is 
manifested by a bleeding tendency. One of the inhibitors of fibrinolysis is TAFIa. TAFI is a plasma 
zymogen, which upon proteolytic activation by trypsin-like enzymes (thrombin, the T/TM complex and 
plasmin) removes C-terminal lysine residues from the partially degraded fibrin blood clot. Thus, TAFIa 
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abolishes the cofactor function of the lysine residues, impedes t-PA-mediated plasmin formation and 
attenuates fibrinolysis [7, 10-13]. The TAFIa moiety is thermally unstable at 37°C which contributes to 
the regulation of the antifibrinolytic properties of TAFIa [48, 49]. The role of TAFIa in fibrinolysis has 
been studied extensively and TAFI inhibition either by gene deletion or by pharmacological inhibition 
was reported to enhance endogenous thrombolysis and/or t-PA-induced exogenous thrombolysis as 
well as to reduce the t-PA requirements in a number of animal models (cfr. Table 1.2, page 15, 
Chapter 1) [44, 60, 78, 81, 83, 95, 97, 102]. Many clinical studies have correlated TAFI antigen levels 
with cardiovascular events such as angina pectoris [168], coronary artery disease [169], ischaemic 
stroke [170], myocardial infarction [73] and venous thrombosis [69]. Therefore, in a broader 
perspective the rest of the sections of this thesis was designed to identify and characterize biologicals 
which can later be applied to fine-tune the thrombolytic therapy. Our study also provides evidence for 
the use of a human TAFI inhibitor as a profibrinolytic agent in vitro (Chapter 3) and Chapter 5). In 
spite of the increasing list of TAFIa inhibitors, the lack of specificity, the poor bioavailability, the 
biphasic effect and the toxicity remains a problem with most of the low molecular weight TAFI 
inhibitors. Alternatively, MA have been established as therapeutic molecules. These MA have a high 
stability and a high specificity against their target proteins. Although, MA have an extended plasma 
half life compared to the small molecule inhibitors, intravenous administration, high costs and a long 
manufacturing time are major limitations of MA over small molecule inhibitors. However, the specificity 
and the potency of an inhibitor are more critical parameters for clinical applications than the route of 
application and the cost-effectiveness. 
TAFIa exerts its effect by two different mechanisms; (a) by inhibiting plasminogen activation 
e.g. fibrinolysis and (b) by clearing active inflammatory mediators. Along with fibrin, TAFIa also has 
substrate specificity towards anaphylatoxins (C3a, C5a), annexin ll, bradykinin, thrombin-cleaved 
osteopontin and plasmin-cleaved chemerin. Therefore, TAFIa might be involved in a wide range of 
physiological processes indicating its possible role in angiogenesis, blood pressure, cell migration, 
inflammation and sepsis [25, 57-61, 194]. Thus, TAFIa may be related to various pathologies either 
having a protective (e.g. inflammation, abdominal aortic aneurysm, rheumatoid arthritis, unilateral 
ureter obstruction and wound healing) or a deteriorating (thrombosis, glomerulonephritis/kidney 
fibrosis, lung fibrosis and pulmonary hypertension) effect [83, 184]. In various recent studies, 
increased plasma TAFI(a) levels have been found to be associated with different pathological 
conditions like cancer/multiple myeloma [195-197], diabetic nephropathy [198, 199], early recurrent 
fetal loss [200], inflammatory bowel disease (crohns disease or ulcerates colitis) [201], hypertension 
[202] and meningococcal infection in children [203] etc. However, the role of TAFI(a) in any of above 
pathologies, except thrombosis and inflammation is not clearly understood and it is difficult to conclude 
whether an increase in plasma TAFI(a) is a cause or a result of the pathology. Here, it is also 
important to note that in all the above mentioned processes, except fibrinolysis in blood vessels (due 
to localization of TM at the endothelium), plasmin-mediated TAFI activation could be more relevant 
than T/TM-mediated TAFI activation. Therefore, further studies are required to identify/confirm various 
human pathological conditions which are clear cut associated with elevated TAFI(a) levels as well as 
to determine the involvement of different TAFI activators (thrombin, the T/TM complex and plasmin) 
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associated with those pathologies to develop a potent and selective TAFI(a) inhibitor for the clinical 
applications.  
Evaluation of relative contribution of different TAFI activators in regulation of 
fibrinolysis 
TAFIa is involved in the regulation of fibrinolysis without disturbing the coagulation process. As its 
name suggests, TAFI can be activated by thrombin alone but its rate of activation is 1250-fold 
accelerated in presence of TM [38, 41]. From a number of in vitro and in vivo studies it was deduced 
that T/TM is the main physiological activator of TAFI [42-44]. However, the localization of TM on the 
surface of endothelial cells suggests that the T/TM complex would only activate TAFI at the 
endothelium and often the fibrin-rich blood clot extends away from the endothelium. Therefore, 
involvement of other TAFI activators cannot be ruled out. Compared to thrombin, plasmin is a 10-fold 
stronger activator of TAFI and the efficiency of plasmin-mediated activation compared to thrombin is 
further enhanced in the presence of glycosaminoglycans like heparin. However, the catalytic efficiency 
of the plasmin-heparin complex is still 10-fold lower compared to the T/TM complex [38, 178]. Studies 
suggest that a very low concentration (< 2% of the total plasma concentration of TAFI) of TAFIa is 
required to attenuate fibrinolysis [25, 38]. However, the physiological relevance of plasmin-mediated 
TAFI activation is a matter of debate. To elucidate the physiological activators of TAFI we have tried to 
unravel the relative contribution of different TAFI activators (the T/TM complex vs. plasmin) in the 
regulation of fibrinolysis (Chapter 3 and Chapter 4). In Chapter 3 we revealed that along with the 
T/TM-mediated TAFI activation, the plasmin-mediated TAFI activation also plays an important role in 
regulation of fibrinolysis. This is supported by in vitro studies in which MA selectively inhibiting 
plasmin-mediated TAFI activation was used (Chapter 3) and by in vitro studies using TAFI variants 
that are selectively activatable by plasmin or the T/TM complex (Chapter 4). MA that mainly inhibit the 
plasmin-mediated TAFI activation (e.g. MA-TCK11A9) and the plasmin- and the thrombin-mediated 
TAFI activation (e.g. MA-TCK22G2) were shown to accelerate fibrinolysis in in vitro clot lysis 
experiments. We confirmed our findings using TAFI variants which are selectively activatable by either 
the T/TM complex (TAFI-K133A) or by the plasmin (TAFI-P91S). From our data it could be deduced 
that the plasmin-mediated TAFI activation constitutes to the complete antifibrinolytic effect exerted by 
TAFI (Chapter 4). In an in vitro thromboelastometry model using whole blood from human TAFI 
transgenic mice, MA that inhibit the plasmin-mediated TAFI activation (MA-TCK11A9) and T/TM-
mediated TAFI activation (MA-T12D11) revealed similar profibrinolytic effects, whereas an antibody 
that inhibits plasmin-, thrombin- and T/TM-mediated TAFI activation (MA-TCK27A4) revealed an 
enhanced fibrinolysis (Chapter 5). These data are in accordance with the chandler loop ex vivo 
analysis using whole human blood thrombi [179] and with the in vivo evaluation of MA-TCK26D6 in a 
mouse thromboembolism model [81]. However, a recent unpublished study suggested that MA-
TCK11A9 and MA-TCK26D6, in addition to their effect on the plasmin-mediated TAFI activation, can 
also interfere with the TAFIa activity when large substrates (e.g. fibrin) are involved but not when small 
substrates like C3a and C5a are involved (Semeraro et al., submitted). This would implicate that the 
role of plasmin in the activation of TAFI is overestimated in in vitro assays using large substrate and in 
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in vivo experiments. This also unravels a novel mechanism of TAFIa inhibition which can discriminate 
between large and small substrates. Till date no small molecule inhibitor is known, which can either 
inhibit TAFI activation or discriminate between TAFIa inhibition for large vs. small substrates. Here MA 
have an advantage over small molecule inhibitors and can be used to develop such type of selective 
inhibitors against different pathologies. 
Prediction of molecular determinants involved in binding of the T/TM complex and 
plasmin on TAFI 
MA are large protein molecules (145 Å x 85 Å x 40 Å), which bind to their target molecules by non-
covalent interactions [204]. Studies with MA that interfere with the functional properties of TAFI 
revealed a selective inhibition of either T/TM- and/or plasmin-mediated TAFI activation in spite of using 
the same cleavage site (Arg
92
) suggesting different secondary binding sites for thrombin, the T/TM 
complex and plasmin in TAFI [88]. Studies on the characterization of different TAFI variants i.e. TAFI-
R92A (non-activatable by thrombin, the T/TM complex and plasmin), TAFI-P91S (selectively resistant 
to T/TM-mediated activation), TAFI-S90P (selectively resistant to plasmin-mediated TAFI activation) 
and TAFI-R92K (selectively resistant to thrombin-mediated TAFI activation) also confirm that Arg
92
 is 
the primary binding site for all the TAFI activators (Chapter 2 and Chapter 4) (Fig. 6.1A and B). A 
recent study revealed that the positively charged amino acid residues Lys
42-44
 of TAFI are the 
secondary binding site of TM in TAFI (Fig. 6.1A) [175]. In a previous study, it was shown that MA-
T12D11 which inhibits exclusively T/TM-mediated TAFI activation recognizes Gly
66
 as the major 
residue for its binding to TAFI [88]. Lys
42-44
 residues are in close proximity (14-16 Å) of Gly
66
. 
Therefore it appears that TM binds to TAFI around Lys
42-44
. The same study reported that Val
41
 is a 
major residue in the binding of MA-T94H3 which inhibits T/TM- and plasmin-mediated TAFI activation, 
whereas involvement of Ile
182-183
 seems to abolish the plasmin-, thrombin- and T/TM-mediated TAFI 
activation [205].  
Vercauteren et al. generated the TAFI-K133A variant which appears to be selectively not 
activatable by plasmin (Fig. 6.1B) [81]. Other mutations around the 12 Å region of Lys
133
 (H126A, 
S129A, P135A, Y137A generated during epitope mapping of MA-TCK22G2) also exhibited a reduced 
plasmin-mediated TAFI activation. Therefore, it appears that the region around Lys
133
 of TAFI is 
involved in plasmin binding. This is also supported by the fact that MA-TCK11A9 and MA-TCK22G2 
mainly inhibiting plasmin-mediated TAFI activation bind in close proximity of Lys
133
. Asn
87
 and Thr
88
 
are the major residues involved in the binding of MA-TCK26D6 to TAFI [81]. MA-TCK26D6 also 
inhibits mainly the plasmin-mediated TAFI activation but it differs from MA-TCK11A9 since it can also 
inhibit the plasmin-mediated TAFI activation of rat and mouse TAFI. However, to fully unravel the 
secondary binding sites of plasmin and the T/TM complex, further studies are required. More direct 
methods like X-ray crystallography or hydrogen-deuterium exchange mass spectroscopy can be used 
to determine the residues directly involved in binding of plasmin, thrombin and the T/TM complex 
binding in TAFI. 
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Human TAFI transgenic mice 
The MA and Nbs used in this study were generated towards human TAFI and except for MA-
TCK26D6 do not cross-react with mouse TAFI. Therefore, they cannot be evaluated in vivo using a 
mouse model. The amino acid sequence of mouse and rat TAFI share approximately 85% identity 
with human TAFI, including the conservation of important residues involved in substrate binding, 
glycosylation and zinc binding. They also share conserved biochemical characteristics with respect to 
their activatability by the T/TM complex and their antifibrinolytic effect [34-36]. A previous study 
revealed that addition of human TAFI in mouse and rat plasma increases clot lysis time [35]. 
Recently, mice expressing human TAFI (hTAFI) have been generated [181]. Therefore, in the last part 
of the thesis we aimed to set up an in vivo thromboembolism mouse model in which the human anti-
TAFI MA could be evaluated in order to confirm their inhibitory effect (Chapter 5). Surprisingly, hTAFI 
mice exhibited an intermediate fibrinolytic phenotype between TAFI KO and WT mice. In addition, a 
high variability in fibrin deposition in the lungs of these mice prevented us to use hTAFI mice in in vivo 
experiments in which the profibrinolytic properties of anti-human TAFI MA could be evaluated in vivo. 
The intermediate phenotype might be due to a less efficient activation of human TAFI by the mouse 
T/TM complex or plasmin and/or due to a less efficient catalytic activity of human TAFIa on mouse 
fibrin. However, using whole blood from hTAFI mice in rotational thromboelastometry, we were able to 
develop an alternative in vitro model next to the human whole blood thrombi model [179] for the 
evaluation of the profibrinolytic properties of the anti-human TAFI inhibiting MA.  
Adjuvent therapy vs. monotherapy 
Studies suggest that TAFI(a) inhibitors can be used as an adjuvant therapy in addition to the currently 
used thrombolytic therapy against thrombosis. However, at this moment it is not clear whether TAFI(a) 
inhibitors alone (monotherapy) are able to prevent and/or to treat thrombosis. Various studies reported 
contradictory results (cfr. Table 1.2, page 15, Chapter 1). Therefore, detailed in vivo animal studies as 
well as clinical studies in human are required to confirm the applicability. A variety of small molecule 
TAFIa inhibitors have been used in clinical trials. However, their potency, specificity, toxicity and 
bioavailability are still a concern [103, 192, 193]. Therefore, the enhancement of translational usage of 
highly potent and highly selective TAFI(a) inhibitors is need of the hour. Along with a rational drug 
design approach based on best available information on small molecule inhibitors, peptides and MA, 
extensive studies are required to identify/confirm pathologies associated with increased TAFIa levels 
as well as to determine the involvement of TAFI activators in different pathologies in order to get a 
competent TAFI(a) inhibitor into the hospitals. 
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Figure 6.1: Ribbon diagram of TAFI (based on the crystal structure of Marx et al. [55]) representing molecular 
determinants involved in binding of MA as well as the T/TM complex and plasmin on TAFI. The activation peptide, the 
catalytic domain and the dynamic flap is shown in grey, green and cyan, respectively. Arg92 (white sphere) represents 
primary cleavage site for plasmin, thrombin and the T/TM complex. (A) Epitopes of MA-T94H3 (Val41) and MA-T12D11 
(Gly66) are depicted as red and brown spheres, respectively. The residue involved in selective inhibition of TAFI activation by 
the T/TM complex (Pro91) is represented as orange sphere. Lys42-44 (blue spheres) represent the secondary binding site of 
TM on TAFI. (B) Structure A was rotated around y-axis (180), z-axis (-35) and x-axis (-30) to transform into structure B. 
Epitopes of MA-TCK11A9 (Lys268, Ser272 and Arg276 ), MA-TCK22G2 (Thr147 and Ala148) and MA-TCK26D6 (Asp87 and Thr88) 
are depicted as blue, red and pink spheres, respectively. Residues involved in selective inhibition of plasmin-mediated TAFI 
activation are represented as yellow (Lys133) and orange (Ser90) spheres. The yellow ribbon depicts the residues present in 
the 12 Å region of Lys133 i.e. His126, Ser129, Pro135 and Tyr137. 
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Future perspective 
To conclude, this work unravels that stimulated zymogen activity exerts an antifibrinolytic effect 
(Chapter 2) and also verifies the use of a human TAFI inhibitor as a profibrinolytic agent in vitro 
(Chapter 3 and Chapter 5). In addition, this study also unravels the relative contribution of the 
different TAFI activators in the regulation of fibrinolysis (Chapter 3 and Chapter 4). However, there is 
still a long way to go to establish the currently used Nbs and MA as therapeutic molecules (Table 6.1) . 
Table 6.1: Lesson learnt and future perspectives.  
What have we learnt What needs to be performed 
1. Characterization of TAFI zymogen stimulating Nbs: 
 The stimulated( zymogen activity of TAFI exerts an 
antifibrinolytic effect. 
 
 Similar to the zymogen activity, the (stimulated( zymogen 
activity might cleave small substrate of TAFI. 
 Could be evaluated in a haemophilia mouse 
model. 
  
 Could be evaluated in in vitro assays 
 Could be evaluated in an inflammation 
mouse model. 
 
2. Characterization of anti-human TAFI MA which inhibit TAFI activation by different mechanisms: 
 Irrespective of the mode of inhibition, all MA exhibited a 
profibrinolytic effect in vitro, but cannot be evaluated in 
hTAFI mice in vivo. 
 
 TAFIa has anti-inflammatory properties and therefore MA 
may cause inflammation. 
 Could be evaluated in non-human primates. 
  
 
 
 Could be evaluated in in vitro assay  
 Could be evaluated in an inflammation 
mouse model.  
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Upon proteolytic activation by plasmin, thrombin or the T/TM complex, Thrombin Activatable 
Fibrinolysis Inhibitor (TAFI) is converted into its active form i.e. TAFIa. TAFI(a) exerts its antifibrinolytic 
effect by cleaving C-terminal lysine residues from partially degraded fibrin and thereby downregulates 
the t-PA-mediated activation of plasminogen into plasmin, a major enzyme for fibrin degradation.  
Previous studies have demonstrated that TAFI zymogen is an active plasma 
carboxypeptidase, which exhibits an 18-fold lower catalytic efficiency compared to TAFIa. In this study, 
we have generated and characterized human-TAFI zymogen stimulating Nbs (Vhh-TAFI-a51 and Vhh-
TAFI-i103) and a non-activatable TAFI variant (TAFI-TI-R92A) in order to evaluate the role of the 
stimulated zymogen activity of TAFI in the regulation of fibrinolysis (Chapter 2). From our analysis, 
we can conclude that the stimulated zymogen activity of TAFI can cleave C-terminal lysine residues 
from larger substrates like partially degraded fibrin, eventually resulting in the prolongation of clot lysis 
time. 
Thromboembolism is one of the major causes of morbidity and mortality in western world and 
found to be correlated with TAFI(a) antigen levels. Because TAFIa exerts an antifibrinolytic effect, the 
pharmacological inhibition of TAFI(a) seems to be a promising approach to treat thromboembolism. 
Therefore, we further evaluated the pharmacological inhibition of human TAFI. We selected three 
monoclonal antibodies (MA) raised toward human TAFI, which selectively inhibit the activation of 
human TAFI by plasmin (MA-TCK11A9), by plasmin and thrombin (MA-TCK22G2) and by plasmin, 
thrombin and the T/TM complex (MA-TCK27A4) and characterized their profibrinolytic properties using 
in vitro assays (Chapter 3). These three MA were also used to determine the relative contribution of 
the different TAFI activators in the regulation of fibrinolysis in vitro. We have demonstrated that along 
with the T/TM complex, plasmin also plays a critical role in the TAFI activation in the regulation of 
fibrinolysis. This was supported by (a) the profibrinolytic efficacy of MA-TCK11A9, a monoclonal 
antibody (MA), which mainly inhibits the plasmin-mediated TAFI activation, (b) the ability of MA-
TCK11A9 to reduce both TAFIa activity peaks during in vitro clot lysis assay and (c) the reduced 
antifibrinolytic effect of TAFI variants TAFI-P91S and TAFI- K133A which are selectively not activated 
by the T/TM complex and the plasmin, respectively (Chapter 3 and Chapter 4). Therefore, we 
concluded that plasmin can regulate its own generation through TAFI activation and that the T/TM 
complex and plasmin both play an important role in TAFI activation in regulation of fibrinolysis.  
MA used in present studies cannot be evaluated in vivo in mouse model due to their lack of 
cross-reactivity with mouse TAFI. Recently, mice expressing human TAFI (hTAFI) have been 
generated. Therefore, we tried to set up an in vivo mouse thromboembolism model and an in vitro 
thromboelastometry model using hTAFI transgenic mice to evaluate the effect of anti-human TAFI MA 
in vivo and in vitro, respectively (Chapter 5). Surprisingly, hTAFI transgenic mice exhibited an 
intermediate fibrinolytic phenotype between TAFI KO and WT mice in in vivo mouse 
thromboembolism model. In addition, a high variability in fibrin deposition in lungs of hTAFI transgenic 
mice prevented us to use these mice for the evaluation of the profibrinolytic properties of anti-human 
TAFI MA in vivo. However, using whole blood from hTAFI mice in rotational thromboelastometry, we 
were able to develop an alternative in vitro model next to the human whole blood thrombi model for the 
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evaluation of the profibrinolytic properties of the anti-human TAFI MA. The profibrinolytic properties of 
MA-T12D11, MA-TCK11A9 and MA-TCK27A4 were also evaluated in vitro (Chapter 5)  
To conclude, this study describes the role of the stimulated zymogen activity of TAFI and 
elucidates the contribution of the various TAFI activators (plasmin and the T/TM complex) in the 
regulation of fibrinolysis. We also confirmed the profibrinolytic capacity of the anti-human TAFI MA in 
vitro and in vitro. In rotational thromboelastometry using whole blood from hTAFI mice we were able to 
develop an alternative in vitro model in addition to the human whole blood thrombi model for the 
evaluation of anti-human TAFI MA. 
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Thrombin Activatable Fibrinolysis Inhibitor is een zymogeen dat na proteolytische splitsing ter hoogte 
van Arg
92
 wordt omgezet naar het actief enzyme TAFIa. TAFI(a) splitst eindstandige lysine residues 
van (partieel gedegradeerd) fibrine. De eindstandige lysines zorgen ervoor dat plasminogeen 
efficiënter door weefsel-type plasminogeen activator naar plasmine wordt omgezet. TAFIa vermindert 
de aanmaak van plasmine en vertraagt bijgevolg de fibrinolyse. 
Eerdere studies toonden aan dat het zymogeen TAFI ook een carboxypeptidase activiteit 
bezit. De catalytische efficiëntie van dit proces verloopt echter 18 keer trager in vergelijking met die 
van TAFIa. In het laboratorium werd een panel van nanobodies tegen TAFI(a) gegeneerd. 
Karakterisering van de nanobodies toonden aan dat twee van de nanobodies, Vhh-TAFI-a51 en Vhh-
TAFI-i103, de carboxypeptidase activiteit van zowel wild-type TAFI als van een inactieve TAFI-TI-
R92A variant verhogen (Chapter 2). Uit de in vitro experimenten bleek dat de “gestimuleerde” 
zymogeen activiteit van TAFI resulteert in een verlenging van de clot lysis tijd en dus de fibrinolyse 
vertraagt.  
Cardiovasculaire ziekten zijn nog steeds de voornaamste doodsoorzaak in de Westerse 
wereld. Eerdere studies toonden een correlatie tussen trombose en verhoogde TAFI(a) waarden. 
TAFI(a) is dus een mogelijke doel eiwit in de ontwikkeling van geneesmiddelen om trombose te 
voorkomen/behandelen. In deze studie werden drie monoklonale antilichamen geselecteerd die de 
activatie van humaan TAFI verhinderen. MA-TCK11A9 gaat de activatie van TAFI door plasmine 
verhinderen. MA-TCK22G2 verhindert de activatie van TAFI door plasmine en trombine terwijl MA-
TCK27A4 de activatie van TAFI door plasmine, trombine en trombine/trombomoduline verhindert. 
Toevoeging van deze drie antilichamen aan plasma resulteerde in een verkorting van de clot lysis. 
Deze drie antilichamen hebben dus profibrinolytische eigenschappen. Hiermee werd aangetoond dat 
de activatie van TAFI door zowel plasmine als door het trombine/trombomoduline complex relevant is 
en bijdraagt tot het antifibrinolytisch effect van TAFI. Deze conclusie werd gestaaft door de volgende 
bevindingen tijdens in vitro clot lysis experimenten: 1) MA-TCK11A9, een monoklonaal antilichaam dat 
de plasmine gemedieerde TAFI activatie verhindert vertoont een profibrinolytisch effect (Chapter 3); 
2) MA-TCK11A9 vermindert beide TAFIa activiteitspieken waargenomen tijdens een in vitro clot lysis 
assay (Chapter 3); 3) TAFI-P91S en TAFI-K133A, twee TAFI varianten die beide niet/slecht 
activeerbaar zijn door het trombine/thrombomoduline complex maar wel door plasmine, verlengen na 
toevoeging aan TAFI aan TAFI deficient plasma de clot lysis tijd (Chapter 4).  
Van de monoklonale antilichamen die opgewekt werden tegen humaan TAFI is er slechts één, 
namelijk MA-TCK26D6 dat cross-reageert met muis en rat TAFI. Al de andere monoklonalen konden 
wegens een gebrek aan cross-reactiviteit niet uitgetest worden in een in vivo muis model. Om het 
effect van de verschillende monoklonalen in vivo te bestuderen werden transgene muizen die geen 
muis TAFI maar wel humaan TAFI tot expressie brengen verkregen van Prof. Joost Meijers, AMC 
Amsterdam. Wanneer echter een tromboembolisme model werd uitgevoerd in deze muizen 
vertoonden deze een lagere fibrine afzetting in de longen dan de wild-type muizen. De fibrine afzetting 
was intermediair tussen dat van de TAFI KO muizen en de wild-type muizen. Daarenboven werd er bij 
deze transgene muizen een grote variatie in fibrine afzetting in de longen na injectie van 
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tromboplastine waargenomen waardoor het quasi onmogelijk was om deze muizen te gebruiken om 
het effect van de verschillende monoklonale antilichamen in vivo uit te testen. We slaagden er wel in 
om met vol bloed van deze transgene muizen condities te definiëren waarin het effect van de 
verschillende monoklonalen in een in vitro tromboelastometry model kan getest worden (chapter 5).  
Als besluit kunnen we stellen dat deze studie heeft bijgedragen om de rol van de 
“gestimuleerde” zymogeen activiteit van TAFI op te helderen. Deze studie heeft ook de bijdrage van 
de verschillende TAFI activatoren geillustreerd. Gebruik makend van vol bloed van transgene humane 
TAFI muizen kon het effect van de anti-humaan TAFI monoklonale antilichamen in vitro geconfirmeerd 
worden.  
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FkzkfEcu ,fDVosVscqy Qkbfczuksykbfll bfUgfcVj ¼VkQh ¼TAFI½ IykfTeu] FkzksfEcu ;k 
FkzksfEcu@FkzksEckseksMqfyu ladj }kjk çksfVvksfyfVd lfØ;.k ls lfØ; FkzkfEcu ,fDVosVscqy 
Qkbfczuksykbfll bfUgfcVj ¼VkQ+h&,½ esa ifjofrZr gks tkrk gSA VkQh&, vkaf'kd :i ls 
fo?kfVr Qkbfczu ds dkcksZfDl&Nksj ij fLFkr ykbflu vo'ks"kksa dks Qkbfczu v.kqvksa ls gVk 
dj dj Vhlw&VkÃi IykfTeukstu ,fDVosVj mRçsfjr IykfTeukstu ds lfØ; IykfTeu esa 
:ikUrj.k dks v/kksfofu;fer djrk gS vkSj ifj.kke Lo:i jDr ds teus ls cus FkDds ds 
fo?kVu ¼Qkbfczuksykbfll½ dks jksdrk gSA IykfTeu Qkbfczu vi?kVu esa ,d egRoiw.kZ ,atkbe 
gSA 
iwoZ v/;;uksa ls çnf'kZr gksrk gS fd VkQh T+kkbekstsu Hkh ,d lfØ; IykTek 
dkcksZfDlisfIVMst gS] ftldh mRçsjd {kerk VkQh&, dh mRçsjd {kerk ls vBkjg xquk de gSA 
bl orZeku v/;;u esa mRçsfjr VkQh tkbekstsu lfØ;rk dh Hkwfedk dk Qkbfczuksykbfll ds 
fu;eu esa ewY;k¡du djus ds Øe esa geus ekuoh;&VkQh fof'k"V tkbekstu mRçsjd 
uSuksckWfM;ksa (nanobodies) vkSj lfØ; u gks ldus okys mRifjorhZ ekuoh;&VkQh çfr:i 
VkQh&vkj92, (TAFI-R92A) dks mRié dj mudk LoHkko&fPk«k.k fd;k ¼v/;k; „½A gekjs 
fo'ys"k.k ls ;g lR;kfir gksrk gS fd mRçsfjr VkQh tkbekstsu Hkh vkf'kad :i ls fo?kfVr 
Qkbfczu tSls cM+s fØ;k/kkj (substrate) ds dkcksZfDl&Nksj ls ykbflu vo'ks"kksa dks gVk dj 
Qkbfczuksykbfll dks fu;af«kr dj ldrk gSA 
FkzkEcks,EcksfyTe ¼jDr ds FkDdk teus ds dkj.k jDr&okfgfu;ksa esa mRié jDr çokg 
vojks/k½ ik'PkkR; ns'kksa esa #X.krk vkSj e`R;q ds çeq[k dkj.kksa esa ls ,d gS vkSj bls 
VkQh@VkQh&, çfrtu ds jDr Lrj ls lglEc) fd;k tk ldrk gSA VkQh&, dh 
Qkbfczuksykbfll dks v/kksfofu;fer djus dh {kerk ds dkj.k VkQh ds lfØ;.k@VkQh&, 
lfØ;rk fu"ks/k dks laHkkfor vkS"k/kh; y{; ds :i esa ns[kk tk jgk gSA vr% geus VkQh 
lfØ;.k ds vkS"k/kh;@Hks"kt fu"ks/k (pharmacological inhibition) dk v/;;u fd;kA 
Qyr% geus ekuoh;&VkQh ds fo:) mRié Pkkj eksuksDyksuy çfrjf{k;ksa ¼,UVhckWMh½] tks 
Pk;ukRed rjhds ls Øe'k% FkzksfEcu@FkzksEckseksMqfyu ladj ,e,&Vhƒ„Mhƒƒ (MA-T12D11)] 
IykfTeu ,e,&Vhlhdsƒƒ,‹ (MA-TCK11A9)] IykfTeu vkSj FkzksfEcu ,e,&Vhlhds„„th„ 
(MA-TCK22G2) vkSj IykfTeu] FkzksfEcu vkSj FkzksfEcu@FkzksEckseksMqfyu ladj 
,e,&Vhlhds„‰,† (MA-TCK27A4) }kjk ekuoh;&VkQh ds lfØ;.k dks jksdrhs gSa] dk var% 
ik«k ¼bu foVªks½ Pkfj«k&fPk«k.k dj budh Qkbczksuksykbfll&o/kZu ¼çksQkbfczuksykbfVd½ çÑfr 
dk ewY;kadu fd;k ¼v/;k; … vkSj v/;k; †½A geus bu eksuksDyksuy çfrjf{k;ksa dk mi;ksx 
Qkbfczuksykbfll ds fofue;u esa fofHké VkQh lfØ;.k dkjdksa ¼IykfTeu vkSj 
FkzksfEcu@FkzksEckseksMqfyu½ ds VkQh lfØ;.k esa lkisf{kr ;ksxnku ds bu&foVªkss v/;;u esa Hkh 
fd;kA vius ijh{k.kksa ls geus ;g çnf'kZr fd;k fd FkzksfEcu@FkzksEckseksMqfyu ladj ds 
lkFk&lkFk IykfTeu Hkh VkQh lfØ;.k }kjk Qkbfczuksykbfll ds fofue;u esa egRoiw.kZ 
Hkwfedk fuHkkrk gSA ,e,&Vhlhdsƒƒ,‹] tks flQZ IykfTeu }kjk VkQh ds lfØ;.k dks jksdrh 
gS( dh çHkkoh çksQkbfczuksykbfVd {kerk] ,e,&Vhlhdsƒƒ,‹ dk bu foVªks jDr FkDdk y;u 
ijh{k.k esa VkQh lfØ;.k ds nksuksa f'k[kjksa dks vour djus dk lkeF;Z vkSj mRifjorhZ VkQh 
çfr:iksa( VkQh&ih‹ƒ,l (TAFI-P91S) vkSj VkQh&dsƒ……, (TAFI-K133A)] tks Øe'k% 
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Pk;ukRed :i ls FkzksfEcu@FkzksEckseksMqfyu ladj vkSj IykfTeu }kjk lfØ; ugha fd;s tk 
ldrs( dk {kh.k çfrQkbfczuksykbfVd çHkko gekjh [kkst dk leFkZu djrk gS ¼v/;k; … vkSj 
v/;k; †½A vr% gekjs ifj.kkeksa ds vk/kkj ij geus ;g fu"d"kZ fudkyk fd IykfTeu vius 
Lo&mRiknu dks VkQh lfØ;.k ds }kjk Lo;a fu;af«kr dj ldrk gS vkSj 
FkzksfEcu@FkzksEckseksMqfyu ladj vkSj IykfTeu nksuksa gh VkQh lfØ;.k }kjk Qkbfczuksykbfll ds 
fu;a«k.k esa egRoiw.kZ ;ksxnku nsrs gSaA 
bl v/;;u@vuqla/kku esa ç;qDr eksuksDyksuy çfrjf{k;ksa dh ew"kd&VkQh ls 
vfHkfØ;kRedrk ds vHkko esa budk ew"kd&rU«k esa bu fooks ewY;kadu ugha fd;k tk ldrkA 
gky gh esa ekuoh;&VkQh vfHkO;Dr djus okys ijk&mRifÙk ewyd (transgenic) Pkwgs dks mRié 
fd;k x;k gSA blfy;s geus ekuoh;&VkQh vfHkO;Dr djus okys Pkwgs dk mi;ksx bu fooks 
ew"kd FkzkEcks,EcksfyTe ekWMy vkSj bu&foVªks FkzksEcks,ykLVksesVªh ekWMy esa djds ekuoh;&VkQh 
fof'k"V eksuksDyksuy çfrjf{k;ksa ds çksQkbfczuksykbfVd çHkko ds ewY;kadu dk ç;kl fd;k 
¼v/;k; ‡½A bu&fooks ew"kd FkzksEcks,EcksfyLe ekWMy esa v/;;u ds nkSjku ekuoh;&VkQh 
vfHkO;Dr djus okys Pkwgs us vk'Pk;Ztud :i ls ew"kd&VkQh jfgr vkSj ew"kd&VkQh lfgr 
Pkwgs ds chPk ds QkbfczuksykbfVd y{k.kksa (phenotype) dks çnf'kZr fd;kA blds vfrfjDr] 
ekuoh;&VkQh vfHkO;Dr djus okys Pkwgs us bu fooks ew"kd FkzkEcks,EcksfyTe ekWMy esa Pkwgs ds 
QsQM+ksa esa Qkbfczu fuJsi.k ds Lrj esa mPPk ek«kk essa fofo/krk çnf'kZr dhA bl dkj.k geus 
ekuoh;&VkQh fof'k"V eksuksDyksuy çfrjf{k;ksa ds çksQkbfczuksykbfVd çHkko dk ewY;kadu bl 
ekWMy esa ugha djus dk fu.kZ; fy;kA gk¡ykfd ekuoh;&VkQh vfHkO;Dr djus okys Pkwgs ds 
jDr dk mi;ksx FkzksEcks,ykLVksesVªh ekWMy esa djrs gq;s ge ekuoh;&VkQh fof'k"V eksuksDyksuy 
çfrjf{k;ksa ds çksQkbfczuksykbfVd çHkko ds ewY;kadu ds fy;s igys ls mifLFkr ekuo jDr 
FkDdk ekWMy ds vfrfjDr ,d u;s oSdfYid bu&foVªks ekWMy dk fodkl djus esa lQy jgsA 
bl u;s ekWMy dk ç;ksx djrs gq;s geus ekuoh;&VkQh fof'k"V çfrjf{k;ksa( ,e,&Vhƒ„Mhƒƒ] 
,e,&Vhlhdsƒƒ,‹ vkSj ,e,&Vhlhds„‰,† ds çksQkbfczuksykbfVd çHkko dk bu&foVªkss ewY;kadu 
Hkh fd;k ¼v/;k; ‡½A 
lkjka'k esa] ;g 'k¨?k&Áca?k Qkbfczuksykbfll fofue;u esa ¼ƒ½ mRçsfjr tkbekstsu 
lfØ;rk dh Hkwfedk vkSj ¼„½ fofo/k VkQh lfØ;.k dkjdksa ¼IykfTeu vkSj 
FkzksfEcu@FkzksEckseksMqfyu½ ds VkQh lfØ;.k esa lkis{k ;ksxnku dks Li"V djrk gSA geus vius 
ijh{k.kksa }kjk u flQZ ekuoh;&VkQh fof'k"V eksuksDyksuy çfrjf{k;ksa ds çksQkbfczuksykbfVd 
çHkko dh iqf"V dh cfYd ,sls çfrjf{k;ksa ds çksQkbczksuksykbfVd çHkko ds ewY;kadu ds fy;s 
bu&foVªkss ekWMy dk fodkl Hkh fd;kA 
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